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1 General introduction 
1.1 Hyaluronan 
1.1.1 Structure and properties: a chemical point of view 
The polysaccharide hyaluronan (hyaluronic acid, HA) was isolated from bovine vitreous 
humor by Meyer and Palmer in 1934.
1
 Having identified uronic acid and hexosamine as 
constituents of this substance, they suggested the name “hyaluronic acid”, a combination of 
“hyaloid” (vitreous) and “uronic acid”.
1
 At physiological pH, the carboxylic groups of the 
acidic polysaccharide (pKa = 3–4) are predominantly deprotonated.
2
 Hence, the term 
“hyaluronan” is preferably used today.  
In 1954, the exact chemical structure of hyaluronan was elucidated (Figure 1.1).
3
 
Hyalobiurionic acid, the repeating unit of the polymer, consists of D-glucuronic acid and 
N-acetyl-D-glucosamine, linked by a β-1,3 glycosidic bond.
3
 Depending on the origin, 
hyaluronan is polydisperse with each molecule of the unbranched polymer comprising about 
2000–25000 disaccharide moieties,
4
 connected by β-1,4 glycosidic bonds.
2-5
 As each 
disaccharide unit has a molecular mass of approximately 400 Da and an average length of ca. 
1 nm,
2
 these degrees of polymerization correspond to molecular masses of 0.8–10 MDa and 
extended lengths of 2–25 µm. 
 
Hyaluronic acid (hyaluronan): n = 2000–25000 
 
Figure 1.1: General structure of hyaluronan. The biopolymer consists of β1→4-linked hyalobiuronic acid
*
 
(D-glucuronic acid β1→3-linked with N-acetyl-D-glucosamine). Depending on the source, the native 
polysaccharide usually comprises n = 2000–25000 disaccharide moieties.
4
  
Within the family of glycosaminoglycans, hyaluronan differs from chondroitin sulfate, 
dermatan sulfate, keratan sulfate, heparin, and heparan sulfate by being the only non-
sulfated exception. Moreover, hyaluronan is the only glycosaminoglycan, which is not 
                                                      
*
  In literature, the term “hyalobiuronic acid“ is inconsistently used for both the repeating disaccharide unit (as 
depicted in Figure 1.1) and its deacetylated derivative.  
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covalently linked to a protein core, forming a proteoglycan, but is secreted directly into the 
extracellular space during synthesis.
6
 
In a way, the common depiction (also used in this work) of hyaluronan as a sequence of 
disaccharide units, drawn in the same orientation, is misleading. Although hyaluronan 
molecules are simple linear polysaccharide chains, the secondary and tertiary structures of 
this biomolecule are more complex.  
Hyaluronan in solution has been assumed to form a tape-like, two-fold helix with each 
disaccharide rotated by 180° compared to its neighboring repeating units.
7
 The existence of 
hydrophobic patches within the molecule was suggested, allowing for self-aggregation as 
well as for formation of reversible tertiary structures, correlated to the biological 
properties.
7-9
 Recently, this theory was rejected by Almond et al. due to the observation that 
the proposed two-fold helices occurred only transiently in very restricted regions of the 
polysaccharide chains.
10, 11
 Instead, a dynamic local conformation was determined, which (in 
average) could approximately be described as a contracted four-fold helix.
10
 With regard to 
the high concentrations of hyaluronan in the extracellular matrix and the high degrees of 
polymerization, the reported NMR methods were not ideal to prove or exclude the 
formation of structures of higher order under physiological conditions. Hence, Raman 
spectrometry and Raman optical activity (ROA) were applied to this problem, providing 
further evidence against the existence of tertiary structures of hyaluronan.
12
  
Moreover, the theory of stable networks was often referred to the rheological properties of 
hyaluronan in aqueous solution.
9
 By contrast, in a review of analytical studies, Cowman and 
Matsuoka drew the conclusion that the behavior of hyaluronan was quite typical for a linear 
semi-flexible polymer of the respective chain length.
13
 Due to its flexibility, its viscoelastic 
properties, and the space-filling structure, hyaluronan provides perfect conditions for tissue 
remodeling and can serve as a kind of track for migrating cells.
11
  
1.1.2 Occurrence and physiological relevance: a biological point of view 
Physiologically, different amounts of hyaluronan can be found in tissues from all vertebrates 
as well as in the capsules of some strains of Streptococci.
2
 It is an important constituent of 
embryonic and regenerating tissues, where it provides hydrated pericellular zones 
(facilitating cell rounding during mitosis) and pathways for cell migration.
2, 4
 Among mature 
tissues, an extraordinarily high concentration of hyaluronan (7.5 mg/mL) can be found in 
rooster comb, whereas umbilical cord probably has the highest hyaluronan content 
(4 mg/mL) of all mammalian tissues.
2
  
However, half of the 7–8 g of hyaluronan in the body of an average adult human is located in 
the different layers of the skin.
2
 Considering the wet tissue mass, the hyaluronan content of 
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the dermis (ca. 0.5 mg/g) is higher than that of the epidermis (ca. 0.1 mg/g).
2
 Nevertheless, 
the different contents of cells result in opposed conditions with regard to the concentration 
in the extracellular matrix of dermis (ca. 0.5 mg/mL) and epidermis (2–4 mg/mL).
2
 
Considering the high content and the observed turnover time of less than one day within the 
epidermal matrix, hyaluronan seems to be important for migration and shape changes of 
keratinocytes during differentiation.
14
  
In hyaline cartilage, hyaluronan forms aggregates of several hundred million Dalton with 
chondroitin sulfate proteoglycans (aggrecans).
15
 Thereby, hyaluronan serves as backbone 
and retains high concentrations of aggrecan molecules in the matrix, which are essential for 
the biomechanical properties of the cartilage tissue.
2, 15
 
As hyaluronan was first isolated from bovine vitreous humor,
1
 it is not surprising that the 
human vitreous body also contains relatively high amounts (0.1 mg/g wet weight) of 
hyaluronan.
2
 The isolation of hyaluronan from synovial fluid was also described, when 
research on this substance was still in the fledgling stages in 1939.
16
 With a hyaluronan 
content of 3–4 mg/mL, synovial fluid has one of the highest concentrations in the human 
body.
2
 Later, hyaluronan was proven to be responsible for the viscosity of synovial fluid.
17
 
Ogston and Stanier suggested a mainly lubricant function of hyaluronan, considering the 
viscoelastic properties less relevant under physiological conditions.
18
 With regard to the 
pathology of osteoarthritis and rheumatoid arthritis, the role of hyaluronan is discussed 
controversially.
19-23
 Nevertheless, hyaluronan is not only physiologically present in the eye 
and joints. Ophthalmology (e. g. cataract surgery) and orthopedics (treatment of 
osteoarthritis) are also typical examples for the use of this biopolymer as medical device, 
mainly owing to its viscoelasticity and its high capacity to bind water.
24
 
The matrix produced by the cumulus cells around the oocyte also contains significant 
amounts of hyaluronan (ca. 0.5 mg/mL).
2
 Probably the hyaluronan-rich matrix facilitates 
ovulation and transport of the oocyte.
25
 During fertilization, the matrix of the expanded 
cumulus cell–oocyte complex probably forms a barrier, which can only be overcome by fully 
functional sperm.
25
 The sperm hyaluronidase and its role during fertilization will be 
discussed in Section 1.2.2. 
Apart from the mentioned examples of physiological functions, directly related to the 
physicochemical properties of the polymer, hyaluronan can also cause biological effects via 
interaction with hyaluronan binding proteins (hyaladherins), especially with cell surface 
hyaluronan receptors (cf. Section 1.2.3). Moreover, hyaluronan and hyaluronan-derived 
oligosaccharides are proposed to influence many different physiological and patho-
physiological processes in a size-dependent manner (cf. Section 1.2.5). 
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1.2 Hyaluronidases and hyaluronan metabolism 
1.2.1 Occurrence and classification of hyaluronidases 
Hyaluronan degrading enzymes have been identified in bacteria (bacteriophage-associated 
as well as bacterial enzymes), some species of fungi, nematodes, leeches, crustaceans, 
venoms from arthropods (insects, scorpions, spiders) and vertebrates (stonefish, snakes, 
lizards, mammals), and other vertebrate sources (tissues, body fluids).
26-29
 According to the 
conventional classification by Meyer, hyaluronidases are usually sorted into three main 
families with regard to their catalytic mechanism (Figure 1.2).
30
  
 
 
Figure 1.2: Classification of hyaluronidases according to Meyer.
30
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The hyaluronidases from mammals and other vertebrates as well as the bee venom 
hyaluronidase are typical examples of the first group (EC 3.2.1.35).
28, 30-32
 The mechanism of 
these endo-β-N-acetyl-D-hexosaminidases is characterized by the hydrolysis of the β-1,4 
glycosidic bonds of hyaluronan. Tetra- and hexasaccharides accumulate as end products.
31
 
Some hyaluronidases from this family were proven to accept chondroitin sulfates and 
dermatan sulfates as alternative substrates.
31, 33
 By contrast, stonefish hyaluronidase was 
reported to be unique within this group with regard to its substrate specificity for 
hyaluronan.
34
 Moreover, mammalian isoenzymes exhibit differences concerning pH profile, 
minimal substrates, and product spectra.
32, 35
 From many studies, mainly using bovine 
testicular hyaluronidase (BTH), it is known that both hydrolysis and transglycosylation 
reactions occur with these enzymes.
32, 35-42
 
The second group (EC 3.2.1.36) includes hyaluronidases from crustaceans, nematodes, and 
the salivary glands of leeches.
28, 30, 31
 These enzymes are endo-β-D-glucuronidases and 
hydrolyze the β-1,3 glycosidic bonds of hyaluronan. Hence, the products of the reaction have 
a D-glucuronic acid moiety at the reducing end. Similar to the first group, the main products 
are tetra- and hexasaccharides.
31
 The leech enzyme, purified and characterized by Yuki and 
Fishman, was specific for hyaluronan.
43
 Most probably, this hyaluronidase serves as 
spreading factor increasing the permeability of the skin of the host.
28
 By analogy, the 
hyaluronidases (showing activity also against chondroitin sulfate A) from nematodes, 
excreted by the parasites during intestinal invasion, were reported to contribute to 
pathological enteritis.
44
 Hence, these enzymes might be potential drug targets for the 
therapy of nematode infections.  
The same is the case for hyaluronidases from microbial pathogens. In contrast to both other 
types of hyaluronidases, the bacterial enzymes (EC 4.2.2.1, formerly EC 4.2.99.1) catalyze a 
β-elimination reaction.
28, 30, 31, 45
 Except for Streptomyces hyalurolyticus hyaluronidase, which 
degrades hyaluronan to mixtures of unsaturated tetra- and hexasaccharides, the main 
product of microbial hyaluronan lyases is the unsaturated disaccharide 3-(4-deoxy-β-D-gluc-
4-enuronosyl)-N-acetyl-D-glucosamine.
45
 Moreover, the hyaluronidases from Streptococci, 
Staphylococci, Clostridia, Streptomyces, and other microorganisms exhibit different 
substrate specificities, with Streptomyces hyalurolyticus hyaluronidase being highly specific 
for hyaluronan.
45
 Probably, the best characterized bacterial hyaluronidases are those of the 
group B Streptococci, namely Streptococcus agalactiae and Streptococcus pneumoniae. 
These enzymes are supposed to exhibit a catalytic mechanism comprising an initial random 
cleavage step and further processive exolytic degradation of the residual polysaccharide 
chain.
46-51
 Apart from the function of hyaluronidases as spreading factor, the produced 
disaccharides are discussed to serve as nutrients for the bacteria.
52
 Recently, the use of host 
hyaluronan as carbon source by Mycobacterium tuberculosis was reported, although no 
hyaluronidase had previously been identified in the genome of this human pathogen.
53
 The 
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authors also described successful inhibition of hyaluronan-dependent growth of 
Mycobacteria by L-ascorbic acid-6-O-hexadecanoate,
53
 a potent hyaluronidase inhibitor 
found in our group.
54
 
1.2.2 Human hyaluronidases 
Hyaluronidases from venoms and human pathogens are potential drug targets. The same 
holds for human hyaluronidases, which are still far from being understood with regard to 
their physiological and pathophysiological role. Six hyaluronidase-like sequences have been 
identified in the human genome: HYAL1, HYAL2, and HYAL3 clustered on chromosome 
3p21.3; HYAL4, PH-20, and HYALP1 on chromosome 7q31.3.
55
 The human paralogs exhibit a 
sequence identity of about 40%, whereas a much higher degree of homology was observed 
for orthologous human and murine genes.
31, 55
 
HYAL1 is expressed in many tissues. Highest levels of mRNA were detected in liver, heart, 
spleen, kidney, and bone marrow.
56
 The gene was proven to encode the soluble acid-active 
hyaluronidase found in human plasma.
57
 Although differing in molecular mass and some 
other characteristics, similar hyaluronidases were isolated from human liver,
58
 serum,
59
 and 
urine.
60
 As acid-active hyaluronidase is assumed to be a lysosomal enzyme, its presence in 
plasma as well as its pH optimum clearly below the lysosomal pH of 4.5 seem mysterious.
61
 
HYAL1 was described as a candidate tumor suppressor gene, also known as LUCA-1 due to its 
observed deletion in lung cancer.
62, 63
 By contrast, overexpression of Hyal-1 was reported to 
promote growth and aggressiveness of malignant tumors of breast,
64, 65
 bladder,
66
 and 
prostate.
67
 This controversial role is further supported by recent studies, in which blocked as 
well as high expression of Hyal-1 inhibited proliferation of prostate cancer cells.
68
 In addition 
to this ambiguous involvement in cancer, inactivating mutations of the HYAL1 gene were 
observed in the lysosomal storage disorder mucopolysaccharidosis IX.
69, 70
 
Recently, a putative second type of mucopolysaccharidosis IX was proposed from a study 
with mice lacking Hyal-2, the protein encoded by HYAL2.
71
 In human tissues, the HYAL2 gene 
(also known as LUCA-2) is widely expressed, except in brain, with highest mRNA levels found 
in spleen.
56, 72
 Hyal-2 was reported to be either a lysosomal protein or membrane-bound via 
a glycosylphosphatidylinositol (GPI) anchor.
72, 73
 Recently, Hyal-2 was proven to be the only 
hyaluronidase present in platelets.
74, 75
 The enzyme is commonly believed to cleave 
hyaluronan incompletely, yielding fragments down to 20 kDa.
72, 73
 Thus, Hyal-1 and Hyal-2, 
the major hyaluronidases in human somatic tissues, are hypothesized to contribute to the 
degradation of hyaluronan in a concerted and successive manner (cf. Section 1.2.3).
55, 61
 By 
contrast, Hamberger proved the presence of smaller fragments (10–15 kDa) after incubation 
of hyaluronan with Hyal-2.
75
 The products of Hyal-2 are supposed to induce the production 
of proinflammatory cytokines and to play an important role in wound healing (cf. Section 
1.2 Hyaluronidases and hyaluronan metabolism 7 
 
1.2.5).
74
 Overexpression of Hyal-2 in murine astrocytoma cells promoted the formation of 
highly vascularized and invasive tumors in brain, whereas subcutaneous tumorigenicity of 
these glioma cells was not increased, indicating an interaction with the extracellular matrix 
of the brain.
76
 By contrast, murine fibroblasts were reported to become more sensitive to 
tumor necrosis factor alpha (TNF-α) by Hyal-2 overexpression, resulting in increased 
apoptosis.
77
 
Although HYAL3 is widely expressed in humans, no activity of the Hyal-3 protein was proven 
up to now.
61
 Hence, its physiological relevance remains an enigma. Particularly high 
expression can be found in bone marrow and testis.
56
 Human and murine Hyal-3 share about 
80% of their amino acid sequence, which is a much higher sequence identity than that of the 
respective Hyal-1 enzymes (73%).
55
 As Hyal-3 was reported to contribute to the 
hyaluronidase activity in murine sperm and to be expressed also in human sperm, the 
enzyme was proposed to play a role in fertilization in both species.
78
 Considering the stem 
cell-like state of both bone marrow and testis, it was hypothesized that Hyal-3 might be 
relevant for stem cell regulation and fetal development.
31, 55
 
HYAL4 gene expression was determined on the mRNA level in skeletal muscle and 
placenta.
56
 Recently, human Hyal-4 was proven to be an endo-β-N-acetylgalactosaminidase 
with specificity for chondroitin sulfate, thus being the first chondroitin sulfate hydrolase 
identified in a higher organism.
79
 
In 1993, the GPI-anchored human sperm head protein PH-20 (also termed sperm adhesion 
molecule 1, SPAM1), encoded by PH-20, was proven to exhibit hyaluronidase activity.
80
 
Expression of the PH-20 gene is relatively specific for testis, although it was also proven in 
placenta, fetal tissue, some other tissues, and a few malignant tumors.
56, 61
 However, the 
major physiological function of PH-20 is probably its role during fertilization, which is 
described in detail in a recent review article by Martin-DeLeon.
81
 Two different forms of the 
enzyme were identified.
82
 One variant, bound to the plasma membrane via the GPI anchor, 
has a molecular mass of 64 kDa and exhibits hyaluronidase activity at both neutral and acidic 
pH.
80, 82
 A second form with a molecular mass of 53 kDa and activity only at acidic pH, is 
released during the acrosome reaction.
82
 Hyaluronidase activity of PH-20 bound to the 
plasma membrane of the sperm enables degradation and penetration of the hyaluronan-rich 
cumulus extracellular matrix around the oocyte, whereas hyaluronidase released from the 
acrosome is responsible for hydrolysis of hyaluronan in the zona pellucida matrix.
25, 83
 
However, GPI-anchored hyaluronidase seems to fulfill a second function as a membrane 
receptor for hyaluronan, inducing sperm signaling.
83
 PH-20 bound to the inner acrosome 
membrane may also be involved in second or tertiary binding of the sperm to the zona 
pellucida or its penetration.
83, 84
 It should be noted that the well-known enzyme isolated 
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from bovine testis (BTH)
85
 was proven to be nothing else than a soluble fragment of 
membrane-bound bovine PH-20 enzyme.
86
 
Due to two deletions causing premature termination of transcription, HYALP1 is a 
pseudogene in humans but the corresponding ortholog may encode an active protein in 
other species.
56
 
1.2.3 Hyaluronan metabolism 
Hyaluronan levels in the human body are regulated by a dynamic interplay of anabolic and 
catabolic processes. Approximately one third of the 15 g of hyaluronan present in the body 
of a 70 kg adult human is replaced every day.
61
 However, the turnover rate strongly depends 
on the tissue. Whereas hyaluronan of the epidermis is reported to be replaced within 1–2 
days
61
 or even less than one day,
14
 this process takes about 1–3 weeks in cartilage tissue.
61
 
By contrast, intravenously injected hyaluronan has a half-life of only 2.5–4.5 min, 
determined in rabbit.
87
 
Three highly conserved isoforms of hyaluronan synthases (HAS1, HAS2, and HAS3), the 
enzymes of hyaluronan anabolism, have been identified in mammals up to now.
88-90
 In 
contrast to other macromolecules, hyaluronan is not synthesized intracellularly, but 
extruded to the extracellular space by the transmembrane hyaluronan synthases, thus 
allowing for the extraordinarily high degree of polymerization.
89
 HAS1 exhibits the lowest, 
HAS3 the highest activity of the three isoenzymes.
90
 However, the different hyaluronan 
synthases differ not only in the rate of hyaluronan formation. Whereas recombinant murine 
HAS1 and HAS2 were reported to synthesize hyaluronan molecules of 0.2–2 MDa, the 
products of HAS3 reached molecular masses of only 0.1–1 MDa.
91
 Extremely large 
hyaluronan of more than 2 MDa was observed in cell culture medium of stable transfectants, 
expressing the HAS2 protein.
91
 Moreover, HAS2 is probably the major source of hyaluronan 
during embryogenesis, and knock-out mice showed early lethality owing to severe cardiac 
and vascular abnormalities.
92
 Whereas HAS2 therefore seems to be important for the 
production of large amounts of high molecular weight hyaluronan during developmental 
processes and tissue growth, HAS1 might be responsible for maintenance of the required 
minimal level of hyaluronan.
90
 Finally, the smaller products of HAS3 might fulfill distinct 
functions within the extracellular matrix or induce cellular effects via hyaluronan receptors 
and the corresponding signaling cascades.
90
 
Human hyaluronidases, the catabolic enzymes of hyaluronan metabolism, were already 
discussed in Section 1.2.2. The detailed mechanisms of hyaluronan catabolism are still 
unknown. One hypothesis proposes a concerted, but successive action of the two major 
somatic hyaluronidases, Hyal-1 and Hyal-2.
55, 61
 According to this model, hyaluronan might 
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be fixed by hyaluronan receptors (cf. Section 1.2.4) at the cell membrane (putatively CD44), 
degraded by membrane-bound Hyal-2 to fragments of about 20 kDa, subsequently 
internalized by endocytosis, delivered to endosomes, and finally completely degraded in 
lysosomes by the action of Hyal-1, β-glucuronidase, and β-N-acetylglucosaminidase.
55, 61
 
Thereby, enrichment of the initial hyaluronan–CD44–Hyal-2 complex in microdomains 
(caveolae), where degradation of hyaluronan by Hyal-2 might take place, is conceivable.
93
 
However, this hypothetical model remains unproven and other aspects, like the contribution 
of free radicals to the cleavage of hyaluronan into smaller fragments, also have to be 
considered under pathological conditions.
61, 93
 
1.2.4 Hyaluronan receptors 
Recognition of hyaluronan by cellular receptors is a prerequisite for the regulation of both, 
the proposed mechanism of hyaluronan metabolism and the putative size-dependent effects 
on cellular function. The best characterized examples of hyaluronan receptors are the 
lymphocyte homing receptor CD44
94, 95
 and RHAMM, the receptor for hyaluronan-mediated 
motility.
96
 The CD44 epitope is present on the membrane surface of most vertebrate cells, 
but is shared by a group of proteins of 80–200 kDa.
97
 The enormous heterogeneity of these 
proteins, encoded by a highly conserved gene, is caused by alternative splicing as well as 
post-translational modifications.
97, 98
 These modifications, which differ between cell types 
and cell states, influence hyaluronan binding and receptor function.
99
 Apart from its role in 
internalization and degradation of hyaluronan (cf. Section 1.2.3), CD44 probably mediates 
cell–matrix communication by interaction with the cytoskeleton via the ERM protein family 
(ezrin, radixin, moesin, and merlin) or the ankyrin.
94, 100
 Moreover, CD44 was reported to  
interact with tyrosin kinases and specific GTPases.
100
  
Both hyaluronan receptors, CD44 and RHAMM/CD168, were reported to form complexes 
with ERK1,2 in invasive breast cancer cells.
101
 Like CD44, RHAMM exists in different variants 
as a result of alternative splicing.
96, 102
 Moreover, RHAMM is not only localized at the cell 
membrane, but can also be found intracellularly.
96
 Intracellular RHAMM may be involved in 
processes of cytoskeleton assembly.
100
 Moreover, the fast dynamic appearance of RHAMM 
at the cell membrane under certain conditions seems to require some kind of intracellular 
storage of the protein.
96
 By contrast, the protein is permanently present on the surface of 
malignant cells, where it seems to be involved in invasion and metastasis.
96, 100, 103
 Hall et al. 
suggested that binding of hyaluronan to RHAMM promotes cell locomotion by protein 
tyrosin kinase mediated signaling via rapid phosphorylation and dephosphorylation of focal 
adhesion kinase (FAK).
104
 In parallel with this transient phosphorylation, assembly and 
disassembly of focal adhesions were detected, pivotal processes for cell locomotion.
104
 
Hence, it is not surprising that RHAMM is also proposed to be involved in endothelial cell 
migration, angiogenesis, and wound healing.
105
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Less intensively studied hyaluronan receptors are the lymph vessel endothelial hyaluronan 
receptor (LYVE-1),
106
 the toll-like receptor 4 (TLR4),
107, 108
 the hyaluronan receptor for 
endocytosis (HARE),
109
 and layilin.
110, 111
 
1.2.5 Effects of hyaluronan and its oligosaccharide fragments: a matter of 
size? 
As discussed above (cf. Section 1.2.2 and Section 1.2.3), both hyaluronidases and hyaluronan 
synthases produce oligosaccharides and polysaccharides of different chain lengths. However, 
the biological effects of hyaluronan and hyaluronan oligosaccharides are believed to be 
strongly size-dependent.
112
 In this work, hyaluronan oligosaccharides are designated 
according to the number of disaccharide moieties (n = x) as nx (Figure 1.3). 
 
Figure 1.3: Oligosaccharides are designated as multiples of hyalobiuronic acid (disaccharide) as nx (n = x), e. g. 
the tetrasaccharide (n = 2) as n2 and the hexasaccharide (n = 3) as n3. 
Hyaluronan of an average molecular weight below approximately 500 kDa is often referred 
to as low molecular weight (LMW) hyaluronan.
112
 This term is additionally used for poly-
disperse mixtures containing a broad series of hyaluronan oligosaccharides with an average 
molecular weight of less than 10 kDa. 
The proposed size-dependent physiological and pathophysiological functions are manifold. 
Hence, only examples can be discussed here. For a more detailed summary on this topic, see 
the review article by Asari.
112
  
The role of hyaluronan and hyaluronan oligosaccharides in angiogenesis has been a matter 
of discussion since the 1980s. High molecular weight hyaluronan was described to be 
antiangiogenic,
113
 whereas oligosaccharides were reported to induce angiogenesis.
114
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Differential effects on the proliferation of endothelial cells and the stability of cell layers 
were discussed.
115
 Based on these results, hyaluronan and hyaluronan oligosaccharides are 
believed to modulate vascularization and wound healing, probably via the hyaluronan 
receptors CD44 and RHAMM.
102, 105, 116-120
 Thereby, the involvement of size-dependent pro- 
and anti-inflammatory effects is also conceivable. High molecular weight hyaluronan was 
reported to inhibit the activation of NF-κB and the production of pro-inflammatory 
cytokines.
121, 122
 By contrast, smaller fragments seem to act as pro-inflammatory stimuli via 
NF-κB activation and formation of cytokines, chemokines, and nitric oxide.
123-125
 Toll-like 
receptor 4 (TLR4), identified as hyaluronan receptor, may also be involved in inflammatory 
processes.
107
 
Moreover, the smallest oligosaccharides (n2–n9) might have unique effects, different from 
both low molecular weight as well as high molecular weight hyaluronan. The tetrasaccharide 
(n2) was shown to induce heat shock protein 72 (Hsp72) and to suppress apoptosis under 
stress conditions.
126
 By contrast, oligosaccharides of 3–9 disaccharide units (n3–n9) were 
reported to trigger apoptosis in cancer cells.
127
 Thereby, these small oligosaccharides are 
thought to inhibit kinase activity, resulting from polyvalent binding of larger oligosaccharides 
and high molecular weight hyaluronan to cellular receptors, by competitive monovalent 
binding.
127, 128
 
In view of these putative size-dependent effects, the importance of analytical methods for 
the determination of hyaluronan, hyaluronan oligosaccharides, and the enzymological 
particularities of the enzymes of hyaluronan metabolism (especially hyaluronidases) 
becomes obvious. 
1.3 Analytical approaches to the study of hyaluronan, hyaluronan 
oligosaccharides, and hyaluronidases 
1.3.1 Conventional methods 
Meyer reviewed the hyaluronidase activity assays of his time and sorted them into 
biological, physicochemical, and chemical methods.
129
 This classification was adopted for the 
conventional assays described below. Some of them, especially the biological assays, appear 
rather exotic and old-fashioned nowadays.  
One typical biological assay, determines the spreading effect of hyaluronidase on co-
administered dyes due to increased permeability of animal skin.
130
 The method is based on 
the observation that extracts from mammalian testes contain a “spreading factor”,
131
 which 
was made long before this “spreading factor” was identified as hyaluronidase.
132, 133
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Interestingly, comparable results were obtained from the spreading assay developed by 
Jaques in 1952
134
 and physicochemical in vitro assays.
135
 A second biological assay, 
measuring the degradation of the capsules of Streptococci,
136, 137
 may also be considered 
obsolete. 
The mucin clot prevention tests is an example of a physicochemical method.
129
 In acidic 
solutions, hyaluronan and protein form fibrous clots, whereas flocculent or no precipitate is 
obtained after incubation with hyaluronidase, depending on the degree of digestion.
138-140
 
The spinnability method determines the destruction of the spinnability of dialyzed bovine 
synovial fluid by hyaluronidase, requiring a special apparatus for measurement of the length 
of the fiber which can be produced under defined conditions.
141
 Both methods are 
unfavorable with regard to convenient and quantitative determination of hyaluronidase 
activity. Thus, they are no longer used today. 
A conventional physicochemical method, which is still common for the measurement of 
hyaluronidase activity and for the estimation of the average molecular weight of hyaluronan, 
is viscosimetry. In 1940, Madinaveitia and Quibell published a method measuring the 
reduction of viscosity of extracts from vitreous humor by testicular extracts using an Ostwald 
viscosimeter.
142
 Meyer describes this method as very accurate.
129
 However, values for 
hyaluronidase activity determined by viscosimetry depend on the initial viscosity of the 
substrate solution, which is influenced by the average molecular weight of hyaluronan.
143
 
Nevertheless, due to the fast initial reduction of viscosity by mammalian hyaluronidases, the 
determination of hyaluronidase activity using an Ubbelohde viscosimeter was found to 
outperform the sensitivity of turbidimetry and colorimetry by a factor of 10.
33
 For this 
reason, viscosimetry was recently used to determine the low activity of Hyal-2 in human 
platelets.
75
 However, to obtain solutions with sufficient viscosity, hyaluronan must be 
present at relatively high concentrations. Moreover, viscosimetry is only applicable to high 
molecular weight hyaluronan of approximately 1500 disaccharide units and above. 
Determination of low molecular weight hyaluronan or hyaluronan oligosaccharides is not 
possible. Finally, the sensitivity of viscosimetry strongly depends on the type of 
hyaluronidase, as the decrease in viscosity per cleavage step is much more pronounced with 
the random mode of action observed for mammalian enzymes than for processive exolytic 
degradation by the bacterial hyaluronidases.
144
 
The turbidimetric assay can be considered as a standard physicochemical assay for the 
determination of hyaluronidase activity and enzyme inhibition. This relatively old approach 
was first described by Kass and Seastone in 1944, who observed precipitation of high 
molecular mass hyaluronan (but not enzymatically digested material) after addition of 
acidified horse serum.
145
 Subsequently, different modifications, using serum of other sources 
or purified protein fractions, were reported.
129, 146-150
 With regard to the assay described by 
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Meyer,
129
 saccharides of more than 6–8 kDa were reported to cause precipitation.
151
 Today, 
quaternary ammonium salts with long lipophilic chains are preferably used instead of serum 
or serum proteins. Typical reagents are cetyltrimethylammonium bromide
152
 or 
cetylpyridinium chloride.
153
 In this work, a miniaturized version of the turbidimetric assay by 
Di Ferrante
152
 is used. 
The reducing ends resulting from the cleavage of the carbohydrate polymer by 
hyaluronidase activity were often determined using conventional chemical assays for 
reducing sugars.
129, 151
 However, a more specific approach is the determination of the 
N-acetyl-D-glucosamine moiety at the reducing end. In 1933, Elson and Morgan described 
the colorimetric determination of glucosamine and chondrosamine (galactosamine) using an 
acidic solution of p-dimethylaminobenzaldehyde (Ehrlich’s reagent).
154
 One year later, the 
authors reported on a modification of this assay with regard to the corresponding 
N-acetylated hexosamines.
155
 With regard to this article, the method is commonly referred 
to as “Morgan-Elson reaction” or “Morgan-Elson assay”. Reissig et al., further optimized the 
assay.
156
 This modified version, basically, is the one which is still frequently used today. 
Additional alterations of the protocol were described later, especially aiming at 
determination of hyaluronidase activity in serum or plasma.
157, 158
 More recent modifications 
additionally considered the turbidity component of the extinction caused by protein in the 
samples
159
 or used sensitive fluorescence measurement alternatively.
160
 
For quantification of hyaluronan and hyaluronan oligosaccharides with regard to the uronic 
acid content, the carbazole assay can be used.
161, 162
 If the respective amount of reducing 
N-acetyl-D-glucosamine ends is known (e. g. from Morgan-Elson reaction), the average chain 
length can also be calculated by combination of data from both assays. However, no 
information on size distribution is obtained by all chemical assays.  
1.3.2 Chromatographic methods 
Chromatographic techniques were already used in the very early days of hyaluronan 
research. In their first report on the chemical structure of hyaluronan, Weissmann et al. 
described paper chromatography and ion exchange chromatography of hyaluronan 
oligosaccharides for both preparative and analytical purposes.
3
  
Although still used, planar chromatography is less popular with regard to the analysis of 
hyaluronan oligosaccharides today. Only a few articles describe thin layer chromatography 
(TLC) on silica plates with post-chromatographic derivatization
163-166
 or, more recently, 
coupling to time-of-flight mass spectrometry (TOF-MS) using matrix assisted laser desorption 
ionization (MALDI).
164
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Liquid chromatography of hyaluronan oligosaccharides is mainly based on ion exchange, 
using silica-based (in part polymer-coated) amine columns
34, 42, 144, 167, 168
 or different 
polymer-based anion exchange resins as stationary phases.
168-171
 Detection of the analytes 
can be achieved by far-UV absorbance
34, 42, 144, 167, 168, 172
 or pulsed amperometric detection 
(PAD).
169-171
 Gel permeation chromatography (size exclusion chromatography) is often used 
for preparation of purified hyaluronan oligosaccharides.
35, 42, 114, 168, 170-172
 Nevertheless, gel 
permeation chromatography was also applied to kinetic studies on hyaluronan degradation 
by hyaluronidase.
173
 A different approach, using reversed-phase ion pair HPLC, was chosen 
by Cramer and Bailey for studies on BTH and its products.
36, 174
 
1.3.3 Electrophoretic methods 
Electrophoretic methods for the analysis of hyaluronan can be grouped into gel 
electrophoretic and capillary electrophoretic methods.  
The degradation of hyaluronan by Hyal-2, resulting in products of a molecular weight of 
approximately 20 kDa, was often studied by agarose gel electrophoresis.
72, 175, 176
 
Oligosaccharides were thereby visualized with Stains-All, giving diffuse bands due to the 
polydispersity of analytes.
72, 175, 176
 A higher resolution can be obtained by polyacrylamide gel 
electrophoresis (PAGE).
75, 114, 177, 178
 West et al. used radioactive oligosaccharides.
114
 The 
more recent protocols applied a combined alcian blue/silver staining.
75, 177, 178
 Depending on 
the gel size and the exact protocol, oligosaccharides of 8–100 (n8–n100)
177
 or 5–50 (n5–n50)
178
 
disaccharide units, respectively, gave distinct bands. Hence, gel electrophoresis is extremely 
valuable for medium-sized oligosaccharides of more than approximately 25 disaccharide 
moieties, as almost every other method is insufficient with regard to this size range. A 
variant of gel electrophoresis of hyaluronan oligosaccharides is fluorophore-assisted 
carbohydrate electrophoresis, showing excellent sensitivity but requiring fluorescent-labeled 
analytes.
179-181
 
Gels can also be used to fill capillaries for capillary gel electrophoresis. This method is rarely 
applied to hyaluronan analysis.
182, 183
 In most cases, capillary zone electrophoresis (CZE) with 
UV detection is used. Some of the first applications of CZE to the analysis of hyaluronan were 
reported by Grimshaw et al., who analyzed the hyaluronan content of vitreous humor
184
 and 
synovial fluid.
185
 They also used CZE for the determination of oligosaccharides derived from 
various glycosaminoglycans.
186
 Pattanaargson et al. applied CZE to the measurement of 
hyaluronidase activity in animal venoms.
187
 Subsequently, many authors described CZE for 
analysis of hyaluronan samples or the characterization of hyaluronidases.
32, 35, 188-190
 
However, UV detection is not ideal for hyaluronan oligosaccharides. Hence, MS is an 
interesting alternative, which was already applied successfully.
191
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1.3.4 Other methods 
As described above, mass spectrometry is very frequently used after preparative purification 
or analytical separation of oligosaccharides (off-line or on-line).
40, 42, 164, 167, 168, 170-172, 191
 Apart 
from analysis of the steric structure of hyaluronan (cf. Section 1.1.1),
9, 10
 nuclear magnetic 
resonance (NMR) spectroscopy was also reported in the context of oligosaccharides from 
enzymatic
34, 144, 192
 or (preparative) chemical
192
 cleavage. Although comprising a separation 
by gel electrophoresis, zymography cannot clearly be termed an electrophoretic method, as 
the determination of hyaluronidase activity is based on the digestion of hyaluronan in the 
substrate-containing gel.
193-195
 A completely different approach to the determination of 
hyaluronidase activity is the ELISA-like assay developed by Stern and coworkers.
196-198
 
Although the list presented here is not exhaustive, most methods except for electrophoresis 
and chromatography do not provide information on the size-distribution of the substrates 
and products of hyaluronidases. Especially for small oligosaccharides, powerful, sensitive, 
and specific analytical approaches for many scientific problems concerning hyaluronan and 
hyaluronidases are still lacking.  
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2 Scope and objectives 
Hyaluronan and the corresponding degradation products, resulting from enzymatic cleavage 
of the polysaccharide by hyaluronidases, are supposed to influence various physiological and 
pathophysiological processes in a size-dependent manner. However, the biological relevance 
has not been unequivocally proven. Neither has the occurrence of the suggested 
hyalobiuronic acids of different degrees of polymerization in biological systems been 
confirmed, nor their concentration systematically determined. The hyaluronan turnover is 
depending on the balanced activity of both hyaluronan synthases and hyaluronidases. The 
enzymological characterization of hyaluronidase isoenzymes is compromised by the lack of 
suitable analytical methods for the determination of the polydisperse substrates as well as 
the reaction products.  
Aiming at elucidating the molecular mechanisms and the biological relevance of hyaluronan 
metabolism, this work was focused on sensitive and selective methods to complement the 
analytical toolbox in this field. Hence, appropriate techniques had to be developed and 
optimized, especially with regard to the determination of hyaluronan oligosaccharides. For 
this purpose, the most promising approaches were hyphenated chromatographic and 
electrophoretic methods.  
Another objective of this thesis was to explore the applicability of the new methods, in 
combination with conventional techniques, to (bio)analytical investigations of samples of 
different origin. Therefore, enzymological and biological studies of hyaluronidases and 
hyaluronan oligosaccharides in vitro and in biological matrices, e. g. synovial fluid, were 
envisaged. As minimal substrates were required for enzymological characterization of 
isoenzymes, chemically defined oligosaccharides had to be prepared and quantified. 
Exploring the enzymatic cleavage of hyaluronan oligosaccharides, we attempted to gain 
deeper insight into the catalytic mechanisms, accepted substrates, and product spectra 
produced by different hyaluronidase isoenzymes. 
Finally, focusing on the putative (patho)physiological role of hyaluronan, hyaluronan 
oligosaccharides, and hyaluronidases, the developed analytical methods had to be applied to 
complex samples. Furthermore, biological assays were expected to shed light on size-
dependent effects of hyaluronan and chemically defined hyaluronan oligosaccharides on 
processes such as cell migration, cell proliferation, wound healing, and angiogenesis. 
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3 CZE–ESI-TOF-MS for the fast analysis of small 
hyaluronan oligosaccharides 
Note: Prior to the submission of this thesis, parts of this chapter have already been published 
in cooperation with partners.
1
 In addition, parts of the concerted work, realized in the course 
of this collaboration, are already included in the PhD thesis submitted by Marco Grundmann 
in 2012.
2
 For detailed information on the nature of this collaboration, see also 
“Acknowledgements and declaration of collaborations”. 
3.1 Introduction 
Capillary electrophoresis with UV detection (CZE–UV) was used successfully by Grimshaw et 
al. for the analysis of different glycosaminoglycans and their degradation products
3
 as well 
as for the quantification of hyaluronan in biological material after digestion of the 
polysaccharide with hyaluronidases.
4, 5
 By contrast, Pattanaargson studied the action of 
venom hyaluronidases by capillary electrophoresis.
6
 Later on, capillary electrophoresis
7-11
 
and the related technique of capillary gel electrophoresis
12, 13
 were frequently applied to the 
analysis of hyaluronan. In our group, CZE–UV was previously used by Hofinger et al. for the 
analysis of hyaluronan oligosaccharides and hyaluronidase activity.
14, 15
 
However, due to the lack of suitable chromophores, UV detection of hyaluronan 
oligosaccharides is extremely difficult. Therefore, on-line coupling of separation techniques 
to mass spectrometry is a promising approach for glycosaminoglycan analysis. Recently, a 
review on this topic has been published by Zaia.
16
 Kühn et al. lately described methods for 
CE−MS analysis of hyaluronan oligosaccharides using coated capillaries and electrospray ion 
trap mass spectrometry.
17, 18
 Nevertheless, using these methods, migration times were 
apparently too long for fast at-line analysis. For this purpose, total analysis time (including 
sample pretreatment, injection protocol, and electrophoretic separation) should not exceed 
2–5 min. 
Thus, we decided to develop a fast capillary zone electrophoresis separation coupled to 
electrospray ionization time-of-flight mass spectrometry (CZE–ESI-TOF-MS). In order to 
improve separation efficiency and accelerate separation, optimization aimed at the use of 
short capillaries and high electric field strengths. Separations at high electric field strengths, 
often requiring special background electrolytes and experimental setups, have already been 
described for different analytical problems.
13, 19-23
 Additionally, other studies reported short 
capillaries to be of advantage.
24-28
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Finally, a method for a cationic model system, recently published by our cooperation 
partners, used capillaries with a length of 28 cm and inner diameters from 75 µm down to 
5 µm, applying electric field strength of 1.25 kV/cm.
29
 Under these conditions, extremely fast 
electrophoretic separations were achieved.
29
 On this basis, a similar method for the anionic 
hyaluronan oligosaccharides had to be established. Thereby, various parameters were 
optimized in different combinations. The relevant steps are presented in this chapter in a 
logical order. 
3.2 Materials and methods 
3.2.1 Oligosaccharide standards and sample preparation 
Standard oligosaccharides (n2–n4) of 2–4 hyalobiuronic acid moieties (oligoHA from Hyalose, 
Oklahoma City, OK, USA) were purchased from AMSBIO (Abingdon, UK). For CZE–UV a 
mixture of the standard analytes (100 µM each) was dissolved in 10-fold diluted background 
electrolyte containing the EOF marker (cf. Section 3.2.2). For mass spectrometric detection, 
water purified with a Milli-Q system (Millipore, Eschborn, Germany) was used as solvent for 
the analytes. In this case, the oligosaccharide concentration was 20 µM for method 
optimization.  
Hyalo-Oligo, a low molecular weight hyaluronan oligosaccharide mixture with an average 
molecular weight below 10 kDa, was kindly provided by Kewpie (also named Q. P. Corp., 
Tokyo, Japan). Samples from incubation mixtures containing buffer salts and bovine serum 
albumin (Serva, Heidelberg, Germany) were diluted 1:10 with purified water or aqueous 
solution of internal standard (cf. Section 3.2.2) prior to injection. No further pretreatment 
was necessary. 
3.2.2 EOF markers and internal standard 
For UV detection, 0.1% (v/v) of benzyl alcohol (Merck, Darmstadt, Germany) was added to 
the sample solution as a neutral marker of the electroosmotic flow (EOF). In case of CZE–MS 
of hyaluronan oligosaccharides, the choice of an appropriate EOF marker is complicated by 
the m/z range of the analytes. The marker substance has to be of similar molecular weight, 
soluble in the aqueous electrolyte system, uncharged under the separation conditions, and 
suitable for electrospray ionization. Rhodamine B (Figure 3.1), with its fixed positive charge 
and its acidic carboxylic group, was previously reported to be applicable as EOF marker 
having zero net charge at a pH between 8.3 and 9.0.
30
 Moreover, rhodamine B has a 
comparable molecular mass to small hyaluronan oligosaccharides. However, due to its 
structural properties, rhodamine B is ionizable only in the positive ESI mode. In contrast, 
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hyaluronan oligosaccharides were analyzed in the negative ESI mode. Therefore, polarity had 
to be changed during the run. As this step takes approximately 20 s, EOF marker and 
analytes could not be recorded simultaneously in one run under the optimized fast 
separation conditions. Nevertheless, rhodamine B was added to the oligosaccharide mixture 
at a final concentration of 1 µM to record the EOF when possible.  
 
Figure 3.1: Rhodamine B in the charge state under the pH conditions used for CZE–MS. Due to the fixed 
positive charge and the deprotonated carboxylic group at alkaline pH, the molecule has zero net charge. 
Similar difficulties affect the search for an internal standard. Aiming at short run times, the 
substance of choice should migrate faster towards the detector than the analytes. 
Otherwise, analyses would be unnecessarily prolonged. Therefore, acarbose (Bayer, 
Wuppertal, Germany) was used at a concentration of 90 µM. The molecule is depicted in 
Figure 3.2.  
 
Figure 3.2: Acarbose can be used as internal standard because of its favorable migration behavior and an exact 
mass close to the hyaluronan oligosaccharide analytes. 
More details on the use of acarbose as internal standard, especially for fast at-line analysis, 
are discussed below (cf. Section 3.3.8).  
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3.2.3 Preparation of the background electrolytes 
Ammonium acetate solutions were used as background electrolyte. Therefore, a stock 
solution of 1 M ammonium acetate (Merck, Darmstadt, Germany) in water, purified by a 
Milli-Q system (Millipore, Eschborn, Germany), was prepared and stored at 5 °C for a 
maximum period of one month. The background electrolyte was always prepared freshly by 
dilution of this solution with purified water and addition of concentrated ammonia solution 
(Merck, Darmstadt, Germany) for pH adjustment. Prior to use, the solution was filtrated 
through a Millex-GP 0.22 µm syringe filter unit (Merck-Millipore, Darmstadt, Germany). 
Solutions used with the automated Bio-Rad CZE–UV system were additionally degassed by 
centrifugation at 13000 × g for 10 min. 
3.2.4 Instrumentation, capillary material, and separation conditions for 
CZE–UV experiments 
For preliminary tests on background electrolyte composition, a Bio-Rad Biofocus 3000 
system (Bio-Rad, Munich, Germany) was used with UV detection at 200 nm. Separation was 
performed in a fused silica capillary (MicroQuartz, Munich, Germany) with an inner diameter 
of 50 µm, a total length of 75 cm, and an effective length (from injection position to detector 
window) of 70.4 cm. The apparatus was equipped with a liquid cooling system for controlling 
capillary temperature, operated with a mixture of water and methanol. Capillary as well as 
sampler carousels were always cooled to 15 °C. Prior to sample injection, the capillary was 
conditioned with 0.1 M sodium hydroxide solution (300 s), water (200 s), and background 
electrolyte (600 s). Afterwards, the oligosaccharide mixture was injected by pressure 
(20 psi · s) and separated at a constant voltage of 20 kV in normal polarity mode (injection at 
the anodic end, detector window next to the cathode). 
3.2.5 Instrumentation and capillary material for CZE–ESI-TOF-MS 
The general setup for CZE–ESI-TOF-MS experiments is schematically represented in Figure 
3.3. The optional water bath was used to regulate the temperature of incubation mixtures 
when analyzing enzymatic reactions. After appropriate sample preparation (dilution, 
addition of standard), injection was performed using a manual injection technique (cf. 
Section 3.2.7).  
Separation was carried out using a home-made CE system. A high voltage source (model 
HCN 7E-35000, FuG Elektronik, Rosenheim-Langenpfunzen, Germany) was linked to the vial 
containing the background electrolyte by an immersed platinum electrode. Equally, the 
proximal part of the fused silica capillary (Polymicro Technologies, Phoenix, AZ, USA), 
purchased from Optronis (Kehl, Germany), was dipped into the vial. Capillaries had an outer 
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diameter of 360 µm and inner diameters of 5, 10, 15, 20, or 50 µm, respectively. They were 
manually cut to appropriate lengths. High voltage was regulated with an external control 
unit which also served as remote control for data acquisition. 
 
Figure 3.3: General setup for CZE–ESI-TOF-MS: water bath at 37 °C for incubation mixtures (1), incubation vial 
(2), sample injection vial (3), background electrolyte (4), electrode (5), separation high voltage source (6), 
separation capillary (7), insulating box (8), interface (9), sheath liquid flow provided by a syringe pump (10), 
nebulizer gas (11), ESI high voltage source (12), mass detector (13). Processes: sample preparation (A), manual 
injection (B), electrophoretic separation (C), ionization (D), detection (E). 
An insulating box made of acrylic glass protected the operator from the high voltage. The 
distal part of the capillary was passed through a small notch in the acrylic glass box and 
coupled to a micrOTOF-MS (Bruker Daltonik, Bremen, Germany) by a coaxial sheath liquid 
sprayer (Agilent Technologies, Waldbronn, Germany). A constant flow of the sheath liquid 
(cf. Section 3.2.6) was provided by a syringe pump (model 601553, KD Scientific, Holliston, 
MA, USA) equipped with a 2.5 mL glass syringe (ILS, Stützerbach, Germany), both not 
depicted in Figure 3.3. It should be noted that, using the ground as part of the ESI high 
voltage circuit, the ESI high voltage source (number 12) depicted in Figure 3.3 was set 
positive for negative ionization mode and vice versa. 
For long capillaries with an inner diameter of 50 µm, cooling with pressurized nitrogen (using 
an additional silicone tube around the capillary) was found to be advantageous to reduce 
Joule heating. For the short capillaries used in most of the experiments, however, cooling 
was neither necessary nor possible. Resistive heating was low under these conditions and a 
significant part of the capillary was then encased by the MS interface. 
3.2.6 Sheath liquid, MS parameter settings, and mass calibration 
As results of preliminary optimization experiments on ionization and sheath liquid 
composition, negative ionization mode and an acidic sheath liquid were chosen for MS 
coupling. Although for acidic analytes a basic sheath liquid seems reasonable, the addition of 
acid was found to be beneficial. In detail, the mixture consisted of 2-propanol (HPLC–MS 
grade, Carl Roth, Karlsruhe, Germany), water (purified with an Astacus system, MembraPure, 
Bodenheim, Germany), and formic acid (Merck, Darmstadt Germany) at a ratio of 50:50:0.2 
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(v/v/v). The flow rate of the sheath liquid was 8 µL/min. An overview of the instrumental 
settings for mass spectrometry during method optimization (standard) and later 
modifications is provided in Table 3.1.  
Depending on the m/z of the respective analytes, different procedures for mass calibration 
were chosen. For standard calibration (analytes with m/z below approximately 1300), 
sodium formate clusters were used. Using capillaries with inner diameters of 25 µm and 
below, signal intensities of the clusters formed by sodium formate solution were too low for 
mass calibration. Therefore, the reference clusters were formed in situ by forced injection of 
1 M sodium hydroxide solution, prepared from 50% sodium hydroxide solution (Sigma-
Aldrich, Munich, Germany), in combination with the formic acid content of the sheath liquid. 
For single experiments focusing on oligosaccharides with higher molecular mass, cesium 
perfluoroheptanoic acid clusters were used.
31
 For this purpose, a calibration solution was 
prepared from perfluoroheptanoic acid and cesium hydrogen carbonate, both from Sigma-
Aldrich (Munich, Germany).  
For all analytes, extracted ion traces were calculated from the recorded mass spectra. 
Thereby, only m/z values having an abundance of at least 20% of the base peak were 
summed up. This procedure gave reproducible results and best signal-to-noise ratios. When 
significant formation of adduct species, mainly sodium adducts, was observed, the signals 
were included in the extracted ion traces under the same rule. 
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Table 3.1: MS parameter settings. The standard method settings were used for optimization of CZE conditions. 
Later on, some parameters were modified for the analysis of large and small oligosaccharides. 
 Standard method Modification 1  
(large oligosaccharides) 
Modification 2  
(small oligosaccharides) 
Source    
Ionization, polarity ESI, negative  
(positive for EOF marker) 
ESI, negative ESI, negative 
Scan range (m/z) 300–3000 300–3000 300–1200 
Capillary (V) 5000 4500 5000 
End plate offset (V) −500 −500 −500 
Nebulizer (bar) 1.0 1.0 1.2 
Dry heater (°C) 190 190 190 
Dry gas (L/min) 4.0 4.0 4.0 
Ion optics    
Capillary exit (V) −100.0 −100.0 −100 
Skimmer 1 (V) −33.0 −33.0 −33.0 
Hexapole 1 (V) −22.5 −22.5 −22.5 
Skimmer 2 (V) −22.0 −22.0 −22.0 
Hexapole 2 (V) −20.5 −20.5 −20.5 
Hexapole RF (V) 800.0 800.0 300.0 
Transfer time (µs) 113.0 49.0 40.0 
Pre pulse storage (µs) 20.0 10.0 10.0 
Lens 1 storage (V) −30.0 −30.0 −30.0 
Lens 1 extraction (V) −20.8 −20.8 −20.8 
Lens 2 (V) −14.0 −8.0 −8.0 
Lens 3 (V) 20.0 20.0 20.0 
Lens 4 (V) −10.0 0.0 0.0 
Lens 5 (V) −5.0 28.5 28.5 
Data acquisition    
Spectra rate (Hz) 5 or 10 10 10 
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3.2.7 Manual sample injection 
Unlike the automated sample injection in CZE–UV experiments (cf. Section 3.2.4), a manual 
sample injection technique was applied with the CZE–ESI-TOF-MS assembly.
29
 In summary, 
the proximal end of the separation capillary was manually dipped into the sample solution 
for a defined time interval and then removed back to the vial containing the background 
electrolyte. Before, the laminar flow through the capillary, which is caused by the suction 
pressure created at the ESI-MS interface, was determined for each capillary. From these 
experiments, the time of capillary immersion needed for filling an injection zone of desired 
length could be calculated. With capillary diameters of 15 µm or below, however, the 
reduced laminar flow would lead to a drastic prolongation of the injection process. 
Therefore, sealed sample vials were additionally pressurized by injection of a defined volume 
of air using a syringe. 
3.3 Results and discussion 
3.3.1 Preliminary tests using CZE–UV 
Starting with conditions adapted from previously described CZE–UV methods for hyaluronan 
oligosaccharide analysis,
14, 15
 the background electrolyte had to be altered to a volatile 
system with regard to CZE–MS coupling. Therefore, ammonium acetate solutions of various 
pH values (Figure 3.4) and salt concentrations (Figure 3.5) were compared using UV 
detection at 200 nm. The electropherograms clearly indicated an increase in migration times 
of the analyte peaks with decreasing pH and increasing salt concentration. At high pH, 
however, the separation efficiency was negatively affected. For this reason, a pH of 8.5 was 
chosen as starting point for further optimization as a compromise. Ammonium acetate 
concentration was kept below 100 mM in CZE–MS experiments, starting with 25 mM. 
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Figure 3.4: CZE–UV experiment using 100 mM ammonium acetate solutions with pH values of 8.0 (A), 8.3 (B), 
8.5 (C), 8.7 (D), and 9.0 (E) as background electrolytes. Oligosaccharide standards at 100 µM, EOF marked by 
benzyl alcohol. Fused silica capillary with a total length of 75 cm, an effective length of 70.4 cm, and an inner 
diameter of 50 µm. Separation voltage: 20 kV. Capillary temperature: 15 °C. UV detection at 200 nm.   
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Figure 3.5: CZE–UV experiment using 50 mM (A), 100 mM (B), and 150 mM (C) ammonium acetate background 
electrolytes, all adjusted to a pH of 8.5. Oligosaccharide standards at 100 µM, EOF marked by benzyl alcohol. 
Fused silica capillary with a total length of 75 cm, an effective length of 70.4 cm, and an inner diameter of 
50 µm. Separation voltage: 20 kV. Capillary temperature: 15 °C. UV detection at 200 nm. 
3.3.2 Optimization of the injection zone length 
The first parameter to be examined was the length of the injection zone. Using the manual 
injection technique described in Section 3.2.7, the capillary was dipped into the sample vial 
for 10, 20, or 40 s. Under the conditions of this particular experiment, these intervals 
corresponded to injection zones of 0.7%, 1.4%, or 2.9% of the total capillary length (Figure 
3.6). The electropherograms clearly demonstrated that, within the investigated range, no 
adverse effects on peak shape and separation were observed when the capillary was filled 
with sample to a higher percentage. As injection was only driven by the suction pressure, the 
time interval needed for the injection process naturally increases in parallel with the desired 
injection zone. The effect was even more prominent when the inner diameter of the 
capillary was reduced. However, prolongation of the time period required for injection, was 
in conflict with the aim of short run times allowing for fast at-line analysis. Hence, 2% of the 
capillary were filled with the sample solution in the following experiments. It should be 
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noted at this point that, keeping this relative value (percentage of respective capillary 
length) constant, any change in capillary length or inner diameter affects the total volume 
and thus the amount of analyte injected. 
 
Figure 3.6: Variations in the duration of the injection interval and the corresponding sample zone lengths (given 
as percentage of the total capillary length). Oligosaccharide standards at 20 µM, rhodamine B (EOF marker) at 
1 µM. Fused silica capillary with a total length of 75 cm and an inner diameter of 50 µm. Background 
electrolyte: 25 mM ammonium acetate solution, pH = 8.5. Separation voltage: 35 kV. Spectra rate: 5 Hz. 
Electropherograms show extracted ion traces. 
3.3.3 Capillary length and electric field strength 
Using special experimental setups, extremely high voltages can be applied.
13, 20, 23
 However, 
in view of limitations in maximum voltage provided by common high voltage sources, further 
increase in field strength can only be achieved by reducing capillary length. Therefore, 
capillaries of 75, 50, 43, 30, and 28 cm, respectively, were compared, applying a constant 
separation voltage of 35 kV (Figure 3.7).  
0 1 2 3 4 5 6 7 8
0
5000
10000
15000
EOF
n2
n
3
n4
A 10 s
0.7%
0 1 2 3 4 5 6 7 8
S
ig
n
a
l 
in
te
n
si
ty
 (
co
u
n
ts
)
0
5000
10000
15000
B 20 s
1.4%
Migration time (min)
0 1 2 3 4 5 6 7 8
0
5000
10000
15000
C 40 s
2.9%
40 3 CZE–ESI-TOF-MS for the fast analysis of small hyaluronan oligosaccharides 
 
 
Figure 3.7: Increase in electric field strength from 0.47 kV/cm (A) to 1.25 kV/cm (E) by stepwise reduction of 
capillary length from 75 cm (A) to 28 cm (E). Oligosaccharide standards at 20 µM, rhodamine B (EOF marker) at 
1 µM. Injection zone: 2% of the capillary. Fused silica capillaries with an inner diameter of 50 µm. Background 
electrolyte: 25 mM ammonium acetate solution, pH = 8.5. Separation voltage: 35 kV. Spectra rate: 5 Hz. 
Reproduced and adapted from Fig. 2 of the original publication
1
 with kind permission from Springer Science 
and Business Media.  
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Further reduction of capillary length was not feasible using the interface for MS coupling and 
the manual injection technique. Otherwise, the part of the capillary outside the interface 
would have been too short for manual handling. 
The stepwise reduction of capillary length led to considerably shorter migration times of less 
than 90 s instead of approximately 7 min. Moreover, peaks were sharpened by high electric 
field conditions. As a result, separation efficiency deteriorated only slightly. However, signal 
intensities were influenced in different ways when reducing the length of the capillary 
stepwise. Initially, peak heights increased due to peak sharpening, followed by slightly 
decreasing peak heights because of the reduced amount of analyte injected (cf. Section 
3.3.2). Finally the combination of both effects led to constant peak heights. 
3.3.4 Capillary inner diameter 
Recent studies demonstrated the beneficial effect of reduced capillary inner diameters on 
separation efficiency.
29
 Consequently, inner diameters of 50, 25, 15, 10, and 5 µm were 
compared (Figure 3.8). Peaks were sharpened, resulting in constant heights from 50 µm 
down to 15 µm inner diameter. Remarkably, this constancy in signal intensity was achieved 
despite of a reduction of the injected sample volume by a factor of 11. However, according 
to the quadratic correlation between radius and volume, further reduction led to 
considerably lower signal intensities. It should be noted that, as a consequence of the 
narrow and sharp peaks, a data acquisition rate of 5 Hz was insufficient for capillaries with 
inner diameters of 10 and 15 µm. For this reason, the spectra rate was increased to 10 Hz. By 
this change, signal intensities were halved at constant signal-to-noise ratio. Therefore, the 
scaling of the ordinate axes in Figure 3.8 was adapted for better comparability.  
In summary, separation efficiency and peak resolution were improved when using capillaries 
of smaller inner diameters. Thereby, 15 µm was the smallest diameter showing no significant 
loss in sensitivity. Accordingly, capillaries with an inner diameter of 15 µm and a length of 
28 cm were chosen for the following evaluation of background electrolyte composition. To 
obtain a sufficient number of data points for peak calculation, spectra rate of the MS 
detection was set to 10 Hz for future experiments. 
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Figure 3.8: Comparison of capillaries with inner diameters of 50 µm (A), 25 µm (B), and 15 µm (C) at a spectra 
rate of 5 Hz. Data acquisition rate was changed to 10 Hz for 10 µm (D) and 5 µm (E) capillaries. Therefore, the 
ordinate axes of the electropherograms were adapted. Oligosaccharide standards at 20 µM, rhodamine B (EOF 
marker) at 1 µM. Injection zone: 2% of the capillary. Fused silica capillaries with a length of 28 cm. Background 
electrolyte: 25 mM ammonium acetate, pH = 8.5. Separation voltage: 35 kV. Reproduced and adapted from 
Fig. 3 of the original publication
1
 with kind permission from Springer Science and Business Media. 
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3.3.5 Concentration and pH of the background electrolyte 
Having started with experiments on the composition of the background electrolyte using 
CZE–UV (cf. Section 3.3.1), things have come full circle at this point of parameter 
optimization. In this section, background electrolytes of different concentrations (Figure 3.9) 
and pH values (Figure 3.10) are compared under CZE–MS conditions.  
 
Figure 3.9: Comparison of background electrolytes of 10 mM (A), 25 mM (B), 50 mM (C), and 100 mM (E) 
ammonium acetate, all adjusted to a pH of 8.5 by addition of ammonia. Oligosaccharide standards at 20 µM. 
Injection zone: 2% of the capillary. Fused silica capillary with a length of 28 cm and an inner diameter of 15 µm. 
Separation voltage: 35 kV. Spectra rate: 10 Hz. Reproduced and adapted from Fig. 4 of the original publication
1
 
with kind permission from Springer Science and Business Media. 
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Figure 3.10: Comparison of background electrolytes adjusted to pH values of 7.0 (A), 7.5 (B), 8.0 (C), 8.5 (D), 
and 9.0 (E), ammonium acetate concentration was 25 mM. Oligosaccharide standards at 20 µM. Injection zone: 
2% of the capillary. Fused silica capillary with a length of 28 cm and an inner diameter of 15 µm. Separation 
voltage: 35 kV. Spectra rate: 10 Hz. Reproduced and adapted from Fig. 5 of the original publication
1
 with kind 
permission from Springer Science and Business Media.  
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Owing to low inner diameter and short length of the capillary, a broad concentration range 
of the background electrolyte can be used at high electric field strengths without running the 
risk of extensively high currents. Nevertheless, Figure 3.9 illustrates a decrease in signal 
intensities and significant peak broadening with 50 mM and 100 mM ammonium acetate. 
This unexpected effect seems to arise from resistive heating. In contrast, an interaction of 
ions of the background electrolyte with the mass spectrometric detection of the analyte 
anions seems less probable with regard to constant peak areas. At ammonium acetate 
concentrations of 10 mM and 25 mM, no difference in signal intensities was observed. 
Providing a higher buffer capacity, 25 mM ammonium acetate solution was chosen as 
background electrolyte.  
Comparison of different pH values, depicted in Figure 3.10, confirmed the findings from the 
respective CE–UV experiment (cf. Figure 3.4). Increasing pH values resulted in higher signal 
intensities and shorter migration times, whereas separation efficiency was reduced. Thus, 
the choice of a pH value of 8.5 as compromise, already described in Section 3.3.1, was 
corroborated.  
3.3.6 Characterization of the optimized method 
According to the results of the CZE optimization, a 15 µm × 28 cm capillary and a background 
electrolyte of 25 mM ammonium acetate at a pH = 8.5 were chosen for further 
characterization. Under these conditions, mixtures containing 1, 2, 4, 10, 20, and 40 µM of 
each of the three standard oligosaccharides (n2–n4) were separated. Five consecutive 
separations were conducted for each concentration. As a result, linear calibration curves 
were obtained with coefficients of determination (R²) in a range of 0.993–0.997 for the three 
standard substances. Limit of detection (LOD) and limit of quantification (LOQ) were 
estimated from the signal-to-noise ratio (S/N) of the lowest concentration measured. From 
the average S/N for 1 mM standard oligosaccharide mixture, LOD and LOQ were calculated 
as S/N = 3 and S/N = 10, respectively. Exact values are listed in Table 3.2.  
Although concentration ranges of 0.46–0.76 µM for LOD and 1.54–2.54 µM for LOQ seem 
rather high at first sight, the injection volume should be considered. For an injection zone of 
2% of the total capillary length and this particular capillary, the volume of the sample can be 
calculated as a cylinder with a radius of 7.5 µm and a height/length of 5.6 mm. Accordingly 
990 pL were injected. In view of this extremely low sample volume, the concentrations for 
LOD and LOQ can be converted into absolute amounts of 0.46–0.75 fmol and 1.53–
2.51 fmol, respectively. Hence, CZE–ESI-TOF-MS is perfectly suited for the analysis of small 
sample volumes but disadvantageous for the investigation of highly diluted samples. 
46 3 CZE–ESI-TOF-MS for the fast analysis of small hyaluronan oligosaccharides 
 
Additionally, the repeatability of the method was examined. With regard to the migration 
times, values for all 30 separations performed for linearity studies were included. Mean and 
standard deviation for peak heights and peak areas, in contrast, were calculated from 5 
consecutive measurements using a 1 µM solution of the standard analytes. These results are 
also shown in Table 3.2. An interesting detail is the relatively high standard deviation for 
peak height and peak area of n3 in comparison to the other oligosaccharides. This can be 
explained by the observation of two differently charged species ([M−H]
−
 and [M−2H]
2−
 ions) 
for the hexasaccharide. The ratio of the two ions, which are detected with different 
sensitivity, shows certain variability. 
Table 3.2: Limit of detection, limit of quantification, calibration parameters, and repeatability of the optimized 
CZE−ESI-TOF-MS method (nx: oligosaccharides consisting of x hyalobiuronic acid moieties). 
 n2 n3 n4 
LOD, LOQ, calibration parameters    
Limit of detection, LOD, S/N = 3,  
given as sample concentration (µM) 
0.76 0.52 0.46 
Limit of detection, LOD, S/N = 3,  
given as total amount injected (fmol) 
0.75 0.51 0.46 
Limit of quantification, LOQ, S/N = 10,  
given as sample concentration (µM)  
2.54 1.72 1.54 
Limit of quantification, LOQ, S/N = 10,  
given as total amount injected (fmol) 
2.51 1.71 1.53 
Linear range investigated,  
given as sample concentration (µM) 
1–40 1–40 1–40 
Coefficient of determination, R² 0.997 0.997 0.993 
Repeatability    
Migration time (s): mean ± SD (RSD), N = 30 44.30 ± 0.39 
(0.88%) 
46.69 ± 0.45 
(0.96%) 
48.17 ± 0.50 
(1.04%) 
Peak height (counts): mean ± SD (RSD),  
standards at 10 µM, N = 5  
1936 ± 136 
(7.02%) 
2992 ± 430 
(14.37%) 
3727 ± 108 
(2.90%) 
Peak area (counts · s): mean ± SD (RSD),  
standards at 10 µM, N = 5  
637.4 ± 68.5 
(10.75%) 
1070.3 ± 221.2 
(20.67%) 
1360.8 ± 79.2 
(5.82%) 
 
It should be emphasized that migration times of all three standard oligosaccharides were 
less than 50 s, although the anionic analytes show counter-electroosmotic migration. 
Therefore, the method promised to allow for high throughput as well as fast at-line analysis 
of hyaluronidase action. 
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3.3.7 Application to a complex hyaluronan oligosaccharide mixture 
For optimization purposes, a mixture of three defined standard oligosaccharides of 2–4 
hyalobiuronic acid moieties had been used. To assess the newly developed method for its 
ability for separation and detection of a broad variety of hyaluronan oligosaccharides, a 
complex mixture (Hyalo-Oligo) was analyzed. A concentrated solution of the mixture was 
injected and separated as described but using a 25 µm instead of a 15 µm capillary. For 
unknown samples, the expected m/z cannot be predicted. The most feasible approach to 
this problem is the visualization of the results in a density plot. Therein, mass-to-charge 
ratios are plotted versus migration time. The intensity of each signal is reflected by a color 
scale. A density plot for the oligosaccharide mixture, including assignment of the detected 
signals, is depicted in Figure 3.11. 
 
Figure 3.11: Density plot visualizing the separation of a complex mixture of hyaluronan oligosaccharides. CZE 
conditions: 25 µm × 28 cm capillary, ammonium acetate background electrolyte (25 mM, pH = 8.5), 35 kV. 
Analytes are designated according to the number of disaccharide units and charge state. Black: normal 
oligosaccharides consisting of an integer number of hyalobiuronic acid moieties. Grey: oligosaccharides lacking 
one N-acetyl-D-glucosamine moiety. Green: oligosaccharides with an additional ethyl substitution in two series 
(light and dark green). Orange and brown: two series of di-ethylated species. 
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In this mixture, multiple homologous series of hyaluronan oligosaccharide species were 
identified in charge states from −1 to −4. As expected, the most prominent signals 
corresponded to the normal oligosaccharides consisting of an integer number (namely 2–20) 
of disaccharide units (cf. Figure 3.11, black rectangles). However, to a certain extent, 
additional species were detected. Some oligosaccharides consisted of an odd number of 
monosaccharides, lacking an N-acetyl-D-glucosamine moiety (cf. Figure 3.11, grey 
rectangles). Probably due to the increased relative content of negatively charged glucuronic 
acid moieties, these substances showed faster migration against the electroosmotic flow, 
compared to the respective even-numbered oligosaccharides.  
The opposite effect was observed for the mono- (cf. Figure 3.11, light and dark green 
rectangles) and di-ethylated (cf. Figure 3.11, orange and brown rectangles) oligosaccharides 
present in the mixture, possibly due to esterification. Interestingly, species of both 
ethylation states (mono- and di-ethylated) each gave two series of signals, marked in 
different colors. Mass spectra of the corresponding signals from these two series showed no 
differences. Consequently, it may be assumed that variations in migration times originate 
from different hydrodynamic radii, depending on the respective position of ethylation. In 
spite of many benefits of ESI-TOF-MS with regard to the challenging detection of hyaluronan 
oligosaccharides, this particular mass spectrometric detection is insufficient to discriminate 
between isomers. Nevertheless, the existence of isomers in the mixture was proven by 
combination with a complementary separation method (CZE). Hence, this example clearly 
illustrates the advantages of hyphenated techniques. 
3.3.8 Acarbose as internal standard for at-line analysis 
Aiming at fast qualitative and quantitative at-line monitoring of hyaluronan and hyaluronan 
degradation by hyaluonidases, an internal standard had to be selected. Acarbose was found 
to be a suitable reference (cf. Section 3.2.2). Preliminary experiments (not shown) suggested 
a 1:10 dilution of incubation mixtures with water to avoid peak broadening caused by high 
ionic strength of the sample. Further pretreatment of the samples containing buffer salts 
and bovine serum albumin (cf. Chapter 6 for details) was unnecessary. Therefore, the 
following studies explored the effect on separation when using a 100 µM solution of 
acarbose instead of water for the dilution of the analytes (Figure 3.12). To allow for a fast 
pressure-free injection protocol, a capillary with an inner diameter of 25 µm was used. 
Firstly, the standard oligosaccharides were injected in aqueous solution (Figure 3.12 A). 
Secondly, acarbose was added at a final concentration of 90 µM (Figure 3.12 B). Thirdly, a 
typical incubation buffer was added at a concentration equal to a 1:10 dilution of an aliquot 
from a real incubation mixture (Figure 3.12 C). Finally, this experiment was repeated using 
MS parameter settings optimized for small oligosaccharides (Figure 3.12 D). For each series, 
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ten consecutive injections were carried out (N = 10). One representative electropherogram 
from each series is depicted.  
 
Figure 3.12: Acarbose (90 µM) as internal standard. Oligosaccharides (n2–n4) at a concentration of 16.7 µM. 
Injection (2% of capillary length): aqueous solution (A), additionally containing acarbose (B), containing both 
acarbose and incubation buffer (C, D). Experiment D was performed with MS parameters optimized for m/z 
values of small oligosaccharides. Separation conditions: 25 µm × 28 cm capillary, ammonium acetate 
background electrolyte (25 mM, pH = 8.5), 35 kV. 
Apparently, neither the addition of acarbose as internal standard nor the matrix components 
from the incubation mixtures affected the separation and detection of the oligosaccharides. 
The internal standard was well separated from the analyte peaks. Moreover, the short 
migration time of acarbose, compared to the analytes, is of paramount importance with 
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regard to fast analysis. Hence, the total run time is not prolonged by using this substance as 
internal standard. In the following step, standardization was achieved by dividing peak 
heights and peak areas by the respective value for the acarbose peak. Means, standard 
deviations, and relative standard deviations were calculated (Table 3.3).  
Table 3.3: Acarbose as internal standard. Standardization of peak height and peak area. Experiments from 
Figure 3.12: aqueous solution (A), additionally containing acarbose (B), containing both acarbose and 
incubation buffer (C, D). Experiment D was performed with MS parameters optimized for small 
oligosaccharides. Each series consisted of 10 consecutive injections (N = 10). 
 A (N = 10) B (N = 10) C (N = 10) D (N = 10) 
Tetrasaccharide (n2)     
Height (counts): 
mean ± SD (RSD) 
1742 ± 123  
(7.05%) 
1705 ± 159  
(9.34%) 
1453 ± 84  
(5.81%) 
2316 ± 265  
(11.42%) 
Height ratio:  
mean ± SD (RSD) 
― 0.51 ± 0.04  
(8.40%) 
0.34 ± 0.02  
(7.19%) 
0.37 ± 0.05  
(12.55%) 
Area (counts · s):  
mean ± SD (RSD) 
618 ± 50  
(8.07%) 
612 ± 38  
(6.13%) 
591 ± 54  
(9.18%) 
1043 ± 125  
(12.00%) 
Area ratio:  
mean ± SD (RSD) 
― 0.19 ± 0.01  
(5.44%) 
0.22 ± 0.02  
(10.14%) 
0.22 ± 0.02  
(8.46%) 
Hexasaccharide (n3)     
Height (counts) 
mean ± SD (RSD) 
1276 ± 372  
(29.14%) 
1267 ± 168  
(13.27%) 
1278 ± 198  
(15.51%) 
2719 ± 353  
(12.99%) 
Height ratio:  
mean ± SD (RSD) 
― 0.38 ± 0.05  
(12.57%) 
0.29 ± 0.03 
(10.70%) 
0.43 ± 0.05  
(12.33%) 
Area (counts · s):  
mean ± SD (RSD) 
772 ± 62  
(8.03%) 
781 ± 60  
(7.74%) 
748 ± 55  
(7.32%) 
1786 ± 231  
(12.91%) 
Area ratio:  
mean ± SD (RSD) 
― 0.24 ± 0.02  
(6.21%) 
0.28 ± 0.02  
(7.98%) 
0.37 ± 0.03  
(7.39%) 
Octasaccharide (n4)     
Height (counts):  
mean ± SD (RSD) 
2075 ± 271  
(13.04%) 
2373 ± 211  
(8.88%) 
2175 ± 262  
(12.03%) 
4047 ± 431  
(10.65%) 
Height ratio:  
mean ± SD (RSD) 
― 0.71 ± 0.07  
(9.50%) 
0.50 ± 0.06  
(11.14%) 
0.65 ± 0.07  
(10.54%) 
Area (counts · s): 
mean ± SD (RSD) 
1248 ± 136  
(10.92%) 
1330 ± 102  
(7.69%) 
1201 ± 90  
(7.53%) 
2063 ± 243  
(11.79%) 
Area ratio:  
mean ± SD (RSD) 
― 0.41 ± 0.03  
(6.04%) 
0.44 ± 0.03  
(7.08%) 
0.43 ± 0.03  
(8.06%) 
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From the relative standard deviations it becomes obvious that, within a series of consecutive 
injections (under identical conditions), standardization is beneficial with regard to 
repeatability. Moreover, comparison of the different sets of experiments (under different 
conditions) also revealed well comparable results for the area ratios. The only exception was 
observed for n3, comparing MS settings optimized for different m/z ranges. As already 
described in Section 3.3.6, this oligosaccharide was observed in two differently charged 
states. Obviously, a method detecting both species with high sensitivity (D) leads to higher 
signals for the n3 than a method which is less efficient in detecting the [M−2H]
2−
 ion with its 
lower m/z ratio (A–C). 
3.4 Summary and conclusion 
A fast capillary zone electorophoresis (CZE) method coupled to electrospray ionization time-
of-flight mass spectrometry (ESI-TOF-MS) was established for the analysis of oligosaccharide 
fragments derived from hyaluronan. Best results were achieved using fused silica capillaries 
with an inner diameter of 15 µm and a length of 28 cm, the shortest length possible with the 
experimental setup used. Applying a constant voltage of 35 kV, an electric field strength of 
1.25 kV/cm was achieved. As background electrolyte, a 25 mM solution of ammonium 
acetate was adjusted to a pH of 8.5 to allow for fast separations with good separation 
efficiency. The method was further characterized, revealing an LOD of 0.46–0.76 µM and an 
LOQ of 1.54–2.54 µM with regard to aqueous solutions of the different standard 
oligosaccharides. These values correspond to absolute amounts in the fmol range because a 
volume of only 990 pL (2% of the capillary length) had been injected.  
Standard analytes consisting of 2–4 hyalobiuronic acid moieties and even a complex mixture 
of hyaluronan oligosaccharides were separated within less than 70 s. The benefit of the 
hyphenation was demonstrated by analysis of this complex mixture. Probably, no detection 
method would have been able to provide as much information on the identity of the 
different oligosaccharides in the mixture as mass spectrometry. However, the used ESI-TOF-
MS has its limits with regard to discrimination between isomers (due to identical m/z ratio). 
In this case, additional information on the composition of the oligosaccharide mixture was 
obtained in combination with CZE. Thus, hyphenation of two complementary analytical 
methods makes CZE–ESI-TOF-MS a very powerful tool for the determination of these 
challenging analytes. In preparation of later at-line analysis, capillary inner diameter was 
increased to 25 µm to allow for a faster manual injection. Acarbose was established as 
internal standard. As samples from incubation mixtures can be injected directly after 1:10 
dilution with an aqueous solution of the internal standard, this protocol allows for fast at-
line monitoring of hyaluronidase activity. Moreover, recent developments in injection 
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procedures for small sample volumes are very promising for further acceleration and future 
automation.
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4 HPAEC–PAD for sensitive determination of hyaluronan 
oligosaccharides up to 10 kDa 
4.1 Introduction 
High performance anion exchange chromatography (HPAEC), sometimes also termed high 
pH anion exchange chromatography, is commonly used for the analysis of saccharides in 
food and beverage1-8 as well as for the elucidation of protein glycosylation patterns.9-11 
Moreover, the method was reported to be a useful tool for studies on saccharide-
metabolizing enzymes.12-14 The first separation of hyaluronan oligosaccharides by ion 
exchange was described by Weissmann et al. in 1954.15 Since then, various liquid 
chromatography conditions, using UV absorbance16-20 or pulsed amperometric21-23 detection 
(PAD), were reported for hyaluronan oligosaccharides.  
UV detection of hyaluronan oligosaccharides, especially those produced by mammalian 
hyaluronidases (cf. Chapter 1), is only possible at very short wavelengths. PAD enables more 
sensitive analytical studies of such compounds. Separation of the acidic oligosaccharides can 
be achieved by anion exchange chromatography under alkaline conditions (Figure 4.1 A–D). 
The particularity of the following pulsed amperomety is the sequential application of 
different potentials. In case of the triple pulse sequence, the detection potential is followed 
by oxidative cleaning and reductive electrode regeneration (Figure 4.1 E).  
         
Figure 4.1: Principle of HPAEC–PAD. Column containing cationic solid phase material is preconditioned with 
anionic (alkaline) eluent when sample is injected (A). Analytes are then separated due to differences in ionic 
interaction with the stationary phase (B). A gradient from weak to strong eluent is applied to elute all the 
analytes from the column (C). At the end of the separation, all analytes have been eluted and the column is 
filled with the strong eluent (D). Detection is achieved by a pulsed amperometric method (E). The potential 
used for oxidation of the analytes (signal integration) is followed by an oxidative cleaning step and reductive 
regeneration of the electrode surface. 
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Previously reported conditions for ion exchange chromatography often required long run 
times.16-18, 21 Hence, based on the reported methods we systematically studied the influence 
of various parameters on separation, aiming at optimization for qualitative and quantitative 
analysis of small oligosaccharides. In addition, method development was also directed 
towards the determination of the size distribution of hyaluronan oligosaccharide mixtures. 
Both aspects are necessary for the characterization of different hyaluronidases with regard 
to substrate and product spectra, cleavage mechanisms, and kinetic parameters.  
4.2 Materials and methods 
4.2.1 Oligosaccharide standards and sample preparation 
Oligosaccharide standards (oligoHA from Hyalose, Oklahoma City, OK, USA) were purchased 
from AMSBIO (Abingdon, UK). A standard mixture containing 20 µM (5 µM for comparison of 
columns) of each oligosaccharide was used. Hyalo-Oligo, a low molecular weight hyaluronan 
oligosaccharide mixture with an average molecular weight below 10 kDa, was kindly 
provided by Kewpie (also named Q. P. Corp., Tokyo, Japan). Standards were dissolved in 
water, purified with a Milli-Q system (Millipore, Eschborn, Germany). From incubation 
mixtures (cf. Chapter 6, Section 6.2.2 for exact composition), protein was removed by boiling 
for 15 min, centrifugation at 13000 × g for 10 min, and filtration through a Phenex-NY 4 mm 
syringe filter 0.2 µm (Phenomenex, Aschaffenburg, Germany). 
4.2.2 Preparation and storage of eluents 
A 1 M sodium hydroxide solution was freshly prepared, using water purified with a Milli-Q 
system (Millipore, Eschborn, Germany) and a 50% (w/v) sodium hydroxide solution 
(Mallinckrodt Baker, Griesheim, Germany). For the second eluent, solid sodium acetate 
(electrochemical grade, Dionex/Thermo Fisher Scientific, Idstein, Germany) was dissolved in 
purified water and filtrated through an ExpressTM PLUS 0.22 µm bottle top filter (Merck-
Millipore, Darmstadt, Germany). Afterwards, a suitable amount of 50% (w/v) sodium 
hydroxide solution (Mallinckrodt Baker, Griesheim, Germany) was added to reach a final 
concentration of 1 M sodium acetate and 100 mM sodium hydroxide. Purified water served 
as third component for different eluent compositions. Prior to usage, all eluents were 
degassed with helium and, during chromatography, always kept under helium to avoid 
dissolution of oxygen and carbon dioxide.  
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4.2.3 Instrumentation and chromatography conditions 
Chromatography was carried out on a Dionex DX-600 system, consisting of an AS50 
autosampler (temperature set to 10 °C) and column compartment, GS50 gradient pump, and 
ED50 electrochemical detector for pulsed amperometric detection (Dionex/Thermo Fisher 
Scientific, Idstein, Germany). The chromatography system was equipped with a CarboPacTM 
PA100 guard (2 mm × 50 mm) and analytical column (2 mm × 250 mm) or a CarboPacTM 
PA200 guard (3 mm × 50 mm) and analytical column (3 mm × 250 mm), respectively. All 
columns were from Dionex/Thermo Fisher Scientific (Idstein, Germany). Chromatograms 
were evaluated with the included software PeakNet 6.30 SP1 Build 587. 
Prior to sample application, the column was equilibrated for 10 min. In general, injection 
volumes were 5 µL or 10 µL. For all separations, constant concentrations of sodium 
hydroxide and various linear sodium acetate gradients of 20 min were used. The final eluent 
composition was kept constant for additional 10 min. Detailed information on the separation 
parameters are given with the chromatograms. 
4.2.4 Electrochemical detector settings 
A gold electrode served as working electrode and potentials were measured against a 
silver/silver chloride reference electrode. Data were acquired at a rate of 1 Hz with a 
standard triple pulse sequence (Figure 4.1 E) for carbohydrates, characterized by the 
following electric potentials and durations: E1 = +0.05 V for 0.4 s (integrating from 0.2 s to 
0.4 s), E2 = +0.75 V (0.2 s), and E3 = −0.15 V (0.4 s). 
4.2.5 Assessment of analyte stability by CZE–ESI-TOF-MS 
Studies on analyte stability and formation of chemical degradation products under alkaline 
conditions were performed by dissolution of the standard oligosaccharides in sodium 
hydroxide solution, prepared from 50% sodium hydroxide solution (HPLC–MS grade, Sigma-
Aldrich, Munich, Germany). Samples were analyzed by HPAEC–PAD and in part by the CZE–
ESI-TOF-MS method described in Chapter 3. 
4.2.6 Size-dependent precipitation of hyaluronan fragments  
Precipitation experiments were performed according to the turbidimetric hyaluronidase 
assay described by Di Ferrante.
24
 Solutions of the low molecular weight hyaluronan 
(HA < 10 kDa) preparation Hyalo-Oligo (Kewpie/Q. P. Corp., Tokyo, Japan) and hyaluronan 
from Streptococcus zooepidemicus (Aqua Biochem, Dessau, Germany) were prepared to 
yield concentrations of 2 mg/mL. 50 µL of the respective solution (water for blank) were 
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added to 200 µL of incubation buffer (cf. Chapter 6 for details). 100 µL of a solution 
(0.2 mg/mL) of bovine serum albumin (BSA, Serva, Heidelberg, Germany) were added to 
samples without enzyme. Otherwise, half of the BSA was replaced by bovine testicular 
hyaluronidase (BTH, Neopermease®, kindly provided by Sanabo, Vienna, Austria). The 
enzyme solution had been adjusted to 400 IU/mL (based on the declaration by the supplier) 
by addition of an appropriate portion of the BSA solution. 
The mixtures were incubated at 37 °C for 30 min. 1200 µL of 2.5% (m/v) 
cetyltrimethylammonium bromide (CTAB, Merck, Darmstadt, Germany), dissolved in 0.5 M 
sodium hydroxide solution (Carl Roth, Karlsruhe, Germany), were added. Water instead of 
CTAB was added to the control sample. Turbidity was complete within 20 min at 25 °C and 
was quantified by measurement of extinction at 600 nm using a CARY 100 photometer 
(Agilent Technologies, Darmstadt, Germany).  
Prior to chromatography, the precipitate was removed by short centrifugation (5 min at 
13000 × g). Additionally, samples were cleaned from protein by boiling for 5 min, 
centrifugation for 15 min, and filtration as described (cf. Section 4.2.1). Afterwards, the 
solution was directly injected for HPAEC. Thereby, low temperatures should be avoided to 
prevent precipitation of residual CTAB and clogging of the chromatography system. 
4.3 Results and discussion 
4.3.1 Optimization of the sodium hydroxide concentration 
Standard eluents for the columns used in this study, recommended by the manufacturer, 
consist of constant concentration of sodium hydroxide and an additional gradient of sodium 
acetate. For the analysis of acidic substances, post-column addition of the basic component 
is often performed alternatively.22, 23, 25, 26 However, the latter procedure was not possible 
with the given instrumentation. Therefore, we decided to use a solvent system of sodium 
hydroxide and sodium acetate.  
Figure 3.4 indicates that variation of the sodium hydroxide content from 100 mM to 200 mM 
did not influence separation, when using the same sodium acetate gradient. However, the 
sensitivity of the detection decreased with increasing sodium hydroxide concentration. 
Consequently, a concentration of 100 mM sodium hydroxide was chosen for further method 
development. 
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Figure 4.2: Comparison of eluents containing 100 mM (A), 150 mM (B), and 200 mM (C) sodium hydroxide. 5 µL 
of 20 µM standard mixture (n2−n4) injected. Column: CarboPac
TM
 PA100. Gradient: 200−700 mM sodium 
acetate. Flow: 0.25 mL/min. Temperature: not regulated. 
4.3.2 Sodium acetate gradient 
With increasing chain length, oligosaccharides show higher affinity to the stationary phase. 
To elute these strongly bound analytes in an acceptable run time, gradients of the strong 
eluent sodium acetate are necessary. Keeping the duration of the gradient program 
constant, the end point composition (Figure 4.3) as well as the initial composition of the 
eluent (Figure 4.4) was varied.  
Increasing the final concentration of the gradient from 700 mM to 900 mM gave sharper 
peaks. Consequently, the separation was not negatively affected, although retention times 
were reduced. In contrast, variation of the starting conditions was not beneficial. When 
chromatography was started with 0 mM sodium acetate, retention times increased without 
improvement of resolution. With a higher content of sodium acetate (300 mM) in the initial 
eluent, significant broadening was observed for the tetrasaccharide (n2) peak. Moreover, 
this peak was very poorly separated from the signal associated with the void volume under 
these conditions. A gradient from 200 mM to 900 mM sodium acetate proved to be the 
optimum.  
Retention time (min)
P
A
D
 r
e
sp
o
n
se
 (
n
C
)
0 5 10 15 20 25 30
0
25
50
n2
C
n3 n4
200 mM
NaOH
0 5 10 15 20 25 30
0
25
50
n
2
n3 n4
150 mM
NaOH
B
100 mM
NaOH
0 5 10 15 20 25 30
0
25
50
n
2
A n3 n4
60 4 HPAEC–PAD for sensitive determination of hyaluronan oligosaccharides up to 10 kDa 
 
 
Figure 4.3: Sodium acetate gradients of 200–700 mM (A) and 200–900 mM (B). 5 µL of 20 µM standard mixture 
(n2−n4) injected. Column: CarboPac
TM
 PA100. Sodium hydroxide: 100 mM. Flow: 0.25 mL/min. Temperature: 
not regulated. 
 
Figure 4.4: Sodium acetate gradients of 0–900 mM (A), 200–900 mM (B), and 300–900 mM (C). 5 µL of 20 µM 
standard mixture (n2−n4) injected. Column: CarboPac
TM
 PA100. Sodium hydroxide: 100 mM. Flow: 0.25 mL/min. 
Temperature: not regulated. 
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4.3.3 Column temperature 
To this point, all experiments on eluent optimization were performed at ambient 
temperature without regulation by the column oven. To investigate the influence of the 
column temperature on separation and analyte stability, chromatography was performed at 
different temperatures, varied from 15 °C to 40 °C, while all other conditions were kept 
constant. The resulting chromatograms are depicted in Figure 4.5.  
 
Figure 4.5: Stepwise increase of column temperature from 15 °C (A) to 40 °C (F). 5 µL of 20 µM standard 
mixture (n2−n4) injected. Column: CarboPac
TM
 PA100. Sodium hydroxide: 100 mM. Sodium acetate gradient: 
200–900 mM. Flow: 0.25 mL/min. 
With increasing column temperature, peaks became sharper. However, the area of the void 
volume peak increased, and minor peaks, eluting after the main peaks, were detected. 
Recently, this phenomenon was observed under chromatography conditions different from 
those used in this work.
16
 By mass spectrometry, the authors assigned the minor peaks to 
N-deacetylation products of the standard oligosaccharides, suggesting an enzymatic 
deacetylation by bovine testicular hyaluronidase.
16
 
Although, regarding the study by Chen et al.,
16
 an enzymatic mechanism cannot be 
completely ruled out, the significant increase in the minor peaks at higher temperature (in 
the present work) strongly suggested a non-enzymatic mechanism resulting in the 
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corresponding degradation products. Provided that deacetylation occurs, it might be 
speculated that the increase in the void volume signal resulted from liberated acetate. 
In addition, the formation of odd-numbered oligosaccharides was previously described in 
literature.18, 20, 23 Only minor changes of the chromatographic properties are to be expected 
after removal of an N-acetyl-D-glucosamine moiety from the oligosaccharide, as the 
influence of the negatively charged glucuronic acids is probably predominating under the 
conditions of anion exchange chromatography. Therefore, the oligosaccharides resulting 
from degradation are expected to elute close to the corresponding even-numbered sugars. 
Monosaccharides, cleaved off from oligosaccharides, elute with the void volume under the 
conditions used. Thus, formation of odd-numbered oligosaccharides would equally lead to 
an increase of the void volume signal. 
To scrutinize the formation of minor peaks, stability experiments were performed. The 
results are discussed in Section 4.3.7. 
4.3.4 Comparison of the CarboPac
TM
 PA100 and the CarboPac
TM
 PA200 
column at different flow and temperature conditions 
In the following optimization step, the CarboPacTM PA100 was compared to the CarboPacTM 
PA200 column as stationary phase. Separations on CarboPacTM PA100 were thereby 
conducted at a flow rate of 0.25 mL/min and at low (20 °C) and high (40 °C) temperature. In 
contrast, the CarboPacTM PA200 column was, in accordance with the manufacturer’s 
specifications, operated at 0.50 mL/min and 40 °C. Due to the occurrence of high pressure, 
comparative analysis at 20 °C was not possible with the latter column material. Probably, 
this finding relates to the increasing viscosity of the sodium hydroxide eluent at low 
temperature. Resolution was enhanced by changing the column from CarboPacTM PA100 to 
CarboPacTM PA200 as well as by increasing the temperature. Figure 4.6 illustrates these 
results for the standard oligosaccharides (Figure 4.6 A−C) and a low molecular weight 
hyaluronan preparation (Figure 4.6 D−F). With this complex mixture of hyaluronan 
oligosaccharides, the beneficial effect of the change in stationary phase material is even 
more pronounced than for the standard analytes. A detailed discussion on the analysis of the 
respective saccharide mixture is provided in Section 4.3.6. 
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Figure 4.6: Variation of column, flow, and temperature. 10 µL of 5 µM standard mixture (A−C) or 10 µL of an 
aqueous solution of 0.5 mg/mL Hyalo-Oligo oligosaccharide mixture (D−F) injected. CarboPac
TM
 PA100 column 
operated at 0.25 mL/min and 20 °C (A, D) or 40 °C (B, E), CarboPac
TM
 PA200 column operated at 0.50 mL/min 
and 40 °C (C, F). Eluent: 100 mM sodium hydroxide, gradient of 200−900 mM sodium acetate. 
4.3.5 Characterization of the optimized method 
Best results were achieved using the CarboPac
TM
 PA200 column at a temperature of 40 °C 
and a flow rate of 0.50 mL/min. The sodium hydroxide concentration of the mobile phase 
was kept constant at 100 mM, a 20 min linear gradient of 200–900 mM sodium acetate was 
applied, and final conditions kept constant for additional 10 min. In summary, including an 
equilibration phase of 10 min prior to injection, total run duration was 40 min.  
From the baseline noise, signal-to-noise ratio (S/N) was calculated for a low concentration of 
the standard analytes. Subsequently, the limit of detection (LOD, S/N = 3) and the limit of 
quantification (LOQ, S/N = 10) were deduced from the S/N values. Injecting 10 µL of the 
sample, the limit of detection for the standard oligosaccharides was 20–30 nM or, expressed 
as total amount of the analyte, 0.2–0.3 pmol. A chromatogram for an amount of the 
standard analytes close to the LOD (0.5 pmol each) is depicted in Figure 4.7. 
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Figure 4.7: HPAEC–PAD at very low analyte concentrations. 10 µL of 0.05 µM (0.5 pmol) standard mixture 
(n2−n4) injected. Column: CarboPac
TM
 PA200. Sodium hydroxide: 100 mM. Sodium acetate gradient: 200–
900 mM. Flow: 0.50 mL/min. Temperature: 40 °C. 
Linearity was examined by injecting 10 µL of standard mixtures (n2–n4) at concentrations of 
0.1, 0.25, 0.5, 0.75, 1.0, 2.5, 5.0, 7.5, 10, 25, 50, 75, and 100 µM. For each concentration 
three independent samples prepared from the same stock solution were used. Plotting the 
area of the main peaks versus sample concentration revealed a linear correlation from 0.1 to 
10 µM with coefficients of correlation in the range of 0.9977 to 0.9987. It is noteworthy that 
comparable values were obtained when using the sum of the areas of main and 
corresponding satellite peak (not shown). These findings suggest that the formation of the 
minor peaks is due to an equilibrium process and does not affect the applicability of the 
method for quantitative analysis.  
Average migration time was calculated from all 39 injections performed to determine the 
linearity of the method. In contrast, repeatability of the main peak area was determined 
using standards at a concentration of 0.5 µM (N = 3). All values regarding sensitivity, 
linearity, and repeatability are summarized in Table 4.1.  
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Table 4.1: Limit of detection, limit of quantification, calibration parameters, and repeatability of the optimized 
HPAEC–PAD method (nx: oligosaccharides consisting of x hyalobiuronic acid moieties). 
 n2 n3 n4 
LOD, LOQ, calibration parameters    
Limit of detection, LOD, S/N = 3,  
given as sample concentration (nM), 10 µL injected 
30 20 20 
Limit of detection, LOD, S/N = 3,  
given as total amount injected (pmol) 
0.3 0.2 0.2 
Limit of quantification, LOQ, S/N = 10,  
given as sample concentration (nM), 10 µL injected  
110 70 60 
Limit of quantification, LOQ, S/N = 10,  
given as total amount injected (pmol) 
1.1 0.7 0.6 
Linear range investigated,  
given as sample concentration (µM), 10 µL injected  
0.1–10 0.1–10 0.1–10 
Coefficient of determination, R² 0.9981 0.9977 0.9987 
Sample concentration showing deviation from 
linearity (µM), 10 µL injected 
25 25 25 
Repeatability    
Average retention time (min): mean ± SD (RSD),  
N = 39 
5.598 ± 0.017 
(0.31%) 
8.786 ± 0.023 
(0.26%) 
11.105 ± 0.026 
(0.23%) 
Main peak areas (nC · min): mean ± SD (RSD),  
0.5 µM, 10 µL injected, N = 3  
0.171 ± 0.010 
(5.70%) 
0.215 ± 0.021 
(9.69%) 
0.214 ± 0.009 
(4.35%) 
 
4.3.6 Analysis of a complex mixture of hyaluronan oligosaccharides  
Figure 4.6 already showed chromatograms obtained by separation of a complex mixture of 
hylauronan oligosaccharides, marketed as Hyalo-Oligo. To further characterize this mixture, 
an aqueous solution and an incubation mixture, both containing the Hyalo-Oligo 
preparation, were analyzed (Figure 4.8). The sample, containing buffer salts and bovine 
serum albumin, was prepared as described in Section 4.2.1. It becomes obvious from Figure 
4.8 that, after deproteinization, the matrix components from the incubation mixtures did not 
interfere with the chromatographic separation. The void volume signal increased, whereas 
detection of the analytes was not hampered in any way. The oligosaccharides of the mixture 
were separated from 2 (n2) up to at least 25–30 disaccharide units (n25–n30), corresponding 
to a molecular weight of 9.5–11.4 kDa. The disaccharide (n1), however, could not be 
separated from the void volume signal. The observed size distribution confirmed that the 
low molecular weight hyaluronan preparation Hyalo-Oligo has an average molecular weight 
66 4 HPAEC–PAD for sensitive determination of hyaluronan oligosaccharides up to 10 kDa 
 
below 10 kDa as specified by the manufacturer. The small peaks detected in between the 
main substance peaks probably correspond to ethylated derivatives, which have previously 
been identified by CZE–ESI-TOF-MS of the same oligosaccharide mixture (cf. Chapter 3, 
Section 3.3.7). 
 
Figure 4.8: Separation of a complex mixture of hyaluronan oligosaccharides from aquaeous solution (A) and 
from an incubation mixture (B). Oligosaccharides are labeled as nx according to the number (x) of disaccharide 
units. 10 µL of 0.5 mg/mL Hyalo-Oligo injected. Chromatography conditions: CarboPac
TM
 PA200, 100 mM 
sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
4.3.7 Formation of odd-numbered oligosaccharides under strongly alkaline 
conditions 
In general, the oligosaccharides derived from hyaluronan are even-numbered 
oligosaccharides, consisting of an integer number of hyalobiuronic acid (disaccharide) 
moieties. Nevertheless, some authors also reported the occurrence of odd-numbered 
oligosaccharides.18, 20, 23 These odd-numbered sugars might be the reason for additional 
peaks under the alkaline conditions of HPAEC, especially observed at higher temperature (cf. 
Figure 4.5). To study this phenomenon, the standard oligosaccharides were dissolved in 
20 mM sodium hydroxide solution. Under these conditions, the formation of odd-numbered 
oligosaccharides, even at ambient temperature of 22 °C, was proven by CZE–ESI-TOF-MS 
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analysis (Figure 4.9). The detected odd-numbered oligosaccharides are formed from the 
corresponding even-numbered oligosaccharides by cleavage of one N-acetyl-D-glucosamine 
moiety. The loss of a glucuronic acid moiety was not observed. As already suggested by 
Hoechstetter,20 the mechanism of this alkaline cleavage is presumably similar to the 
proposed mechanism27 of the Morgan-Elson reaction. 
 
Figure 4.9: Formation of odd-numbered oligosaccharides (n1.5, n2.5, n3.5) in 20 mM sodium hydroxide solution at 
22 °C. Initial concentration of each even-numbered standard oligosaccharide (n2, n3, n4) was 4 µM. CZE 
conditions: 15 µm × 28 cm capillary, ammonium acetate background electrolyte (25 mM, pH = 8.5), 35 kV. 
Signals are extracted ion traces from CZE–ESI-TOF-MS coupling. 
The impact of high pH values and elevated temperature on the chemical conversion of the 
analytes was studied by means of HPAEC–PAD. Even-numbered standard oligosaccharides 
were dissolved in water or 100 mM sodium hydroxide solution, simulating the eluent 
conditions. Chromatograms were recorded immediately and after different periods of 
heating at 100 °C (Figure 4.10). Neither the heated aqueous solution (Figure 4.10 B) nor the 
directly injected alkaline solution (Figure 4.10 C) revealed any significant change in peak 
appearance. After incubation under alkaline conditions at 10 °C for 24 h, two peaks, with a 
very small third peak in between, became visible (Figure 4.10 D). The same phenomenon 
was seen after heating of the alkaline solution. Thereby, total peak area dramatically 
decreased, probably due to complete degradation of the oligosaccharides (Figure 4.10 E). 
After 15 min of heating, the peaks had entirely disappeared (Figure 4.10 F).  
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Figure 4.10: Stability of hyaluronan oligosaccharides (n2-n4, 20 µM) against heating and under alkaline 
conditions. 10 µL of sample injected. Chromatography conditions: CarboPac
TM
 PA200, 100 mM sodium 
hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
In contrast to the chromatogram obtained by HPAEC–PAD of the alkaline solution stored at 
10 °C for 24 h (Figure 4.10 D), CZE–ESI-TOF-MS analysis of the same sample revealed only 
signals from the three odd-numbered oligosaccharides and their corresponding sodium 
adducts. Neither oligosaccharides resulting from cleavage of glucuronic acid nor residual 
even-numbered sugars were detected. This finding was in good accordance with the fast 
degradation observed at room temperature. Probably, the distinct peaks correspond to 
isomers of the odd-numbered oligosaccharides, which give the same m/z signal and cannot 
be separated by the CZE method. It is known from recent NMR experiments that elimination 
of N-acetyl-D-glucosamine moieties from hyaluronan oligosaccharides under strongly 
alkaline conditions leads to high amounts (ca. 30%) of stereoisomers by keto-enol 
tautomerizations (Lobry de Bruyn–van Ekenstein transformations).28 We heated the 
oligosaccharides in a 100 mM solution of sodium hydroxide. These harsh conditions are 
expected to cause isomerization to a considerable extent. It might further be assumed that 
the small third peak of each triplet corresponds to residual even-numbered oligosaccharide, 
which could not be observed in CZE–ESI-TOF-MS due to very low concentration. 
Within the recorded m/z range from 300 to 3000 (no detection of monosaccharides 
possible) an additional signal at m/z = 405.03 and corresponding sodium adducts were 
observed. This signal was not detected in the kinetic experiment shown in Figure 4.9. The 
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corresponding chemical entity, probably a reaction product with reduced molecular mass, 
showed a single charge in the negative ESI mode. Due to its migration behavior, however, 
this molecular species should be uncharged under the conditions of the CZE, hence not 
containing a glucuronic acid moiety. Assuming a dimeric adduct of the anhydro-derivative of 
N-acetyl-D-glucosamine proposed by Muckenschnabel et al. (Figure 4.11),27 the calculated 
m/z of 405.15 for [M−H]− does not fit exactly the measured value. However, this discrepancy 
of 0.12 might lie within the limits of the experimental errors. The signal for the disaccharide 
would be expected at m/z = 396.12 ([M−H]
−
).  
 
Figure 4.11: The anhydro-derivative of N-acetyl-D-glucosamine (proposed by Muckenschnabel et al.)
27
 probably 
occurs when hyaluronan oligosaccharides are destructed under strongly alkaline conditions. 
4.3.8 Studies on the size-dependent precipitation of hyaluronan fragments 
in the turbidimetric hyaluronidase activity assay 
For the turbidimetric hyaluronidase assay described by Meyer,
29
 the size limit for 
precipitation of hyaluronan is supposed to be in a molecular weight range of 6–8 kDa.
30
 
Assuming a similar behavior in the assay according to Di Ferrante,
24
 the HPAEC–PAD should 
be able to detect a decrease in the corresponding oligosaccharide peaks. Therefore, the 
oligosaccharide preparation Hyalo-Oligo (molecular weight < 10 kDa) as well as high 
molecular weight hyaluronan were precipitated with cetyltrimethylamonium bromide 
(CTAB). The results from the precipitation experiments are depicted in Figure 4.12.  
For the Hyalo-Oligo mixture, peaks in the respective region of the chromatogram 
disappeared after addition of the CTAB reagent (red circles in Figure 4.12 B, C). Precipitation 
was also confirmed by the corresponding extinction at 600 nm. Enzymatic cleavage by 
bovine testicular hyaluronidase led to a reduction in molecular weight, disabling 
precipitation (Figure 4.12 D). No turbidity occured in this case. The small oligosaccharides 
were not removed and could still be detected by HPAEC–PAD. The same effect was observed 
using high molecular weight hyaluronan of bacterial origin. Prior to digestion, hyaluronan 
was precipitated by CTAB leading to high turbidity. Enzymatic action resulted in the 
formation of products with low molecular weight which had not been detected without 
addition of enzyme (green rectangles in Figure 4.12 E, F). Turbidity after addition of CTAB 
was thereby reduced to a level comparable to control. The tetrasaccharide (n2) and 
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hexasaccharide (n3), produced by the action of bovine testicular hyaluronidase, clearly 
showed the characteristic two peaks (blue arrows in Figure 4.12 D, F), discussed in Section 
4.3.7, due to the treatment with alkaline CTAB reagent and boiling for deproteinization. 
 
Figure 4.12: Chromatograms of supernatants after precipitation of hyaluronan with cetyltrimethylammonium 
bromide (CTAB). High molecular weight hyaluronan (HA) or the oligosaccharide mixture Hyalo-Oligo 
(HA < 10 kDa) were used. Addition of bovine testicular hyaluronidase (BTH) led to enzymatic degradation (D, F). 
For each sample, the extinction at 600 nm (E600) is given as turbidity value. Red circles: region of precipitation. 
Green rectangles: undigested versus digested hyaluronan, formation of oligosaccharides. Blue arrows: two 
peaks due to instability during boiling in alkaline solution. 
In summary, the results confirm that precipitation with CTAB only occurs for hyaluronan 
oligosaccharides and polysaccharides beyond a molecular weight of approximately 6–8 kDa. 
Smaller oligosaccharides are still present in the supernatant after removing the precipitate 
by centrifugation. 
4.4 Summary and conclusion 
Parameters for high performance anion exchange chromatography with pulsed 
amperometric detection (HPAEC–PAD) were optimized with regard to the analysis of 
hyaluronan oligosaccharides. For PAD, a standard triple pulse sequence for carbohydrates 
(E1 = +0.05 V, E2 = +0.75 V, and E3 = −0.15 V) was applied. Using a CarboPac
TM
 PA200 column 
at 40 °C and a flow rate of 0.50 mL/min, 100 mM sodium hydroxide eluents with an 
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additional gradient of 200–900 mM sodium acetate were chosen. With 10 min of 
equilibration, a gradient duration of 20 min, and additional 10 min at 900 mM sodium 
acetate concentration, each run lasted 40 min. Under these conditions, the separation of 
oligosaccharides of 2 (n2, molecular weight: ca. 0.8 kDa) up to 25–30 (n25–n30, molecular 
weight: ca. 9.5–11.4 kDa) hyalobiuronic acid moieties was successful. For small 
oligosaccharides (n2–n4), LOD was 0.2–0.3 pmol (depending on the oligosaccharide), 
expressed as absolute amounts injected. 
Buffer components from incubation mixtures did not interfere with the analysis of a 
hyaluronan oligosaccharide mixture, recommending HPAEC–PAD for mechanistic and 
enzymological studies on hyaluronidases. Moreover, HPAEC–PAD together with additional 
CZE–ESI-TOF-MS analysis provided deeper insight into the chemical formation of odd-
numbered oligosaccharides under alkaline conditions. Finally, HPAEC–PAD was successfully 
used to elucidate the size-dependent precipitation of hyaluronan oligosaccharide in the 
turbidimetric assay by Di Ferrante.24 
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5 Preparation of purified hyaluronan oligosaccharides 
and planar chromatography for quality control 
Note: As stated in the list of publications, major parts of this chapter have already been 
published (in cooperation with partners from the Department of Pharmaceutical Biology) 
prior to the submission of this thesis.
1
 For detailed information on the nature of this 
collaboration, see also “Acknowledgements and declaration of collaborations”. 
5.1 Introduction 
Purified oligosaccharides derived from hyaluronan are indispensable tools for proper 
enzymological characterization of hyaluronidase isoenzymes and for pharmacological 
experiments. Consequently, convenient methods for quality control of these substances are 
required. Historically, hyaluronan oligosaccharides were separated by paper 
chromatography.2 However, more recently, mainly high performance liquid chromatography 
(HPLC) and related techniques were used for chromatographic analysis and quality control of 
these saccharides.3-5 
Nevertheless, owing to the development of high performance thin layer chromatography 
(HPTLC),6 automating approaches, and hyphenation techniques,7 planar chromatography has 
gained more attention in recent years. As sugars are difficult analytes for reversed phase 
HPLC, planar chromatography and its versatile derivatization options are an especially 
promising alternative. Moreover, planar chromatography enables the convenient and cost-
effective analysis of multiple samples in parallel. Thin layer chromatography (TLC) on normal 
phase standard silica plates in combination with manifold post-chromatographic 
derivatization methods8-11 or direct matrix assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF-MS)9 was also previously reported for hyaluronan 
oligosaccharides. However, a quantitative HPTLC method had not been described in 
literature until publication of the results of the present project.1 
A convenient quantitative HPTLC method with reagent-free derivatization on amino-
modified silica was developed and validated. Coupling of normal phase standard TLC to 
electrospray ionization quadrupole time-of-flight mass spectrometry (ESI-Q-TOF-MS) 
additionally allowed for unambiguous identification of the oligosaccharides. Whereas 
MALDI-TOF-MS requires an electrically conductive aluminum back9 and cannot be applied to 
glass-backed HPTLC plates, ESI-MS can be easily coupled to HPTLC.  
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5.2 Materials and methods 
5.2.1 Standard analytes and preparation of oligosaccharides 
Commercially available oligosaccharides (oligoHA from Hyalose, Oklahoma City, OK, USA) of 
2–4 hyalobiuronic acid moieties (n2–n4), purchased from AMSBIO (Abingdon, UK), served as 
standard analytes. In-house digestion of hyaluronan (HA) from Streptococcus zooepidemicus 
(Aqua Biochem, Dessau, Germany) and subsequent purification, both essentially performed 
according to Hofinger et al.,12 yielded sufficient amounts of these oligosaccharides for 
further studies. In detail, the preparation was carried out as follows. 
The incubation buffer for the enzymatic digestion was prepared by dissolving 0.77 g of 
ammonium acetate (Merck, Darmstadt, Germany) and 0.58 g of sodium chloride (VWR, 
Haasrode, Belgium) in 100 mL of water purified with a Milli-Q system (Millipore, Eschborn, 
Germany). Buffer pH was then adjusted to a value of 5.0 by addition of concentrated 
hydrochloric acid (Merck, Darmstadt, Germany). Bovine testicular hyaluronidase (BTH, 
Neopermease®, kindly provided by Sanabo, Vienna, Austria) was diluted with bovine serum 
albumin (BSA, Serva, Heidelberg, Germany) solution (0.2 mg/mL) to the desired enzyme 
concentration. An activity to 10000 IU/mL (based on the declaration by the supplier) was 
found to be optimal for the preparation of n2, n3, and n4. 50 mL of aqueous HA solution 
(5 mg/mL), 25 mL of bovine serum albumin solution, and 74 mL of purified water were mixed 
with 50 mL of the incubation buffer. Finally, addition of 1 mL of the prepared enzyme 
solution started the reaction. The mixture was incubated at 37 °C in a water bath for 72 h 
before the digestion process was stopped by boiling for 10 min. 
In a first purification step, precipitated protein was removed by centrifugation at 5000 × g 
for 20 min. Aliquots of 100 mL were lyophilized and the obtained lyophilisate was dissolved 
in 2 mL of purified water. After filtration through a Millex-GV 0.22 µm syringe filter (Merck-
Millipore, Darmstadt, Germany), the solution was injected into a gel filtration system, 
equipped with a HiLoad 16/60 SuperdexTM 30 prep grade column (GE-Healthcare Bio-
Sciences AB, Uppsala, Sweden). A 0.1 M solution of ammonium acetate (Merck, Darmstadt, 
Germany), filtrated through an ExpressTM PLUS 0.22 µm bottle top filter (Merck-Millipore, 
Darmstadt, Germany), was used as volatile mobile phase with regard to subsequent 
lyophilization. The chromatographic system was operated using a Pharmacia LKB Gradient 
pump 2249 (Amersham Pharmacia Biotech, Freiburg, Germany) at a flow rate of 0.5 mL/min. 
Elution of the oligosaccharides was monitored at 210 nm with a Shimadzu SPD-6AV UV 
detector (Shimadzu, Kyoto, Japan). Fractions were collected, pooled, lyophilized, and finally 
dissolved in 200 µL of purified water. Purity and identity of the hylauronan oligosaccharides 
were controlled by CZE–ESI-TOF-MS13 (detailed description in Chapter 3) and oligosaccharide 
solutions were stored at −80 °C.  
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5.2.2 HPAEC–PAD of HA oligosaccharide mixtures from enzymatic digestion 
For control and optimization of the digestion conditions, aliquots of the boiled and filtrated 
incubation mixture were analyzed by high performance anion exchange chromatography 
with pulsed amperometric detection (HPAEC–PAD) as described in Chapter 4. Prior to 
injection, the samples were diluted 1:10 with purified water.  
5.2.3 Colorimetric estimation of oligosaccharide concentration 
Oligosaccharide concentrations of the samples from in-house preparation were estimated by 
a colorimetric analysis.14-17 The concentrated stock solution (cf. Section 5.2.1) was diluted 
1:900 with purified water, and 450 µL of the dilution were mixed with alkaline borate 
solution. After 4.5 min of boiling and subsequent cooling on ice for additional 2 min, 1500 µL 
of p-dimethylaminobenzaldehyde solution were added. Both reagents were prepared as 
reported in literature.14 p-Dimethylaminobenzaldehyde was from Sigma-Aldrich (Munich, 
Germany), all other chemicals were from Merck (Darmstadt, Germany). During 20 min of 
incubation at 37 °C the characteristic purple color of the reaction product developed. 
N-Acetyl-D-glucosamine at the reducing ends was determined by measuring absorbance of 
the colored product at 586 nm with a CARY 100 photometer (Agilent Technologies, 
Darmstadt, Germany). N-Acetyl-D-glucosamine (Fluka, Buchs, Switzerland) was used as 
calibration standard. The molar “concentration of reducing ends” equals the molar 
concentration of the (purified) oligosaccharides. Based on the results from the colorimetric 
quantification, samples for HPTLC experiments were diluted to reach a concentration of 
approximately 50 µM. 
5.2.4 Stationary and mobile phases 
TLC plates (aluminum-backed) and HPTLC plates (glass-backed) coated with silica 60 F254 
(Merck, Darmstadt, Germany) were used to explore post-chromatographic staining or 
hyphenation to mass spectrometry. By contrast, for reagent-free derivatization, amino-
modified silica Nano-SIL NH2/UV254 (Macherey-Nagel, Düren, Germany) served as stationary 
phase. Square Nano-SIL NH2 HPTLC plates (10 cm × 10 cm), used for the comparison of 
detection methods (cf. Section 4.3.3) and 2D chromatography (cf. Section 5.3.4), did not 
contain a UV indicator. 
The mobile phases for all separations consisted of 1-butanol (Sigma-Aldrich, Munich, 
Germany), formic acid 98–100% (Merck, Darmstadt, Germany), and water. Ratios of 3:5:2 
(v/v/v) for unmodified silica and 3:4:1 (v/v/v) for amino-modified silica gave the best results. 
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5.2.5 Sample application technique and chromatography conditions 
The highly polar oligosaccharides were dissolved in water. The solution was sprayed on the 
chromatography plates with a Linomat 5 (CAMAG, Muttenz, Switzerland) in bands (length: 
8 mm), 10 mm from the bottom edge of the plate. The application volume for both, samples 
and references, was 10 µL per band. To avoid band broadening during application, the 
settings for sample solvent type were adjusted to aqueous solution. Nitrogen was used as 
spray gas. 
Chromatographic development was performed in a saturated automatic ADC2 Chamber 
(Twin Trough Chamber, CAMAG, Muttenz, Switzerland) to a distance of 70 mm from the 
bottom edge of the plate. Accordingly, considering the application position, the 
chromatogram was developed over a path of 60 mm. A saturated solution of magnesium 
chloride (Merck, Darmstadt, Germany) was used for adjustment of air humidity. 
5.2.6 Post-chromatographic derivatization 
With the hyaluronan oligosaccharides lacking suitable chromophores, visualization of the 
bands on the plates can only be achieved by post-chromatographic derivatization methods. 
A widely used technique is the orcinol/sulfuric acid staining.8, 9 The derivatization reagent for 
this reaction was prepared by dissolving 0.2 g of orcinol (Fluka, Buchs, Switzerland) in 100 mL 
of sulfuric acid (10% or 75%), which was carefully prepared from concentrated sulfuric acid 
(Merck, Darmstadt, Germany) and water at a ratio of 3:1 (v/v), according to literature,18 or 
1:9 (v/v). With a reagent sprayer, the acidic staining reagent was sprayed on the plates. 
Alternatively, the plates were dipped into the reagent using a home-made dipping device. 
Upon heating on a plate heater (Desaga, Sarstedt group, Nümbrecht, Germany) at 100 °C for 
15 min, colored bands developed. Immediately after heating, the plates were scanned for 
densitometric quantification. Scanning time was only 2 min. No fading of the color was 
observed during measurement. 
Another classical post-chromatographic staining method for hyaluronan oligosaccharides is 
the Morgan-Elson reaction,2, 19 performed in two steps.19 Reagent 1 was prepared from a 
solution of 0.5 mL acetylacetone (Fluka, Buchs, Switzerland) in 50 mL of 1-butanol (Sigma-
Aldrich, Munich, Germany) and an alkaline solution, namely a mixture of 1 part of an 
aqueous potassium hydroxide (Merck, Darmstadt, Germany) solution 50% (m/v) and 4 parts 
of ethanol (Carl Roth, Karlsruhe, Germany). 0.5 ml of the alkaline solution and 10 mL of the 
acetylacetone solution were mixed to give reagent 1. For reagent 2, 1 g of p-dimethylamino-
benzaldehyde (Sigma-Aldrich, Munich, Germany) was dissolved in a mixture of 30 mL of 
ethanol (Carl Roth, Karlsruhe, Germany) and 30 mL of concentrated hydrochloric acid 
(Merck, Darmstadt, Germany), followed by dilution with 180 mL of 1-butanol (Sigma-Aldrich, 
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Munich, Germany). Plates then were dipped into reagent 1, heated at approximately 100 °C 
for 5 min, subsequently treated with reagent 2, and finally heated again for 5 min. As a 
result, this procedure revealed characteristic red bands on yellow background. 
Reagent-free derivatization on amino-modified silica plates was achieved by heating the 
plate at approximately 200 °C for 15 min. Carbohydrates thereby probably undergo a 
Maillard-like reaction to form high-molecular products, which emit bright blue fluorescence 
when the plate is illuminated with UV light at a wavelength of 366 nm.20-22 This phenomenon 
has also been previously described for other analytes, such as catecholamines, on amino-
modified TLC plates.23 
5.2.7 Documentation, measurement of absorbance spectra, densitometric 
quantification, and data processing 
Images of the plates at 254 nm, 366 nm, and white light were recorded on a Reprostar 3 
(CAMAG, Muttenz, Switzerland). Absorbance spectra were determined with a TLC Scanner 3 
(CAMAG, Muttenz, Switzerland) in reflection mode. Densitometric quantification was 
performed by reflectance scan at the respective UV–VIS absorbance maximum for each 
derivatization procedure. All data were analyzed with winCATS 1.4.6 (CAMAG, Muttenz, 
Switzerland). In contrast, quadratic curve fitting was conducted with SigmaPlot for Windows 
11.2.0.5 (Systat Software Inc., San Jose, CA, USA). 
5.2.8 Coupling to mass spectrometry 
TLC was directly coupled to mass spectrometry using the TLC–MS interface (Figure 5.1) from 
CAMAG (Muttenz, Switzerland). Desorption of the analytes from the plates was achieved by 
an HPLC pump (Agilent 1260 Infinity Quaternary Pump, Agilent technologies, Waldbronn, 
Germany) driven solvent stream of acetonitrile/water/formic acid (90:10:0.1). High 
resolution mass spectra of the extracted substances were recorded in negative ionization 
mode ([M−H]– and [M−2H]2−) with an Agilent 6540 ultra-high definition (UHD) accurate-
mass-TOF LC/MS (Agilent technologies, Waldbronn, Germany). The internal mass calibration 
standard was hexakis(2,2,3,3-tetrafluoropropoxy)phosphazine. Exact masses of the analytes 
were calculated with Agilent MassHunter Workstation Software B.04.06. 
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Figure 5.1: The CAMAG TLC–MS interface. Device seen slanted from above (A), frontal view (B), laser cross hairs 
for positioning (C), extraction process (D), detailed view of the elution head (E), and trace left on the plate by 
the oval elution head (F). 
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5.3 Results and discussion 
5.3.1 Optimization of oligosaccharide preparation by enzymatic digestion 
With regard to high yields of the small oligosaccharides comprising 2–4 disaccharide units 
(n2–n4), different enzyme concentrations were tested for optimization of the digestion of 
hyaluronan. HPAEC–PAD chromatograms of the obtained oligosaccharide mixtures are 
depicted in Figure 3.4. 
 
Figure 5.2: HPAEC–PAD chromatograms of incubation mixtures (diluted 1:10) from preparation of small 
hyaluronan oligosaccharides (n2, n3, and n4). Incubation buffer for digestion: ammonium acetate, pH = 5.0 
(containing BSA and NaCl). Activity of bovine testicular hyaluronidase: 2000 IU (A), 10000 IU (B), or 50000 IU (C) 
per 200 mL. Incubation for 72 h. Chromatography: CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 
200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
Under the given conditions and after an incubation time of 72 h, 10000 IU of the enzyme 
preparation in a total volume of 200 mL incubation mixture were found to be the optimum 
for the preparation of the desired size range of oligosaccharides. Lower enzyme 
concentrations led to high content of larger oligosaccharides, which, in addition, were 
difficult to purify. Inversely, with higher concentration of the enzyme the amount of the 
octasaccharide n4 was very low. 
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5.3.2 Choice and optimization of mobile phase for HPTLC 
Articles dealing with TLC of hyaluronan oligosaccharides can roughly be divided into two 
groups according to the solvent system used. The older publications describe a 
2-propanol/water (66:34) mixture containing 0.05 M sodium chloride,8, 10 whereas more 
recently reported procedures use 1-butanol/formic acid/water at a ratio of 4:8:111 or 3:4:19 
as mobile phase. The latter system was chosen, because, with respect to TLC–MS coupling, 
salt contamination should be avoided. Therefore, various mixtures of 1-butanol, formic acid, 
and water were initially tested on TLC plates. As a result, a composition of 3:4:1 was found 
to be ideal for amino-modified silica, whereas in case of unmodified silica the ratio was 
slightly changed to 3:5:2 in order to increase Rf values.  
5.3.3 Comparison of stationary phase materials and post-chromatographic 
derivatization methods 
Having determined the ideal composition of the mobile phase, the stationary phases (normal 
phase and amino-modified silica) and derivatization methods (orcinol/sulfuric acid staining, 
Morgan-Elson reaction, and thermal derivatization on amino-modified phase) had to be 
compared in the next step. For this purpose, the n2 standard oligosaccharide at 
concentrations of 10, 25, 50, 100, 250, and 500 µM and a 75 µM mixture of n2, n3, and n4 
standard (10 µL per band) were used. As derivatization by spraying is not ideal for 
densitometry, the content of sulfuric acid in the orcinol reagent had to be reduced from 75% 
to 10% for a dipping procedure. As shown in Figure 5.3, this modification of the reagent did 
not affect the detection. 
 
Figure 5.3: Effect of the sulfuric acid content of the orcinol reagent on the detection of the analytes. Silica high 
performance thin layer chromatography (HPTLC) plate after spraying with orcinol in 10% (left) and 75% (right) 
H2SO4. Tetrasaccharide (n2) 100, 250, 500, 1000, 2500, and 5000 pmol/band (lanes 1−6, 9−14), standard 
oligosaccharide mixture (n2−n4) 750 pmol/band (lanes 7, 15), blank (lane 8). Mobile phase: 1-butanol/formic 
acid/water (3:5:2). Developing distance: 6 cm (7 cm from the bottom edge). Vertical axis indicates the Rf scale. 
Reproduced from Fig. 2 of the original publication
1
 with kind permission from Elsevier. 
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Figure 5.4 compares the different stationary phases and derivatization methods. Both 
stationary phases allowed for efficient separation of the standard oligosaccharides. With 
regard to derivatization, however, the pictures clearly indicate the superiority of the orcinol 
staining method on silica and the thermal derivatization on amino-modified silica in 
comparison to the Morgan-Elson reaction.  
 
Figure 5.4: Separation of hyaluronan oligosaccharides by high performance thin layer chromatography (HPTLC) 
on silica or amino-modified silica and visualization by different detection methods. Silica HPTLC plates after 
dipping into orcinol/10% H2SO4 reagent (A) and Morgan-Elson reagent (B). Amino-modified silica HPTLC plate 
after heating, illuminated with white (C) and UV light at 366 nm (D). Tetrasaccharide (n2) 100, 250, 500, 1000, 
2500, and 5000 pmol/band (lanes 1−6), oligosaccharide mixture (n2−n4) 750 pmol/band (lane 7). Mobile phase: 
1-butanol/formic acid/water (silica (A, B): 3:5:2, amino-modified silica (C, D): 3:4:1). Developing distance: 6 cm 
(7 cm from the bottom edge). Reproduced from Fig. 3 of the original publication
1
 with kind permission from 
Elsevier. 
To pinpoint the differences in sensitivity for the tested derivatization methods, 
densitometric scans in the measured UV–VIS absorbance maxima after visualization were 
conducted in reflectance mode. As for coupling to MS the position of the unmodified 
analytes on the plate must be localized, the plates were additionally scanned at 205 nm prior 
to any treatment with derivatization reagents. Peak heights were then plotted versus the 
total amount of n2 (Figure 5.5).  
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Figure 5.5: Sensitivity of different derivatization modes for the tetrasaccharide (n2). Calibration curves for 
densitometric scans (reflectance mode) of the plates from Figure 5.4. Silica plate prior to derivatization 
scanned at 205 nm (circle, cyan), after orcinol staining at 540 nm (triangle, green), and after Morgan-Elson 
staining (square, red). Amino-modified silica plate untreated at 205 nm (diamond, blue) and after heating at 
300 nm (x, dark pink). Peak heights expressed as arbitrary units (AU). Reproduced in a colored version from 
Fig. 4 of the original publication
1
 with kind permission from Elsevier. 
It should be noted that the amino-modified silica phase allows for the most powerful 
detection by a fast and simple thermal in situ derivatization method at retained band 
resolution, when compared to unmodified silica. Localization of the underivatized 
oligosaccharides at 205 nm was also successful although the detection limits were high. 
By analogy with paper chromatography, one could also think of cellulose as stationary phase. 
Due to the sulfuric acid content of the orcinol reagent and the absence of amino-groups 
required for the reagent-free derivatization, the use of this phase, however, is incompatible 
with the preferred detection modes.  
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5.3.4 Stability of the analytes 
Stability of the analytes during separation was investigated on a square (10 cm × 10 cm) 
HPTLC plate by two-dimensional (2D) chromatography. After spot application of a mixture of 
the three oligosaccharide standards (75 µM each, 5 µL), 10 mm from the bottom edge and 
20 mm from the left edge, the plate was developed twice under identical conditions to a 
distance of 70 mm from the edge. Afterwards, all three bands were located on a diagonal 
between the application point and the intersection of the solvent front lines (Figure 5.6). 
Thus, the stability and constant chromatographic properties of the analytes were proven. 
 
Figure 5.6: Stability of the analytes proven by 2D high performance thin layer chromatography (HPTLC) on 
amino-modified silica. Bands visualized after heating at 366 nm. Standard oligosaccharides (n2−n4, spot 
application, 75 µM each, 5 µL). Mobile phase: 1-butanol/formic acid/water (3:4:1). Developing distance: 6 cm 
(direction 1) and 5 cm (direction 2), each 7 cm from the edge of the plate. Reproduced from Fig. 5 of the 
original publication
1
 with kind permission from Elsevier. 
5.3.5 Optimization of the quantitative detection method 
For densitometric quantification using amino-modified silica HPTLC plates, standard mixtures 
of the three oligosaccharides (n2–n4) were applied at amounts of 2500, 1000, 750, 500, 250, 
100, 75, 50, 25, 10, and 5 pmol per band together with three samples of purified 
oligosacchariedes produced in-house. Chromatography was conducted as described in 
Section 4.2.5. When the plates were illuminated with visible light, weak brownish bands 
became obvious (Figure 5.7 A) upon thermal treatment. At 254 nm, however, dark bands 
were detected on the blue fluorescent background of the F254 plate (Figure 5.7 B), whereas a 
bright blue fluorescent was observed at 366 nm (Figure 5.7 C).  
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Figure 5.7: Amino-modified silica high performance thin layer chromatography (HPTLC) plate visualized with 
white light (A), 254 nm UV (B), and 366 nm UV (C). Standard mixture (n2−n4) 2500, 1000, 750, 500, 250, 100, 75, 
50, 25, 10, and 5 pmol/band (lanes 1−12), n2 sample (lane 13), n3 sample (lane 14), n4 sample (lane 15). Mobile 
phase: 1-butanol/formic acid/water (3:4:1). Developing distance: 6 cm (7 cm from the bottom edge). Vertical 
axes indicate the Rf scale. Reproduced from Fig. 6 and Supplementary Material 2 of the original publication
1
 
with kind permission from Elsevier. 
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Fluorescence measurement was taken into consideration for quantification, but showed 
relatively low signal-to-noise ratio compared to absorbance. Therefore, UV–VIS absorbance 
spectra (Figure 5.8) were recorded to determine the absorbance maxima. 
 
Figure 5.8: Overlay of the normalized UV–VIS absorbance spectra for the standard oligosaccharides n2, n3, and 
n4 after heating on amino-modified silica HPTLC plate. Maximum value is set as 95 arbitrary units (AU). 
Reproduced from Fig. 7 of the original publication
1
 with kind permission from Elsevier. 
In contrast to plates without a fluorescence indicator (λmax = 300 nm, not shown), λmax on 
Nano-SIL NH2/UV254 was 310 nm. Thus, this wavelength was used for quantification. 
5.3.6 Characterization of the optimized quantitative method 
Densitograms of the plate from Figure 5.7 were recorded at 205 nm prior to derivatization 
(Figure 5.9 A) and at 310 nm after thermal derivatization (Figure 5.9 B). 
  
Figure 5.9: Densitograms (reflectance mode) of the plate from Figure 5.7 at 205 nm prior to derivatization (A) 
and at 310 nm after derivatization (B). Absorbance expressed as arbitrary units (AU). Reproduced from Fig. 8 of 
the original publication
1
 with kind permission from Elsevier. 
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Limit of detection (LOD, signal-to-noise ratio 3:1) and limit of quantification (LOQ, signal-to-
noise ratio 10:1) were determined from the densitogram at 310 nm as described.24, 25 LOD 
was calculated by extrapolation. In contrast, LOQ was determined by interpolation of the 
linear lower part of the calibration curves (25–100 pmol). Depending on the oligosaccharide, 
LOD was 7–19 pmol per band and LOQ 37–71 pmol per band.  
Compared to the LOD of 7.4 pmol for a recently published study using fluorophore-assisted 
carbohydrate electrophoresis (FACE),26 the established HPTLC is a powerful and competitive 
alternative. Even the CZE–ESI-TOF-MS method presented in Chapter 3 revealed comparable 
or slightly lower LOD, considering analyte concentrations and the differences in applied 
sample volumes (10 µL for HPTLC, 990 pL for CZE).  
Subsequently, quadratic calibration curves were constructed in the range between the 
respective LOQ and 2500 nm per band for the three oligosaccharides (Figure 5.10).  
 
Figure 5.10: Quadratic calibration curves from absorbance scans at 310 nm (reflectance mode) of five 
individual plates. Tetrasaccharide (n2, triangle, green), hexasaccharide (n3, square, red) and octasaccharide (n4, 
diamond, blue). Data presented as mean ± standard deviation. Peak heights expressed as arbitrary units (AU). 
Reproduced in a colored version from Fig. 9 of the original publication
1
 with kind permission from Elsevier. 
Correlation coefficients R2 for the fitted curves ranged from 0.9968 to 0.9996. An overview 
of the quantification parameters is provided by Table 5.1. To further validate and 
characterize the method, the precision of the quantification was determined by intra-day 
and inter-day analysis. Analyses (N = 5) were conducted three times on the same day 
(repeatability) and on two following days (intermediate precision) by different 
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experimentators. The calculated amounts of the analytes, Rf values, and the corresponding 
precision parameters are listed in Table 5.2. 
Table 5.1: Sensitivity of quantitative analysis (nx: oligosaccharides consisting of x hyalobiuronic acid moieties). 
Content reproduced from Table 1 of the original publication
1
 with kind permission from Elsevier. 
 n2 n3 n4 
LOD, LOQ, calibration parameters    
Limit of detection (pmol), LOD, S/N = 3  19 10 7 
Limit of quantification (pmol), LOQ, S/N = 10  71 48 37 
Calibration range investigated (pmol) 75–2500 50–2500 50–2500 
Coefficient of determination, R² 0.9991 0.9996 0.9968 
Quadratic calibration curve y = ax² + bx + c    
a −4.2104 · 10
−6
 −7.8426 · 10
−5
 −9.9323 · 10
−5
 
b 0.2730 0.3868 0.4501 
c 8.4472 10.1879 18.9139 
 
Table 5.2: Precision of Rf values and quantification for the optimized HPTLC method on amino-modified silica 
(nx: oligosaccharides consisting of x hyalobiuronic acid moieties). Content reproduced from Table 2 of the 
original publication
1
 with kind permission from Elsevier. 
 n2 n3 n4 
Rf value: mean ± SD (RSD)    
Intra-day, N = 3  0.31 ± 0.03 
(7.78%) 
0.24 ± 0.03 
(12.91%) 
0.17 ± 0.03 
(17.65%) 
Inter-day, N = 3 0.35 ± 0.04 
(10.20%) 
0.26 ± 0.04 
(15.81%) 
0.20 ± 0.05 
(22.91%) 
Overall, N = 5 0.34 ± 0.03 
(9.11%) 
0.25 ± 0.03 
(12.94%) 
0.19 ± 0.03 
(18.19%) 
Calculated amount (pmol): mean ± SD (RSD)    
Intra-day, N = 3  445 ± 30  
(6.82%) 
286 ± 23  
(8.10%) 
330 ± 30  
(8.98%) 
Inter-day, N = 3 432 ± 18  
(4.15%) 
289 ± 35  
(12.13%) 
320 ± 20  
(6.30%) 
Overall, N = 5 440 ± 26  
(5.86%) 
292 ± 27  
(9.37%) 
331 ± 21  
(6.47%) 
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5.3.7 Robustness 
To evaluate robustness of the analytical method, the developing distance was increased, and 
the chromatography material was changed from HPTLC plates (glass-backed) to TLC plates 
(aluminum-backed). The former change simulates inadvertent exceeding of the validated 
developing distance in case of a device lacking automatic front detection. The latter variation 
explores a simplification, which might be relevant for screening purposes without the need 
of special HPTLC material. Rf values were determined for both variations. In addition, the 
amount of the oligosaccharides was calculated from the calibration standards on the 
respective plate. Mean, standard deviation, and relative standard deviation of all data from 
this experiment are summarized in Table 5.3.  
Table 5.3: Robustness of separation and thermal derivatization (nx: oligosaccharides consisting of x 
hyalobiuronic acid moieties). Content reproduced from Table 3 of the original publication
1
 with kind permission 
from Elsevier. 
 n2 n3 n4 
Robustness of separation    
Initial Rf  0.37 0.27 0.20 
Rf upon extension of developing distance to 80 mm 0.41 0.34 0.27 
Rf on aluminum-backed TLC plate  0.35 0.24 0.16 
Rf: mean ± SD (RSD) 0.38 ± 0.03  
(8.11%) 
0.28 ± 0.05  
(18.11%) 
0.21 ± 0.06  
(26.51%) 
Calculated amount (pmol): mean ± SD (RSD) 444 ± 34  
(7.59%) 
288 ± 20  
(6.94%) 
347 ± 13  
(3.70%) 
Robustness of derivatization    
Initial peak height (AU) 129.4 115.6 166.7 
Peak height (AU) after 5 d  125.4 112.3 161.7 
Peak height (AU) after 5 d + 1 h heating  126.1 121.9 188.0 
Peak height (AU): mean ± SD (RSD) 127.0 ± 2.1  
(1.68%) 
116.6 ± 4.9  
(4.18%) 
172.1 ± 14.0  
(8.11%) 
Calculated amount (pmol): mean ± SD (RSD) 449 ± 4  
(0.86%) 
272 ± 4  
(1.37%) 
339 ± 8  
(2.30%) 
 
When developing distance was 80 mm (from the bottom edge) instead of 70 mm, Rf values 
slightly increased, whereas the use of TLC material led to reduced Rf values. The range of 
standard deviations (0.03–0.06 Rf units), however, is comparable to that between different 
runs (Table 5.2). Peak heights were reduced in both cases due to peak broadening and, in 
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the case of the slim and flexible aluminum-backed TLC plate, probably also owing to the less 
tight contact between the TLC plate and the heater. Nevertheless, quantification is not 
affected, as it becomes obvious from the low relative standard deviations (3.70–7.59%). 
Additionally, the detection procedure was modified with respect to the time from heating to 
scanning and the heating period itself. To evaluate the effect on peak heights and 
quantification, the same plate was re-scanned after 5 days, heated again for 1 h, and 
scanned for a third time. It turned out that band intensities were stable over at least 5 days. 
Although absolute peak heights increase with the heating period, the quantification is not 
affected (Table 5.3) because the calibration standards on the plate are always treated the 
same way as the sample. It should be noted that the signal-to-noise ratio can be improved 
by prolonged heating, enabling the quantification of low amounts of hyaluronan 
oligosaccharides. To increase throughput, however, 15 min of heating may be considered 
adequate for routine analysis. 
In view of the optimal application, band length was varied between 4 and 12 mm (4, 6, 8, 10, 
and 12 mm) with an application volume of 5 or 10 µL (Figure 5.11). In this experiment, the 
validated conditions of 8 mm and 10 µL proved to be ideal. 
 
Figure 5.11: Variation of band length and spray volume. Amino-modified silica high performance thin layer 
chromatography (HPTLC) plate illuminated with UV light at 366 nm. Standard oligosaccharide mixture (n2–n4) 
500 pmol/band. Band length: 4 mm (lanes 1, 2), 6 mm (lanes 3, 4), 8 mm (lanes 5, 6), 10 mm (lanes 7, 8), 
12 mm (lanes 9, 10). Application volume: 10 µL (lanes 1, 3, 5, 7, and 9) or 5 µL (lanes 2, 4, 6, 8, and 10). Mobile 
phase: 1-butanol/formic acid/water (3:4:1). Developing distance: 6 cm (7 cm from the bottom edge). Vertical 
axes indicate the Rf scale. Reproduced from Supplementary Material 3 of the original publication
1
 with kind 
permission from Elsevier. 
  
92 5 Preparation of purified hyaluronan oligosaccharides and planar chromatography for quality control 
 
5.3.8 Thin layer chromatography coupled to mass spectrometry 
Hyphenation of thin layer chromatography and mass spectrometry (TLC–MS) with an 
appropriate interface broadens the applicability of planar chromatography for quality 
control of hyaluronan oligosaccharides. In this study, as proof of concept, ESI-Q-TOF-MS was 
used with standard silica TLC plates. In contrast to MALDI,9 ESI is compatible with aluminum 
and glass as carrier material for the stationary phase and can be applied on both, normal TLC 
and HPTLC material. 
A mixture (10 µL) of the purified oligosaccharide samples (250 µM each) was separated by 
normal phase TLC. Bands were located by densitometric scans at 205 nm. MS coupling in 
negative ionization mode revealed high resolution mass spectra with [M−H]− and [M−2H]2− 
ions as characteristic peaks. Full scan mass spectra obtained for the three oligosaccharides 
are depicted in Figure 5.12. The respective bands are marked in the inserted densitograms at 
205 nm. 
To identify the unknown peak at a mass-to-charge ratio of 982.99, the isotope pattern 
(Figure 5.13) was compared to the calculated and the experimental isotope pattern of the 
hyaluronan tetrasaccharide (n2) [M−H]
−
 ion (Figure 5.14). Calculated and experimentally 
observed isotope pattern for the sugar were in good accordance. The isotope pattern of the 
unidentified peak, however, suggested very low carbon content. Therefore, the signal 
probably corresponds to a highly fluorinated reaction product of the calibration standard 
hexakis(2,2,3,3-tetrafluoropropoxy)phosphazine.  
As a result from TLC–MS, the identity and purity of the oligosaccharides prepared by 
enzymatic digestion and column chromatographic purification were confirmed. In particular, 
no odd-numbered oligosaccharides or other sugar impurities could be detected. Regardless 
of the relatively high amounts of analytes required, hyphenation of automated HPTLC to ESI-
Q-TOF-MS represents an attractive tool for both, quantitative and unequivocal qualitative 
analysis of small hyaluronan oligosaccharides.  
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Figure 5.12: Full scan high resolution mass spectra of the hyaluronan oligosaccharides n2 (A), n3 (B), and n4 (C) 
obtained by direct TLC–MS coupling (calculated masses in parentheses, densitograms from localization of 
underivatized analytes at 205 nm). Each oligosaccharide 2.5 nmol/band. Stationary phase: silica. Mobile phase: 
1-butanol/formic acid/water (3:5:2). Developing distance: 6 cm (7 cm from the bottom edge). Reproduced from 
Supplementary Material 4 of the original publication
1
 with kind permission from Elsevier. 
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Figure 5.13: Isotope pattern of the signal at m/z = 982.9906 indicating the presence of a compound with a very 
low carbon content, probably corresponding to a reaction product of the highly fluorinated mass calibration 
standard hexakis(2,2,3,3-tetrafluoropropoxy)phosphazine. Reproduced from Supplementary Material 5 of the 
original publication
1
 with kind permission from Elsevier. 
 
Figure 5.14: Overlay of experimental (blue) and calculated (red) isotope pattern of the tetrasaccharide (n2) 
[M−H]
−
 ion (calculated mass in parentheses, densitogram: underivatized analytes scanned at 205 nm). 
Reproduced from Supplementary Material 6 of the original publication
1
 with kind permission from Elsevier. 
5.4 Summary and conclusion 
In addition to the fast CZE–ESI-TOF-MS method (cf. Chapter 3) and the sensitive 
electrochemical detection used in HPAEC–PAD (cf. Chapter 4), a convenient and cost-
effective HPTLC method for the analysis of small saturated hyaluronan oligosaccharides 
consisting of 2–4 hyalobiuronic acid moieties (n2–n4) was established, allowing for qualitative 
as well as quantitative determination. The separation on amino-modified silica plates and 
subsequent label-free detection is superior to classical colorimetric reactions like orcinol or 
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Morgan-Elson reagent staining. Furthermore, unequivocal identification of the hyaluronan 
oligosaccharides from normal phase TLC plates is enabled by direct ESI-Q-TOF-MS coupling. 
Quantitative HPTLC is comparable to sophisticated methods like fluorophore-assisted 
carbohydrate electrophoresis26 and CZE–ESI-TOF-MS (cf. Chapter 3) in terms of sensitivity. 
Although not reaching the excellent LOD values of HPAEC–PAD (cf. Chapter 4), in view of the 
low costs, the qualitative and quantitative analysis of multiple samples in parallel makes 
HPTLC an extremely interesting alternative, especially for quality control of hyaluronan 
oligosaccharides. 
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6 Product spectra of hyaluronidases from bovine testes 
and from Streptococcus agalactiae 
6.1 Introduction 
In our lab, bovine testicular hyaluronidase (BTH) and hyaluronidase from Streptococcus 
agalactiae, strain 4755, are used to identify hyaluronidase inhibitors. In addition, a lot of 
work was done on the characterization and comparison of these enzymes and respective 
preparations.1-3 Both of them are representative examples of mammalian type 
hyaluronidases and those of bacterial origin, respectively. Mammalian and bacterial 
hyaluronidases are of particular medical and pharmacological interest and are known to 
exhibit fundamentally different mechanisms of hyaluronan degradation (cf. Chapter 1, 
Section 1.2.1).4  
Testicular hyaluronidase is an endolytic enzyme, randomly hydrolyzing the β-1,4 glycosidic 
bonds of the hyaluronan chains.4, 5 Thereby, oligosaccharide mixtures, mainly containing the 
tetrasaccharide (n2) and the hexasaccharide (n3), are yielded after exhaustive digestion of 
hyaluronan.6-8 In addition, the enzymatic process is characterized by the parallel occurrence 
of hydrolysis and transglycosylation reactions, both contributing to the observed product 
formation.6-14  
Hyaluronidase from Streptococcus agalactiae catalyzes β-elimination with unsaturated 
disaccharides accumulating as end products.4, 15 A simplified reaction, assuming the 
theoretical minimal substrate (tetrasaccharide, n2), and the use of abbreviations for the 
oligosaccharides are illustrated in Figure 6.1. Oligosaccharides are abbreviated as nx 
according to the number of disaccharide units (x), asterisks indicate molecules with double 
bonds in the ring. Having observed no other oligosaccharides in partially digested 
hyaluronan, Pritchard et al. suggested a mechanism consisting of an initial random cleavage 
step followed by processive release of unsaturated disaccharides (n1*) from the end of the 
hyaluronan chain.15 Thereby, the enzyme is assumed to move along the polysaccharide 
chain.15 The processive mode of action was confirmed later by digestion studies16 as well as 
structural information of the enzyme in complex with substrate molecules of varying chain 
length.17-19 Nevertheless, the models differ with regard to the direction of enzymatic action. 
While Li and Jedrzejas propose degradation from the reducing to the non-reducing end,18 
Baker and Pritchard suggest the opposite direction.16 
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Figure 6.1: Formation of saturated (nx) and unsaturated (nx*) oligosaccharides by hyaluronidase from 
Streptococcus agalactiae, assuming the tetrasaccharide n2 as substrate. Oligosaccharides are abbreviated 
according to the number of disaccharide units (x). Asterisks indicate molecules with double bonds in the ring. 
Using hyaluronan and hyaluronan oligosaccharides of various molecular weights as 
substrates, this work aimed at deeper insight into the mechanisms of enzymatic action. 
Thereby, the focus was set on small oligosaccharides as these products of hyaluronan 
degradation are supposed to play important roles in physiological and pathophysiological 
processes.20 Moreover, enzymological characterization, which is only possible when minimal 
substrates are used, was carried out for the bacterial enzyme using HPAEC–PAD. 
6.2 Materials and methods 
6.2.1 Enzymes and substrates 
Bovine testicular hyaluronidase (BTH, Neopermease®) was kindly provided by Sanabo 
(Vienna, Austria). Bacterial hyaluronidase from Streptococcus agalactiae, strain 4755, was a 
gift from id-Pharma (Jena, Germany). Hyaluronan and hyaluronan oligosaccharides of various 
chain lengths were used as substrates. High molecular weight hyaluronan of bacterial origin 
(Streptococcus zooepidemicus) was purchased from Aqua Biochem (Dessau, Germany). 
Hyalo-Oligo, kindly provided by Kewpie (also named Q. P. Corp., Tokyo, Japan), served as low 
molecular weight hyaluronan oligosaccharide mixture with an average molecular weight 
+ 
n2 
n1 n1* 
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below 10 kDa. Purified oligosaccharides of 2–4 hyalobiuronic acid moieties (n2–n4) were 
prepared from high molecular weight hyaluronan as described in Chapter 5. For 
quantification, the colorimetric method was used (cf. Chapter 5, Section 5.2.3). 
6.2.2 Incubation mixtures 
The protocol for hyaluronan digestion was based on the conditions previously used in the 
colorimetric assay for the determination of hyaluronidase activity21, 22 and in studies by 
Hofinger et al.7, 10 on hyaluronan degradation by different hyaluronidases. A 0.2 M solution 
of disodium hydrogen phosphate (Merck, Darmstadt, Germany) was mixed with a 0.1 M 
solution of citric acid (Merck, Darmstadt, Germany), both containing 0.1 M sodium chloride 
(VWR, Haasrode, Belgium), to yield the desired pH value of 5.0. In general, incubation 
mixtures consisted of 4 parts of the incubation buffer, 2 parts of water (purified with a 
Milli-Q system, Millipore, Eschborn, Germany), 1 part of a 0.2 mg/mL solution of bovine 
serum albumin (Serva, Heidelberg, Germany), and 1 part of an aqueous solution of 
hyaluronan or hyaluronan oligosaccharides. For high molecular weight hyaluronan and the 
Hyalo-Oligo mixture, this solution contained 5 mg/mL of the respective hyaluronan 
preparation. The purified oligosaccharides were adjusted to the desired molarity using the 
concentration values calculated from colorimetric determination. 
Enzyme solutions were diluted by addition of bovine serum albumin solution to yield an 
activity of 500 or 400 IU/mL (BTH) and 500, 400, or 20 IU/mL (bacterial enzyme), based on 
the activity declaration by the supplier. 1 part of this enzyme solution was added to 8 parts 
of the incubation mixtures to start the enzymatic reaction, resulting in final activities of 
55.56, 44.44, and 2.22 IU/mL. The respective value is given with each experiment. To 
reference samples, bovine serum albumin solution was added instead.  
6.2.3 HPAEC–PAD 
After incubation at 37 °C for appropriate periods of time, the reaction was stopped by 
boiling. Precipitated protein was removed by centrifugation and filtration as described in 
Chapter 4 (Section 4.2.1). Prior to injection, samples were diluted 1:10 with purified water. 
Chromatography was then carried out as described (cf. Chapter 4), using the CarboPacTM 
PA200 column (Dionex/Thermo Fisher Scientific, Idstein, Germany) at an eluent flow rate of 
0.5 mL/min at 40 °C, 100 mM sodium hydroxide, and a gradient of 200–900 mM sodium 
acetate. In contrast to at-line CZE–ESI-TOF-MS (cf. Section 6.2.4), an additional sample 
(t = 0 min) was boiled immediately after addition of enzyme. 
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6.2.4 Fast at-line CZE–ESI-TOF-MS 
CZE–ESI-TOF-MS analysis was basically carried out according to the description in Chapter 3. 
For at-line experiments, a water bath (heated to 37 °C) was placed next to the CE system. 
The exact setup, including the water bath, was already presented in Section 3.2.5. To allow 
for pressure-free injection, a 25 µm × 28 cm capillary was used. The background electrolyte 
was ammonium acetate (25 mM, pH = 8.5). Aliquots from the incubation mixtures (cf. 
Section 6.2.2) in the water bath were taken after defined time intervals. After dilution with 9 
parts (1:10 dilution) of a 100 µM aqueous solution of acarbose (Bayer, Wuppertal, Germany) 
and short mixing, a 30 s pressure-free injection (using the suction from ESI-MS) was 
performed. For the first short time intervals, only single injections could be performed. 
Multiple consecutive injections were conducted for the later measurements. Control with 
bovine serum albumin instead of enzyme was measured at t = 0 min. 
6.2.5 Saturation experiment 
To determine enzymological parameters for the hyaluronidase from Streptococcus 
agalactiae, a saturation experiment was performed. Incubation mixtures were prepared as 
described (cf. Section 6.2.2), containing the tetrasaccharide (n2) at concentrations of 1, 2, 5, 
10, 20, 50, 100, 200, 500, 1000, and 2000 µM (determined by colorimetry). The enzyme was 
diluted to yield an activity of 5 IU/mL (according to the specification by the supplier) in the 
incubation mixture. Bovine serum albumin was added to control (t = 0 min) instead of 
enzyme. After 5, 10, 20, 30, 40, and 60 min of incubation at 37 °C, the reaction was stopped 
by 10 min of boiling, and protein was removed by centrifugation and filtration (cf. Chapter 4, 
Section 4.2.1). Samples with initial concentrations above 10 µM were diluted with purified 
water to a concentration of 10 µM to ensure linearity of the following HPAEC–PAD analysis. 
Chromatography conditions were the same as listed in Section 6.2.3. For each incubation 
period, the substrate concentrations were calculated from the initial concentration and the 
ratio of peak areas compared to control. Curves were fitted with SigmaPlot for Windows 
11.2.0.5 (Systat Software Inc., San Jose, CA, USA). 
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6.3 Results and discussion 
6.3.1 Degradation of a low molecular weight hyaluronan oligosaccharide 
mixture by bovine testicular hyaluronidase 
The bacterial enzyme shows maximum activity at a pH value of 5.0.1 In addition, this value 
lies in between the different maxima of the activity curves obtained for bovine testicular 
hyaluronidase (BTH) by turbidimetric and colorimetric determination7 as well as for the 
different fractions from size exclusion chromatography of the BTH preparation.1, 7 
Consequently, reactions were carried out at pH = 5.0. 
The time-dependent degradation of a mixture of hyaluronan oligosaccharides of low 
molecular weight by bovine testicular hyaluronidase was analyzed by HPAEC–PAD (Figure 
6.2). Thereby, a series of oligosaccharides was observed, exhibiting a time-dependent 
decrease in molecular weight. These findings and the accumulation of n2 and n3 as end 
products were consistent with the degradation of high molecular weight hyaluronan (at 
pH = 5.5) followed by CZE analysis.7 Moreover, the proposed random endolytic mechanism 
of bovine testicular hyaluronidase4, 5 was supported. In addition, Deschrevel et al. recently 
reported that the most stable enzyme–substrate complexes were formed with 
oligosaccharides of 8–20 hyalobiuronic acid moieties (n8–n20).
23 In agreement with this data, 
we observed fast degradation of the oligosaccharides of this size range at the beginning of 
the incubation. The formed fragments seemed to be much poorer substrates, resulting in 
only very slow further cleavage. 
After 72 h, the tetrasaccharide (n2) and the hexasaccharide (n3) were the main products. 
Nevertheless, n3 was produced much faster than n2. Within the first 24 h, more n3 than n2 
was present in the mixture (Figure 6.2 B). Hence, the time-dependent curves were in very 
good accordance to the results reported by Cramer et al. for the degradation of the 
decasaccharide (n5) who obtained basically identical curve shapes for n2, n3, and n4.
6 The 
formation of relatively high amounts of n2 seemed to correlate with the disappearance of n4 
(Figure 6.2 B), which might be cleaved into two molecules of n2. Another possible reason for 
the increased amount of n2 after prolonged incubation is the additional contribution of 
transglycosylation to the formation of this saccharide from n3,
6, 9 becoming more relevant 
with increasing concentrations of n3. To study the turnover of small oligosaccharides in 
detail, additional CZE–ESI-TOF-MS experiments were performed. The results are discussed in 
Section 6.3.3. 
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Figure 6.2: Time-dependent degradation of a low molecular weight hyaluronan oligosaccharide mixture by 
bovine testicular hyaluronidase (44.44 IU/mL) at pH = 5.0. Chromatograms (A) and peak areas (B). HPAEC–PAD: 
10 µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–
900 mM sodium acetate, 40 °C, 0.5 mL/min. 
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6.3.2 Size-dependent degradation of hyaluronan by bovine testicular 
hyaluronidase 
The incubation of both, high molecular weight hyaluronan (HMW HA) and low molecular 
weight hyaluronan (LMW HA), led to the intermediate formation of multiple 
oligosaccharides and accumulation of n2, n3, and n4 after 24 h (Figure 6.3). Hence, no 
principal differences in the mechanism and the formed main products were observed for 
HMW and LMW substrates. As the enzyme acts randomly,5 higher amounts of small 
oligosaccharides were observed after 1 h for the LMW mixture (Figure 6.3 E), compared to 
the long chains providing more possible positions for endolytic attack (Figure 6.3 B). As 
already discussed in Section 6.3.1, the small oligosaccharides are relatively poor substrates 
to the enzyme. For this reason and due to their increased formation from LMW hyaluronan, 
significant amounts of residual oligosaccharides n5, n6, and n7 were still present after 24 h in 
Figure 6.3 F, but not in Figure 6.3 C. In summary, this is in agreement with the mechanism 
proposed in Section 6.3.1. 
 
Figure 6.3: Incubation of high molecular weight hyaluronan (HMW HA, A–C) and a low molecular weight 
hyaluronan oligosaccharide mixture (LMW HA, D–F) with bovine testicular hyaluronidase (44.44 IU/mL) at 
pH = 5.0 for 1 h (B, E) and 24 h (C, F). Controls (A, D) contained bovine serum albumin instead of enzyme. 
HPAEC–PAD: 10 µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient 
of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
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6.3.3 Fast at-line analysis of hyaluronan oligosaccharide degradation by 
bovine testicular hyaluronidase 
In an at-line CZE–ESI-TOF-MS experiment, 500 µM of the octasaccharide (n4, Figure 6.4), the 
hexasaccharide (n3, Figure 6.5), and the tetrasaccharide (n2, Figure 6.6) were incubated with 
55.56 IU/mL bovine testicular hyaluronidase. Although signals of different analytes cannot 
be compared quantitatively due to differences in ionizability and MS sensitivity at the 
respective m/z ratio, qualitative and semi-quantitative conclusions are possible. 
Interestingly, the disappearance of n4 was accompanied by an almost parallel formation of 
n2 and n3 (Figure 6.4 B). Hence, the mechanism cannot be described by simple hydrolysis. 
Otherwise, significant amounts of n1 would have been expected from the formation of n3. 
Moreover, the formation of two molecules of n2 out of one molecule of n4 should have led to 
higher amounts of n2 compared to n3, assuming comparable contribution of both reactions. 
However, the findings are absolutely consistent with recent results by Kakizaki et al. and 
their mechanistic model.11 The authors suggested the intermediate formation of a 
disaccharide unit (n1) which is immediately transferred to the non-reducing end of a second 
oligosaccharide.11 However, free n1 was only detected in their incubation mixtures at trace 
concentrations using mass spectrometry.11 By CZE–ESI-TOF-MS we were able to confirm the 
occurrence of only traces of n1 (Figure 6.4, insets, light blue). Additionally, the formation of 
the decasaccharide (n5) as product of transglycosylation was proven by Kakizaki et al.
11 as 
well as by our own experiments (Figure 6.4, insets, violet). We could even detect traces of 
the dodecasaccharide (n6) after approximately 60–120 min of incubation (Figure 6.4, insets, 
orange). Assuming the described mechanism, the parallel formation of n2 and n3 can be 
explained by the transfer of intermediately formed n1 to n4, followed by the hydrolysis of the 
resulting n5 yielding n2 and n3. 
Neither n3 (Figure 6.5) nor n2 (Figure 6.6) showed any degradation. Although n3 is known to 
be the minimal substrate of bovine testicular hyaluronidase,6, 8-11 the hexasaccharide is 
reported to be an extremely poor substrate of the enzyme.10, 11 Kakizaki et al. reported the 
degradation of approximately 10% of n3 after 24 h.
11 In addition, Hofinger et al. described an 
inhibitory effect of n3 on enzyme activity at concentrations of 200–800 µM (depending on 
pH).10 With regard to the 1:10 dilution step, necessary for at-line CZE–ESI-TOF-MS, a 
relatively high oligosaccharide concentration of 500 µM had been chosen. Thus, substrate 
inhibition may explain why n3 was not degraded. 
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Figure 6.4: Incubation of the octasaccharide (n4, 500 µM) with bovine testicular hyaluronidase (55.56 IU/mL) at 
pH = 5.0. Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 
sample dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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Figure 6.5: Incubation of the hexasaccharide (n3, 500 µM) with bovine testicular hyaluronidase (55.56 IU/mL) at 
pH = 5.0. Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 
sample dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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Figure 6.6: Incubation of the tetrasaccharide (n2, 500 µM) with bovine testicular hyaluronidase (55.56 IU/mL) at 
pH = 5.0. Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 
sample dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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6.3.4 Degradation of a low molecular weight hyaluronan oligosaccharide 
mixture by hyaluronidase from Streptococcus agalactiae 
HPAEC–PAD of the time-dependent degradation of a low molecular weight hyaluronan 
oligosaccharide mixture by hyaluronidase from Streptococcus agalactiae (2.22 IU/mL) 
revealed a significant increase in the void volume signal (Figure 6.7). Additionally, 
considerable amounts of an intermediate product (with a retention time of approximately 
7.2 min) were formed. This peak was followed by a series of small peaks eluting at retention 
times in between those observed for the standard oligosaccharides (n2–n4, grey arrows in 
Figure 6.7 A). By additional CZE–ESI-TOF-MS analysis, the unsaturated tetrasaccharide (n2*) 
was proven to be the major intermediate product. Consequently, the peak at a retention 
time of 7.2 min was assigned to n2*. Hence, the unsaturated oligosaccharides (nx*) are 
eluted after the respective saturated equivalents (nx) under the given chromatography 
conditions. The observation of additional unsaturated (apart from n1*), but no saturated 
oligosaccharides, was in accordance with previous reports.3, 16 Nevertheless, to our 
knowledge the intermediate formation of such remarkable amounts of n2* has not been 
described so far.  
Hyaluronidase from Streptococcus agalactiae is supposed to act via an initial random 
cleavage step, followed by processive exolytic degradation of the residual hyaluronan 
chains.15-19, 24 Our observations support the assumption by Hoechstetter that every initial 
attack leads to the liberation of an unsaturated oligosaccharide,3 predominantly the 
tetrasaccharide (n2*). In this case, the relatively high number of single molecules in a low 
molecular weight hyaluronan oligosaccharide mixture, compared to native hyaluronan, 
should promote the formation of these intermediate products. This aspect will be discussed 
in Section 6.3.5. After prolonged periods of incubation, the intermediately formed 
oligosaccharides were also accepted as substrates and further degraded (Figure 6.7 B). 
Hence, this result raised the question if small saturated oligosaccharides were substrates of 
Streptococcus agalactiae hyaluronidase as well. Further studies on this subject are discussed 
in Section 6.3.6. 
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Figure 6.7: Time-dependent degradation of a low molecular weight hyaluronan oligosaccharide mixture by 
hyaluronidase from Streptococcus agalactiae (2.22 IU/mL) at pH = 5.0. Chromatograms (A) and peak areas (B). 
HPAEC–PAD: 10 µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient 
of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
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6.3.5 Size-dependent degradation of hyaluronan by hyaluronidase from 
Streptococcus agalactiae 
The theoretical considerations from Section 6.3.4 were supported by the size-dependent 
degradation of hyaluronan. If high molecular weight hyaluronan (HMW HA) was used as 
substrate for hyaluronidase from Streptococcus agalactiae, the amount and variety of 
oligosaccharides accumulating after 24 h was significantly lower than for a low molecular 
weight oligosaccharide mixture (Figure 6.8). As the number of individual molecules per mass 
unit is much higher for the oligosaccharide mixture than for native hyaluronan, the liberation 
of oligosaccharides by the initial random attack becomes more probable. 
 
Figure 6.8: Incubation of high molecular weight hyaluronan (HMW HA, A–C) and a low molecular weight 
hyaluronan oligosaccharide mixture (LMW HA, D–F) with hyaluronidase from Streptococcus agalactiae 
(2.22 IU/mL) at pH = 5.0 for 1 h (B, E) and 24 h (C, F). Controls (A, D) contained bovine serum albumin instead of 
enzyme. HPAEC–PAD: 10 µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, 
gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. Asterisks indicate the presence of double bonds in 
the oligosaccharides. 
When the enzyme activity in the incubation mixture was increased (44.44 IU/mL instead of 
2.22 IU/mL), the reaction was much faster. After 1 h, considerable amounts of n2* were 
detectable. However, after 24 h it had completely disappeared, thus proving that n2* is only 
an intermediate product of the reaction (Figure 6.9).  
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Figure 6.9: Incubation of high molecular weight hyaluronan (HMW HA) with hyaluronidase from Streptococcus 
agalactiae (44.44 IU/mL) at pH = 5.0 for 1 h (A) and 24 h (B). HPAEC–PAD: 10 µL of diluted (1:10) sample 
injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 
0.5 mL/min. The intermediately formed unsaturated tetrasaccharide is abbreviated as n2*. 
6.3.6 Fast at-line analysis of hyaluronan oligosaccharide degradation by 
hyaluronidase from Streptococcus agalactiae 
By analogy with Section 6.3.3, 500 µM of the octasaccharide (n4, Figure 6.10), the 
hexasaccharide (n3, Figure 6.11), and the tetrasaccharide (n2, Figure 6.12) were incubated 
with 55.56 IU/mL hyaluronidase from Streptococcus agalactiae.  
Degradation of n4 yielded a complex mixture of saturated (nx) and unsaturated (nx*) 
intermediate products with n1 and n1* accumulating at the end of the incubation (Figure 
6.10). Interestingly, the direct formation of n1* and n3 from n4 was not observed. By 
contrast, both of the two other possible reactions (n4 → n2 + n2* and n4 → n1 + n3*) were 
catalyzed by the enzyme. Again, n2* seemed to be the preferred intermediate product. 
Assuming a roughly comparable ionizability of both, the maximum concentration of n2 was 
much lower than that of n2*. Therefore, it may be concluded that n2 tends to be retained in 
the active site of the enzyme and to be further degraded faster than n2*. At first sight, the 
presence of free saturated oligosaccharides in the mixture seemed to contradict a processive 
mode of action.15-19, 24 Nevertheless, the affinity of small oligosaccharides for the active site 
of the enzyme may be considerably lower compared to highly polymeric hyaluronan. As a 
consequence, saturated oligosaccharides would be liberated to a certain extent after the 
initial attack of the enzyme. As the intermediate products disappeared from the incubation 
mixture, the concentration of n1* increased continuously. Both disaccharides (n1 and n1*) 
were not accepted as substrates, leading to accumulation of these molecules. 
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In the next step, the enzyme was provided with n3 as substrate to further investigate if n2* 
or n1* was the predominant reaction product at the beginning of the incubation (Figure 
6.11). The results were in good accordance with the previous experiments. Initially, the 
formation of n2* (n3 → n1 + n2*) prevailed over n1* (n3 → n1* + n2). As n1 was produced in 
parallel to n2*, more n1 accumulated when compared to Figure 6.10. It should be noted 
again that the sensitivity of ESI-TOF-MS differs, depending on the respective 
oligosaccharides. For this reason the sum of the standardized peak areas of the end products 
was lower than expected from the stoichiometric relation of educt (n3) to products (n1, n1*). 
Finally, n2 was proven to be the minimal substrate of hyaluronidase from Streptococcus 
agalactiae (Figure 6.12). Although an equimolar mixture of n1 and n1* was expected as end 
products, the standardized peak areas were not equal. As discussed above, this can be 
explained by differences in ionization and sensitivity of ESI-TOF-MS. Both disaccharides were 
not further degraded. 
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Figure 6.10: Incubation of the octasaccharide (n4, 500 µM) with hyaluronidase from Streptococcus agalactiae 
(55.56 IU/mL) at pH = 5.0. Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple 
injections. Asterisks indicate unsaturated oligosaccharides (containing a double bond). CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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Figure 6.11: Incubation of the hexasaccharide (n3, 500 µM) with hyaluronidase from Streptococcus agalactiae 
(55.56 IU/mL) at pH = 5.0. Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple 
injections. Asterisks indicate unsaturated oligosaccharides (containing a double bond). CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
Migration time (s)
20 30 40 50
S
ig
n
a
l 
in
te
n
si
ty
 (
co
u
n
ts
)
0
2500
5000
7500
10000
12500
Acarbose
n1
n1*
n2
n2*
n3
Control
1 min
3 min
6 min
10 min
22 min
30 min
40 min
60 min
90 min
120 min
180 min
15 min
Incubation time (min)
0 30 60 90 120 150 180
R
a
ti
o
 o
f 
p
e
a
k
 a
re
a
s 
(A
/A
A
ca
rb
o
se
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
n1
n1*
n2
n2*
n3
0 10 20 30
0.0
0.1
0.2
6.3 Results and discussion  115 
 
A 
 
B 
 
Figure 6.12: Incubation of the tetrasaccharide (n2, 500 µM) with hyaluronidase from Streptococcus agalactiae 
(55.56 IU/mL) at pH = 5.0. Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple 
injections. Asterisks indicate unsaturated oligosaccharides (containing a double bond). CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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6.3.7 Saturation experiment using the minimal substrate (n2) for 
Streptococcus agalactiae hyaluronidase 
Having identified the tetrasaccharide (n2) as minimal substrate of hyaluronidase from 
Streptococcus agalactiae, strain 4755, this molecule was used for the determination of 
Michaelis-Menten kinetics. 5 IU/mL of the enzyme were incubated with increasing 
concentrations of n2. Time-dependent reduction of the n2 peak area was determined by 
HPAEC–PAD. Concentration of n2 was plotted versus incubation time (Figure 6.13 A). From 
quadratic curve fits, the initial degradation velocities were calculated as slope of the tangent 
line at an incubation time of 0 min (derivative of the curve).  
The absolute values of the initial degradation velocity were plotted versus substrate 
concentration (Figure 6.13 B). Hyperbolic curve fitting was carried out according to the 
Michaelis-Menten equation. From the curve, maximum velocity (vmax) and Michaelis 
constant (Km) were calculated. Given as calculated values ± standard error from the fit, Km 
was 923 ± 106 µM, vmax was 3.68 ± 0.20 nmol/min. Hence, Km was considerably higher (by a 
factor of 6) than the apparent Km values reported by Hofinger for mammalian testicular 
hyaluronidases and their respective minimal substrates but comparable to recombinant 
human Hyal-1.25 In conclusion, the affinity of the tetrasaccharide (n2) for the bacterial 
enzyme was relatively low. This finding confirmed the theoretical considerations with regard 
to affinity and liberation of saturated oligosaccharides in Section 6.3.6. 
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Figure 6.13: Determination of Michaelis-Menten kinetics for hyaluronidase (5 IU/mL) from Streptococcus 
agalactiae, strain 4755, at pH = 5.0. Time-dependent degradation of the tetrasaccharide (n2) with quadratic 
curve fits (A) and initial degradation velocity plotted versus substrate concentration (B). Concentrations were 
calculated from the relative reduction of the educt peak in HPAEC–PAD chromatograms. Km and vmax/2 were 
determined by hyperbolic curve fitting according to the Michaelis-Menten theory. 
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6.4 Summary and conclusion 
A combination of HPAEC–PAD and fast at-line CZE–ESI-TOF-MS provided new insights into 
the enzymatic mechanisms of hyaluronidases from bovine testes and Streptococcus 
agalactiae, strain 4755. Thereby, we focused mainly on the turnover of hyaluronan 
oligosaccharides. Bovine testicular hyaluronidase was confirmed to attack the hyaluronan 
chains randomly. Moreover, a degradation study for the octasaccharide (n4) supported the 
mechanism recently suggested by Kakizaki et al. after similar studies.11  
With the bacterial enzyme, unsaturated disaccharide (n1*) accumulated as end product. 
Among the intermediately liberated unsaturated oligosaccharides, the tetrasaccharide (n2*) 
seemed to play a predominant role. Therefore, we suggested that n2* is preferably cleaved 
off during the initial step of enzymatic action of Streptococcus agalactiae hyaluronidase. 
When small saturated oligosaccharides were used as substrates, saturated and unsaturated 
oligosaccharides were liberated. By contrast, saturated intermediate products are usually 
not observed upon the degradation of high molecular weight hyaluronan. As the saturated 
disaccharide (hyalobiuronic acid, n1) was not accepted as substrate, n1 accumulated together 
with n1*. 
The saturated tetrasaccharide (n2) was identified as minimal substrate of the Streptococcus 
agalactiae hyaluronidase. Hence, it was used at increasing concentrations for a saturation 
experiment with 5 IU/mL of the enzyme. Kinetic parameters according to the Michaelis-
Menten theory (Km = 923 ± 106 µM, vmax = 3.68 ± 0.20 nmol/min) were determined.  
By analogy with BTH and hyaluronidase from Streptococcus agalactiae, the presented 
experimental protocols can easily be applied to the characterization of human enzymes as 
well as hyaluronidases from different pathogens or animal venoms. HPAEC–PAD and CZE–
ESI-TOF-MS allow for the determination of product spectra, minimal substrates, and kinetic 
parameters. Moreover, analysis of the enzymatic degradation of other glycosaminoglycans 
(e. g. chondroitin sulfate) is conceivable.  
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7 In vitro studies on recombinant human PH-20, 
PEG-PH-20, and Hyal-1 
7.1 Introduction 
In Chapter 6, bovine testicular hyaluronidase (BTH) has been presented as a typical 
mammalian hyaluronidase. With their catalytic domains being highly conserved, the 
different mammalian hyaluronidase isoenzymes are supposed to exhibit very similar 
catalytic mechanisms.1 Nevertheless, it is known from previous studies that these 
isoenzymes vary with regard to degradation of hyaluronan2 and hyaluronan 
oligosaccharides.3 Understanding the particularities of the human hyaluronidases is a 
prerequisite for elucidating the physiological and pathophysiological role of these enzymes. 
The human counterpart of BTH is the sperm protein PH-20, which was identified as 
hyaluronidase in 1993.4 By analogy with the physiological role of PH-20,5 pharmaceutical 
preparations of recombinant human PH-20 (rhPH-20) were successfully applied to 
intracytoplasmic sperm injection (ICSI).6, 7 Furthermore, co-administered rhPH-20 has been 
reported to increase subcutaneous bioavailability of drugs.8, 9 
Human plasma hyaluronidase (Hyal-1) was also successfully cloned and expressed using 
different expression systems.10, 11 Independent from the expression system, recombinant 
human Hyal-1 (rhHyal-1) exhibited maximum activity at pH values of 3.5–4.0,10, 11 
comparable to hyaluronidases isolated from human plasma,10 serum,12 liver,13 and urine.14 
By contrast, BTH and rhPH-20 showed completely different pH profiles with maximum 
activity at pH > 4.0.2, 10 
Both human hyaluronidases, Hyal-1 and PH-20, have previously been cloned, expressed, 
purified, and comparatively characterized in our group.2, 3, 11, 15 Now, additional recombinant 
enzyme preparations from a different source became available. Hence, these enzymes had 
to be characterized in terms of pH profiles, mode of action, and potential inhibitors. By 
analogy with Chapter 6, we focused especially on the degradation of hyaluronan 
oligosaccharides, which not only promised best insight into the mechanisms of the 
enzymatic cleavage but are also supposed to play an important biological role.16 
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7.2 Materials and methods 
7.2.1 Enzymes, activity units, substrates, and putative inhibitors 
Recombinant human PH-20 (rhPH-20), PEGylated  PH-20 (PEG-rhPH-20), and Hyal-1 
(rhHyal-1) preparations from Halozyme Therapeutics (San Diego, CA, USA) were a kind gift 
from Gregory I. Frost, PhD. Bovine testicular hyaluronidase (BTH, Neopermease®), kindly 
provided by Sanabo (Vienna, Austria), was additionally used for comparison of product 
spectra.  
The activities of the recombinant human enzymes were determined by a colorimetric assay 
(cf. Section 7.2.4). To fit the calibration range, rhPH-20 and PEG-rhPH-20 were diluted by 
addition of histidine buffer (10 mM histidine, 130 mM sodium chloride, pH = 6.5), the 
solvent of these enzymes. By contrast, rhHyal-1 was diluted by addition of incubation buffer. 
Activity was determined at pH = 5.0 for rhPH-20 and PEG-rhPH-20 (for better comparability 
to BTH) or at pH = 3.5 for rhHyal-1. According to Oettl, a formation rate of 0.1 nmol N-acetyl-
D-glucosamine equivalents per minute (0.1 mU) is equivalent to approximately 1 IU for 
bovine testicular hyaluronidase (using hyaluronan from rooster comb).17 Although 
hyaluronan from Streptococcus zooepidemicus (Aqua Biochem, Dessau, Germany) was used 
in this work, all activities of the recombinant human hyaluronidases are given as IU using this 
conversion factor. Activities for BTH are based on the specification by the supplier.  
By analogy with Chapter 6, Hyalo-Oligo (Kewpie/Q. P. Corp., Tokyo, Japan), and purified 
oligosaccharides (prepared and quantified by colorimetry according to Chapter 5) were used 
as substrates in addition to hyaluronan from a bacterial source. For inhibition studies, 
diclofenac, indomethacin, and L-ascorbic acid-6-O-hexadecanoate (vitamin C palmitate) were 
purchased from Sigma-Aldrich (Munich, Germany). 
7.2.2 Determination of protein content 
Protein content of the enzyme preparations was determined by the Bradford method.18 
Human serum albumin (Behringwerke, Marburg, Germany) was used for calibration at 
concentrations of 50–600 µg/mL. The determination was carried out in a miniaturized 
version of the Bio-Rad protein assay. Different dilutions of the rhPH-20 (1:100, 1:10), the 
PEG-rhPH-20 (1:50, 1:10), and the rhHyal-1 (1:10, 1:5, 1:2) preparations were made. 10 µL of 
the calibration standards and the sample dilutions were transferred to a 96-well plate (in 
duplicate). 200 µL of the 1:5 diluted Bio-Rad protein assay dye reagent concentrate (Bio-Rad, 
Munich, Germany) were added. After 5 min of incubation, absorbance at 580 nm (slit 10 nm) 
was measured with a Tecan GENios Pro plate reader (Tecan, Crailsheim, Germany). Data 
were recorded with the corresponding XFluor GENios Pro software V.4.55. Apart from the 
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1:2 dilution of the rhHyal-1 preparation, all other dilutions were within the calibrated 
concentration range and therefore used for calculation of protein content. 
7.2.3 Incubation mixtures 
The composition of incubation mixtures was essentially the same as in the experiments of 
Chapter 6 (Section 6.2.2.). However, incubation buffers of different pH values were used in 
this chapter. Thereby, adjustment of pH was achieved by mixing the two buffer components 
in appropriate ratios. By analogy with Chapter 6, enzymes were diluted with a 0.2 mg/mL 
solution of bovine serum albumin (BSA, Serva, Heidelberg, Germany), which was also added 
to the negative (enzyme-free) controls instead of the enzyme-containing samples.  
7.2.4 Colorimetric hyaluronidase activity assay 
The incubation mixture was placed in a water bath at 37 °C for 30 min. The reaction was 
stopped by addition of alkaline borate solution and boiling for 4.5 min. The formation of 
oligosaccharides with N-acetyl-D-glucosamine at the reducing end was measured by the 
Morgan-Elson reaction.19-22 Details were already described in Chapter 5 (Section 5.2.3). 
7.2.5 Turbidimetric hyaluronidase activity assay 
The turbidimetric hyaluronidase activity assay was a modification of the method by 
Di Ferrante23 adapted for 96-well plates. Incubation mixtures were prepared as described (cf. 
Chapter 6, Section 6.2.2), except for the hyaluronan solution (2 mg/mL instead of 5 mg/mL). 
For the determination of pH dependency, pH of the buffer was adjusted to values of 2.0–9.0. 
Inhibition was determined at pH = 5.0 for rhPH-20 and PEG-rhPH-20, at pH = 3.5 for 
rhHyal-1. 3 µL of the putative inhibitor, dissolved in DMSO (Merck, Darmstadt, Germany), or 
pure solvent as control were pipetted into the wells of the 96-well plate. 60 µL of a prepared 
mixture (containing 31 µL of buffer, 8.1 µL of BSA solution, 12.8 µL of water, and 8.1 µL of 
hyaluronan solution) were added. Reaction was started by addition of 10 µL of enzyme 
solution (diluted with BSA solution). Control A contained no inhibitor and BSA solution 
instead of enzyme (no activity, equivalent to 100% inhibition). Control B also contained no 
inhibitor, but the respective amount of enzyme (maximum activity, 0% inhibition).  
After incubation at 37 °C (30 min for pH profile, different  time intervals for inhibitor testing), 
200 µL of 2.5% (m/v) cetyltrimethylammonium bromide (CTAB, Merck, Darmstadt, 
Germany), dissolved in 0.5 M sodium hydroxide solution (Carl Roth, Karlsruhe, Germany), 
were added to each well. Plates were kept for additional 20 min at room temperature. 
Afterwards, turbidity was determined by measurement of extinction at 580 nm with a Tecan 
GENios Pro plate reader (Tecan, Crailsheim, Germany). Activity was expressed as relative 
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enzymatic activity compared to control A (0% activity) and control B (100% activity). 
SigmaPlot for Windows 11.2.0.5 (Systat Software Inc., San Jose, CA, USA) was used for fitting 
of inhibition curves (ligand binding, sigmoidal concentration-response curve, variable slope). 
7.2.6 HPAEC–PAD and fast at-line CZE–ESI-TOF-MS 
HPAEC–PAD and fast at-line CZE–ESI-TOF-MS protocols were the same as described in 
Chapter 6 (Sections 6.2.3 and 6.2.4). In detail, the methods were presented in Chapter 3 
(CZE–ESI-TOF-MS) and Chapter 4 (HPAEC–PAD), respectively. For CZE–ESI-TOF-MS, control 
with BSA instead of enzyme was measured at t = 0 min. For HPAEC–PAD, an additional 
measurement of an immediately boiled sample was performed. 
7.3 Results and discussion 
7.3.1 Protein content and activity 
Protein content and activities of the rhPH-20, PEG-rhPH-20, and rhHyal-1 preparations are 
listed in Table 7.1. 
Table 7.1: Protein content (Bradford assay) and activity (Morgan-Elson assay) of the recombinant human 
hyaluronidases rhPH-20, PEG-rhPH-20, and rhHyal-1. Activities expressed as IU (marked with 
#
) were calculated 
from the activity unit U using a factor of 10000 by analogy with BTH
17
 as discussed in Section 7.2.1.  
Enzyme pH of activity 
determination 
Protein content 
(µg/mL) 
Activity per mL 
(µmol/min) 
Specific activity 
(U/mg) 
rhPH-20  5.0 (!) 10.1 44.6 (≈ 446000 IU)
#
 4.4 (≈ 44000 IU/mg)
#
 
PEG-rhPH-20 5.0 (!) 5.2 9.0 (≈ 90000 IU)
#
 1.7 (≈ 17000 IU/mg)
#
 
rhHyal-1 3.5 1.3 4.7 (≈ 47000 IU)
#
 3.6 (≈ 36000 IU/mg)
#
 
 
Although pH optima of rhPH-20 and PEG-rhPH-20 later were found to be at more acidic pH 
of 4.0 (cf. Section 7.3.2), activity values listed in Table 7.1 were determined at pH = 5.0. This 
value lies in between the different maxima of the activity curves obtained for a previously 
described preparation of rhPH-20 by turbidimetric and colorimetric determination.2 
Moreover, for comparison with BTH (cf. Chapter 6), experiments on oligosaccharide 
degradation were carried out at pH = 5 (cf. Section 7.3.4). However, activity at the optimum 
(pH = 4.0) can be calculated considering the pH profiles (Figure 7.1) of rhPH-20 (75% of 
maximum activity at pH = 5.0, colorimetric assay) and PEG-rhPH-20 (71% of maximum 
activity at pH = 5.0, colorimetric assay). 
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7.3.2 Influence of pH on enzymatic activity 
The enzymatic activity of the recombinant human hyaluronidase preparations depending on 
pH was determined using both the colorimetric and the turbidimetric assay (Figure 7.1). In 
previous studies, the pH optima of BTH and a different rhPH-20 preparation were assay-
dependent.2, 24 By contrast, the curves obtained from both assays were equivalent for the 
enzyme preparations discussed in this chapter. The variants of the testicular enzyme 
(rhPH-20 and PEG-rhPH20) showed maximum activity at a pH of 4.0 (Figure 7.1 A, B). Thus, 
the optimum was slightly shifted towards more acidic pH values compared to the study of 
Hofinger et al., who reported optima of pH = 4.5 (colorimetric assay) and pH = 5.5 
(turbidimetric assay) for their preparations of rhPH-20.2 However, for rhHyal-1 the optimum 
at an acidic pH of 3.5 (Hofinger et al.: pH = 3.5–4.0)2 with a very fast decrease in activity at 
higher pH was confirmed (Figure 7.1 C). 
Apart from the enzymes, the composition of the incubation mixtures was identical to the 
conditions by Hofinger et al.,2 whereas incubation time was reduced to 30 min. As the pH 
optimum of BTH is known to depend on buffer type and composition,20, 25 identical 
parameters were chosen for the colorimetric assay and the turbidimetric assay. According to 
previous protocols, only the concentration of hyaluronan differed by a factor of 2.5 to 
guarantee linearity in the turbidimetric assay.2  
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Figure 7.1: Enzymatic activity of the rhPH-20 (A), PEG-rhPH-20 (B), and rhHyal-1 (C) preparations as a function 
of pH. Activities were determined by colorimetric (circle, red) and turbidimetric (square, blue) assay. Data 
presented as mean of three independent experiments (additionally performed in duplicate for the 
turbidimetric assay). Maximum values set as 100%. 
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7.3.3 Degradation of a low molecular weight hyaluronan oligosaccharide 
mixture by rhPH-20, PEG-rhPH-20, and BTH 
A low molecular weight hyaluronan oligosaccharide mixture was incubated with BTH (Figure 
7.2 and Figure 7.3), rhPH-20 (Figure 7.4 and Figure 7.5), and PEG-rhPH-20 (Figure 7.6 and 
Figure 7.7) and analyzed by HPAEC–PAD. By analogy with the CZE experiments on the 
degradation of high molecular weight hyaluronan described in an article by Hofinger et al., 
incubation buffers of pH = 4.5 and pH = 5.5 were chosen in view of the reported pH-
dependent differences.2 
Neither from the chromatograms (Figure 7.2) nor from the areas of the peaks for the 
oligosaccharides n2–n6 (Figure 7.3), pH-dependent differences in product formation became 
obvious for BTH. The results at pH = 4.5 as well as pH = 5.5 were comparable to digestion at 
pH = 5.0, discussed in Chapter 6 (Section 6.3.1). After initial formation of mainly n3, n2 
became the main product after prolonged incubation. This is in agreement with the 
observation discussed in detail in Chapter 6 (Section 6.3.1). Using the same concentration of 
BTH, product formation was generally faster at pH = 4.5 (Figure 7.3 A) compared to pH = 5.5 
(Figure 7.3 B). This outcome correlates with the pH profile of BTH as determined by 
colorimetry.24 From comparison of the colorimetric and the turbidimetric activity assay in 
combination with CZE analysis, Hofinger et al. concluded that the degradation of native 
hyaluronan and fragments consisting of more than 20 disaccharide units (> n20) was 
preferred at pH = 5.5.2 In this study, a mixture of hyaluronan oligosaccharides was used. 
Therefore, degradation of high molecular weight hyaluronan did not contribute to the 
measured velocity of product formation. Additionally, transglycosylation, competing with 
hydrolysis, is known to play an increasing role at higher pH.25, 26 Both aspects may explain 
why the degradation of low molecular weight hyaluronan by BTH was faster at pH = 4.5. 
When high molecular weight hyaluronan was used as substrate, pH-dependent differences 
in enzymatic activity and product spectra were reported to be much more pronounced with 
BTH than rhPH-20.2 The opposite was observed for the oligosaccharide mixture. While 
product spectra from digestion by BTH were almost identical at pH = 4.5 and pH = 5.5, the 
portion of n2 within the product mixture after incubation with rhPH-20 was considerably 
higher at pH = 5.5 (Figure 7.4 B and Figure 7.5 B) compared to pH = 4.5, at which n3 
remained the main product (Figure 7.4 A and Figure 7.5 A). The profile at pH = 4.5 resembles 
the characteristics of rhHyal-1 at pH = 3.5 (cf. Section 7.3.5). Thus, the product spectrum of 
rhPH-20 was rhHyal-1-like at pH = 4.5 and more BTH-like at pH = 5.5. This may be due to 
increased transglycosylation activity at pH = 5.5, which is also known to be much more 
pronounced for BTH than for rhHyal-1.2, 3 Previous studies suggested that the 
hexasaccharide (n3), which is the minimal substrate for BTH, is not degraded by both 
rhPH-20 and rhHyal-1.3 Consequently, the binding mode of hyaluronan was assumed to be 
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different at the human enzymes and BTH, respectively.3 Thus, the prevailing formation of n3 
instead of n2 might be a consequence of different catalytic mechanisms. However, 
permanent intermediate formation of n5 from transglycosylation and subsequent cleavage 
(n5 → n2 + n3) at pH = 5.5 may provide an explanation for the liberation of considerable 
amounts of n2 under these conditions.  
Chromatograms (Figure 7.6) and time-dependent curves (Figure 7.7) for the PEGylated 
variant (PEG-rhPH-20) were well comparable to unmodified rhPH-20. Taking also the pH 
profiles into consideration (cf. Section 7.3.2), PEGylation does not have an appreciable 
influence on the activity of rhPH-20. Hence, further studies were performed with rhPH-20. 
Like BTH, both rhPH-20 and PEG-rhPH-20 produced a continuous decrease in the average 
molecular weight of low molecular weight hyaluronan, yielding complex mixtures of small 
oligosaccharides. Hence, observations from previous studies on the digestion of high 
molecular weight hyaluronan by mammalian type hyaluronidases were confirmed.2 
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A pH = 4.5 
 
B pH = 5.5 
 
Figure 7.2: Time-dependent degradation of a low molecular weight hyaluronan oligosaccharide mixture by BTH 
(44.44 IU/mL) at pH = 4.5 (A) and pH = 5.5 (B). HPAEC–PAD chromatograms: 10 µL of diluted (1:10) sample 
injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 
0.5 mL/min. 
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A pH = 4.5 
 
B pH = 5.5 
 
Figure 7.3: Time course of peak areas for the oligosaccharides n2–n6 from the chromatograms of Figure 7.2. 
Degradation of a low molecular weight hyaluronan oligosaccharide mixture by BTH (44.44 IU/mL) at pH = 4.5 
(A) and pH = 5.5 (B). HPAEC–PAD: 10 µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM sodium 
hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
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A pH = 4.5 
 
B pH = 5.5 
 
Figure 7.4: Time-dependent degradation of a low molecular weight hyaluronan oligosaccharide mixture by 
rhPH-20 (44.44 IU/mL) at pH = 4.5 (A) and pH = 5.5 (B). HPAEC–PAD chromatograms: 10 µL of diluted (1:10) 
sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 
40 °C, 0.5 mL/min. 
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A pH = 4.5 
 
B pH = 5.5 
 
Figure 7.5: Time course of peak areas for the oligosaccharides n2–n6 from the chromatograms of Figure 7.4. 
Degradation of a low molecular weight hyaluronan oligosaccharide mixture by rhPH-20 (44.44 IU/mL) at 
pH = 4.5 (A) and pH = 5.5 (B). HPAEC–PAD: 10  µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM 
sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
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A pH = 4.5 
 
B pH = 5.5 
 
Figure 7.6: Time-dependent degradation of a low molecular weight hyaluronan oligosaccharide mixture by 
PEG-rhPH-20 (44.44 IU/mL) at pH = 4.5 (A) and pH = 5.5 (B). HPAEC–PAD chromatograms: 10 µL of diluted 
(1:10) sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–900 mM sodium 
acetate, 40 °C, 0.5 mL/min. 
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A pH = 4.5 
 
B pH = 5.5 
 
Figure 7.7: Time course of peak areas for the oligosaccharides n2–n6 from the chromatograms of Figure 7.6. 
Degradation of a low molecular weight hyaluronan oligosaccharide mixture by PEG-rhPH-20 (44.44 IU/mL) at 
pH = 4.5 (A) and pH = 5.5 (B). HPAEC–PAD: 10 µL of diluted (1:10) sample injected, CarboPac
TM
 PA200, 100 mM 
sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
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7.3.4 Fast at-line analysis of hyaluronan oligosaccharide degradation by 
recombinant human PH-20 
For fast at-line CZE–ESI-TOF-MS analysis of oligosaccharide degradation by recombinant 
human PH-20 in comparison with BTH (cf. Chapter 6, Section 6.3.3), 500 µM of the 
octasaccharide (n4, Figure 7.8), the hexasaccharide (n3, Figure 7.9), or the tetrasaccharide 
(n2, Figure 7.10) were incubated with 55.56 IU/mL rhPH-20 under identical conditions at 
pH = 5.0. 
Degradation of n4 yielded n3 as main product. By analogy with Figure 7.5 A, the portion of n2 
was considerably lower than observed for BTH under identical conditions (cf. Chapter 6, 
Section 6.3.3). Previously, similar studies using a different preparation of recombinant 
human PH-20 revealed the formation of mainly n3 and smaller amounts of n2 from n4.
3 
Moreover, the presence of n1 and n5 in the incubation mixtures was reported.
3 The present 
study confirmed the occurrence of both products (Figure 7.8, insets, light blue and violet). 
Taking together these observations, the prevailing reaction for n4 was hydrolysis yielding n1 
and n3. While n3 accumulated, n1 seemed to be preferably transferred to residual n4 
resulting in n5. However, n1 was partially liberated and could be proven by CZE–ESI-TOF-MS. 
In this regard, the probable mechanism resembles that proposed for BTH.27 Nevertheless, 
the low amounts of n2 and the simultaneous accumulation of n5 suggested that both the 
symmetric cleavage of n4 (n4 → n2 + n2) and the degradation of the newly formed n5 (n5 → n2 
+ n3) were much slower. 
In line with the results by Hofinger et al.,3 neither n3 (Figure 7.9) nor n2 (Figure 7.10) were 
accepted as substrates by rhPH-20. Thus, neither hydrolysis nor transglycosylation reactions 
were observed for these oligosaccharides. 
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A 
 
B 
 
Figure 7.8: Incubation of the octasaccharide (n4, 500 µM) with rhPH-20 (55.56 IU/mL) at pH = 5.0. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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A 
 
B 
 
Figure 7.9: Incubation of the hexasaccharide (n3, 500 µM) with rhPH-20 (55.56 IU/mL) at pH = 5.0. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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B 
 
Figure 7.10: Incubation of the tetrasaccharide (n2, 500 µM) with rhPH-20 (55.56 IU/mL) at pH = 5.0. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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7.3.5 Degradation of a low molecular weight hyaluronan oligosaccharide 
mixture by recombinant human Hyal-1 
Like the other mammalian type hyaluronidases (BTH, rhPH-20, and PEG-rhPH-20) discussed 
in this work, rhHyal-1 continuously reduced the average molecular mass of a hyaluronan 
oligosaccharide mixture (Figure 7.11 A). Hence, the random endolytic mode of action, typical 
for this group of hyaluronidases,2, 28, 29 was confirmed. Thereby, the product spectrum and 
the time-dependent formation of small oligosaccharides (Figure 7.11 B) by rhHyal-1 at a pH 
of 3.5 (the pH optimum of the enzyme) were similar to the degradation by rhPH-20 at 
pH = 4.5 (cf. Figure 7.4 A and Figure 7.5 A). A comparative investigation of rhHyal-1 at 
pH = 4.5 was impossible due to the lack of activity at this pH value (cf. Figure 7.1 C). 
The tetrasaccharide (n2) and the hexasaccharide (n3) accumulated as end products with n3 
being the main component of the product mixture. Other oligosaccharides (n4–n6) were also 
present after 72 h. However, due to the shape of the time-dependent concentration curves, 
these molecules can be considered as intermediate products. The end products and their 
relative occurrence were congruent with the results from incubation of high molecular 
weight hyaluronan with a different preparation of rhHyal-1.2 As discussed above (cf. Section 
7.3.3), the predominant formation of n3, which is different from the results with BTH, may 
result from an altered catalytic mechanism of the human enzymes, also reflected by their 
different minimal substrates.3 
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A 
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Figure 7.11: Time-dependent degradation of a low molecular weight hyaluronan oligosaccharide mixture by 
rhHyal-1 (44.44 IU/mL) at pH = 3.5. Chromatograms (A) and peak areas (B). HPAEC–PAD: 10 µL of diluted (1:10) 
sample injected, CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 
40 °C, 0.5 mL/min. 
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7.3.6 Fast at-line analysis of hyaluronan oligosaccharide degradation by 
recombinant human Hyal-1 
500 µM of the octasaccharide (n4, Figure 7.12 and Figure 7.13), the hexasaccharide (n3, 
Figure 7.14), and the tetrasaccharide (n2, Figure 7.15) were incubated with 55.56 IU/mL 
rhHyal-1 at the pH optimum of the enzyme (pH = 3.5). Substrates and products were 
analyzed at-line by CZE–ESI-TOF-MS. 
During the first 180 min of incubation, enzymatic conversion of n4 into n2 and n3 was proven 
(Figure 7.12). However, the reaction was relatively slow. Hence, the incubation period was 
extended up to 9 h (Figure 7.13). Taking advantage of at-line measurement, this amendment 
could easily be implemented while the experiment was performed. Analytical methods not 
allowing for at-line monitoring of the enzymatic process would have required an additional 
experiment to answer the problem. In contrast to BTH and rhPH-20, in the presence of 
rhHyal-1 the liberation of n5 was not observed. Although n3 was the main product, the 
relative amount of n2 was higher than that produced by rhPH-20. The disaccharide (n1) 
continuously accumulated. However, standardized peak areas were much lower than for n3, 
which should have been formed in equal amounts from hydrolysis (n4 → n1 + n3). Therefore, 
it is conceivable that, by rhHyal-1, n1 was also transferred to an acceptor molecule by 
transglycosylation as suggested for BTH.27  
However, bearing in mind the sensitivity of the analytical method optimized for n2–n4 (cf. 
Chapter 3), it should be noted that the amount of n1 might be partially underestimated 
comparing the peak areas. The lack of n5 and the accumulation of n1, albeit on a relatively 
low level, are hints that hydrolysis prevailed. In their study on this topic, Hofinger et al. also 
reported that the catalytic action of their rhHyal-1 preparation was restricted to hydrolysis 
at 100 µM of n4, whereas at high concentrations (1 mM) the formation of transglyosylation 
products was proven.3 Hence, at 500 µM transglycosylation might occur, although to a much 
lower extent than hydrolysis. In the respective article, the concentration of n1 was reported 
to be close to the limit of detection of the CZE–UV method, even at low substrate 
concentrations.3 Nevertheless, n3 was the major product resulting from digestion of n4 by 
rhHyal-1.3 Provided that this discrepancy was not due to methodological reasons, this finding 
(ratio of n3 and n1), which is basically in agreement with the CZE–ESI-TOF-MS results, is 
incompatible with a simple hydrolytic mechanism. Thus, further research will be necessary 
to elucidate the exact catalytic mechanism of rhHyal-1. 
As already described in literature,3 n3 (Figure 7.14) and n2 (Figure 7.15) were not accepted as 
substrates by rhHyal-1. 
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Figure 7.12: Incubation of the octasaccharide (n4, 500 µM) with rhHyal-1 (55.56 IU/mL) at pH = 3.5. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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Figure 7.13: Prolonged incubation of the octasaccharide (n4, 500 µM) with rhHyal-1 (55.56 IU/mL) at pH = 3.5. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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Figure 7.14: Incubation of the hexasaccharide (n3, 500 µM) with rhHyal-1 (55.56 IU/mL) at pH = 3.5. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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Figure 7.15: Incubation of the tetrasaccharide (n2, 500 µM) with rhHyal-1 (55.56 IU/mL) at pH = 3.5. 
Electropherograms (A) and standardized peak areas (B). Mean ± SEM for multiple injections. CZE: 1:10 sample 
dilution, 30 s injection, 25 µm × 28 cm capillary, ammonium acetate (25 mM, pH = 8.5), 35 kV. 
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7.3.7 The quest for inhibitors 
For the study of the physiological and pathophysiological role of human hyaluronidases, 
potent and selective inhibitors of these enzymes are strongly needed as pharmacological 
tools. Therefore, the search for such substances has been the matter of several PhD projects 
in our group. Commonly used reference compounds with inhibitory activity on 
hyaluronidases are diclofenac, indomethacin, and L-ascorbic acid-6-O-hexadecanoate 
(vitamin C palmitate).30 Especially vitamin C palmitate was proven to be a potent inhibitor of 
bovine testicular hyaluronidase as well as the bacterial hyaluronidases from Streptococcus 
agalactiae and Streptococcus pneumoniae.31  
To assess the potency of the reference inhibitors with regard to these particular enzyme 
preparations, the inhibitory effects on rhPH-20 at pH = 5.0 (Figure 7.16) and rhHyal-1 at 
pH = 3.5 (Figure 7.17) were determined within a concentration range of 50–1000 µM. 
Different enzyme activities and incubation periods were compared. With increasing enzyme 
activity, the maximum inhibition decreased significantly. Only at low enzyme concentrations 
and prolonged incubation, evaluable curves were obtained. It must be noted that enzyme 
activities are expressed as activities of the enzyme solution added to the incubation mixture. 
For the final concentration in the assay, the dilution of 1:7.3 has to be considered. 
Diclofenac and indomethacin showed inhibition of rhPH-20 only at very high concentrations, 
whereas IC50 values of 156 ± 14 µM (10 IU/mL enzyme solution, 4.5 h) and 168 ± 48 µM 
(10 IU/mL enzyme solution, 2 h) could be calculated from the concentration-response curves 
of vitamin C palmitate. Values are expressed as mean ± SEM from three independent 
experiments. 
By contrast, both vitamin C palmitate and diclofenac had no inhibitory effect on rhHyal-1 at 
pH = 3.5. Only indomethacin was able to inhibit enzyme activity at very high concentrations. 
From these results, it becomes obvious that human hyaluronidases still pose a particular 
challenge with regard to identification of inhibitors. Hence, the quest for inhibitors of these 
isoenzymes is still in the early stages.  
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Figure 7.16: Inhibition of rhPH-20 (at pH = 5.0) by vitamin C palmitate (A), diclofenac (B), and indomethacin (C). 
Determination by the turbidimetric assay using 96-well plates. Concentrations of the enzyme solutions are 
given as values of the prepared solution (prior to addition to the incubation mixture, dilution in assay: 1:7.3). 
Incubation time is stated in parentheses. Data presented as mean ± standard error of three independent 
experiments (each performed in triplicate), curves were fitted with SigmaPlot. 
log (c)
-4.4 -4.2 -4.0 -3.8 -3.6 -3.4 -3.2 -3.0
R
e
la
ti
v
e
 e
n
zy
m
a
ti
c 
a
ct
iv
it
y
 (
%
)
0
20
40
60
80
100
120
10 IU/mL (4.5 h)
10 IU/mL (2 h)
50 IU/mL (2 h)
50 IU/mL (0.5 h)
100 IU/mL (0.5 h)
Enzyme solution
A
log (c)
-4.4 -4.2 -4.0 -3.8 -3.6 -3.4 -3.2 -3.0
R
e
la
ti
v
e
 e
n
zy
m
a
ti
c 
a
ct
iv
it
y
 (
%
)
0
20
40
60
80
100
120
10 IU/mL (4.5 h)
10 IU/mL (2 h)
50 IU/mL (2 h)
50 IU/mL (0.5 h)
100 IU/mL (0.5 h)
Enzyme solution
B
log (c)
-4.4 -4.2 -4.0 -3.8 -3.6 -3.4 -3.2 -3.0
R
e
la
ti
v
e
 e
n
zy
m
a
ti
c 
a
ct
iv
it
y
 (
%
)
0
20
40
60
80
100
120
10 IU/mL (4.5 h)
10 IU/mL (2 h)
50 IU/mL (2 h)
50 IU/mL (0.5 h)
100 mU/mL (0.5 h)
Enzyme solution
C
148 7 In vitro studies on recombinant human PH-20, PEG-PH-20, and Hyal-1 
 
 
 
 
Figure 7.17: Inhibition of rhHyal-1 (at pH = 3.5) by vitamin C palmitate (A), diclofenac (B), and indomethacin (C). 
Determination by the turbidimetric assay using 96-well plates. Concentrations of the enzyme solutions are 
given as values of the prepared solution (prior to addition to the incubation mixture, dilution in assay: 1:7.3). 
Incubation time is stated in parentheses. Data presented as mean ± standard error of three independent 
experiments (each performed in triplicate), curves were fitted with SigmaPlot. 
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7.4 Summary and conclusion 
Recombinant human PH-20 (rhPH-20), PEGylated rhPH-20 (PEG-rhPH-20) and recombinant 
human Hyal-1 (rhHyal-1) were characterized in vitro. All of them showed maximum activity 
at acidic pH values of 4 (rhPH-20 and PEG-rhPH-20) or 3.5 (rhHyal-1). In contrast to bovine 
testicular hyaluronidase (BTH) and a different preparation of rhPH-20,2 neither rhPH-20 nor 
PEG-rhPH-20 exhibited assay-dependent differences regarding pH profiles.  
The degradation of hyaluronan oligosaccharides by the different isoenzymes was monitored 
by HPAEC–PAD and fast at-line CZE–ESI-TOF-MS. Thereby, differences between BTH and 
rhPH-20 became obvious, whereas PEG-rhPH-20 and its non-PEGylated form, rhPH-20 
showed essentially the same behavior. In general, the characteristics reported for 
recombinant human hyaluronidases2, 3 were confirmed. Nevertheless, the conversion of 
hyaluronan and hyaluronan oligosaccharides by these enzymes obviously follows a complex 
mechanism including hydrolysis as well as transglycosylation steps. 
Vitamin C palmitate, indomethacin, and diclofenac showed very low inhibitory effects on the 
examined preparations of rhPH-20 and rhHyal-1. Varying the period of incubation with 
rhPH-20, IC50 values of 156 ± 14 µM and 168 ± 48 µM (mean ± SEM), respectively, were 
determined for vitamin C palmitate. No inhibitory effect on rhHyal-1 was observed. On both 
enzymes, indomethacin and diclofenac had no or only weak inhibitory effects at very high 
concentrations of around 1 mM. Moreover, maximum inhibitory effect was considerably 
reduced with increasing enzyme concentrations, although the time of incubation was 
adjusted to the respective degradation velocity. Hence, evaluable curves were only obtained 
at low enzyme activities, requiring long incubation periods up to 4.5 h. 
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8 Analysis of synovial fluid samples 
8.1 Introduction 
In 1939, Meyer et al. reported the isolation of a polysaccharide, consisting of N-acetyl-D-
glucosamine and glucuronic acid, from synovial fluid.1 The authors identified this 
polysaccharide as hyaluronan, which was isolated from many different sources in the 1930s 
and 1940s.2 In 1950, Sundblad published a chemical characterization of synovial fluid and 
described the crucial role of hyaluronan in determining the viscosity of the synovial fluid.3 He 
also found high amounts, but a decreased degree of polymerization of hyaluronan in case of 
degenerative and inflammatory joint diseases.3 One year before, Ragan and Meyer had 
published similar results for rheumatoid arthritis and had suggested a defect in synthesis as 
the reason for the occurrence of incompletely polymerized hyaluronan.4 Regardless of the 
increased total amount of hyaluronan, other authors reported a reduced concentration in 
synovial fluids from patients due to dramatically increased volume and concomitant dilution 
effects.5, 6  
Recently, the pathological degradation of hyaluronan from synovial fluid to smaller fragment 
has been doubted, at least in osteoarthritis.7 Hence, even more than seven decades after the 
isolation by Meyer et al.,1 the exact role of hyaluronan in synovial fluid and in the pathology 
of arthritis is far from being completely understood. Therefore, synovial fluid remains an 
interesting matrix for hyaluronan analysis. Although the hyaluronan content of 3–4 mg/mL is 
rather high,8 this material is challenging for an application of a new method of hyaluronan 
and hyaluronan oligosaccharide analysis due to the complexity of biological matrices. 
Consequently, CZE–ESI-TOF-MS and HPAEC–PAD were used in combination with colorimetry, 
rheology, gel electrophoresis, and zymography to characterize 12 synovial fluid samples, 
which were available at our lab.  
8.2 Materials and methods 
8.2.1 Origin of samples 
Synovial fluid samples, kindly provided by the Department of Orthopedics (University of 
Regensburg/Asklepios Klinikum, Bad Abbach, Germany), had been obtained from 12 patients 
during knee surgery in 2007 and stored at −80 °C until analysis. Patient data (as provided by 
the Department of Orthopedics) are listed in Table 8.1. 
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Table 8.1: Patient data. Sex abbreviated as f (female) or m (male). 
Patient  
(Sample) 
Age Sex Diagnosis 
1 78 f Osteoarthritis (left knee) 
2 69 f Change of implant 
3 71 f Osteoarthritis (right knee) 
4 59 f Osteoarthritis (left knee) 
5 67 f Osteoarthritis (left knee), chondromalacia, meniscopathy 
6 61 m Osteoarthritis (left knee) 
7 58 f Osteoarthritis (right knee) 
8 69 f Osteoarthritis (left knee) 
9 67 f Osteoarthritis (left knee), rheumatoid arthritis 
10 76 f Osteoarthritis (right knee) 
11 66 m Osteoarthritis (left knee) 
12 55 f Osteoarthritis (left knee) 
 
It should be noted that, in addition to osteoarthritis, patient 9 was also suffering from 
chronic rheumatoid arthritis. 
8.2.2 Macroscopic characterization and microscopy of smears 
The samples were characterized macroscopically with regard to color. For reproducible 
description, a RAL K7 CLASSIC® card (RAL German Institute of Quality Assurance and 
Certification, Sankt Augustin, Germany) was used. In addition, smears of the synovial fluids 
were examined microscopically after Pappenheim’s staining. 
8.2.3 Rheology 
Rheological characterization of the viscoelastic properties was carried out on a TA 
Instruments AR 2000 rheometer (TA Instruments, Eschborn, Germany) with parallel plate 
geometry (diameter of upper steel plate: 20 mm) at 22 °C. 310 µL of the respective sample 
were transferred to the bottom plate of the instrument with a syringe. Then, the upper plate 
was lowered to reach a gap width of 1000 µm. Two consecutive experiments were 
performed. In a non-destructive frequency sweep experiment, oscillatory frequency was 
varied from 0.01 Hz to 10 Hz with torque control set at 10 µNm (oscillatory stress: 6.366 Pa). 
8.2 Materials and methods  155 
 
Afterwards, a destructive stress sweep was carried out at constant frequency of 1 Hz, 
increasing oscillatory stress from 1 Pa to 1000 Pa.  
8.2.4 Determination of protein content 
Protein content of the samples was determined by the Bradford method9 using human 
serum albumin (Behringwerke, Marburg, Germany) as calibration standard. Samples were 
diluted 1:100 with phosphate buffer (pH = 7.2, 10 mM). 50 µL of this dilution were mixed 
with 2.5 mL of an aqueous dilution (1:5) of the Bio-Rad protein assay dye reagent 
concentrate (Bio-Rad, Munich, Germany). Absorbance at 595 nm was measured with a 
CARY 100 photometer (Agilent Technologies, Darmstadt, Germany). A single experiment was 
performed in duplicate. 
8.2.5 Preparation of samples for hyaluronan analysis 
With regard to hyaluronan analysis, the synovial fluid samples were deproteinized by boiling. 
Boiling of the undiluted samples, however, led to a clot of denaturated protein from which 
no liquid supernatant was obtained. Consequently, the synovial fluid was diluted 1:5 with 
purified water prior to boiling. The volume of the synovial fluid was measured with a plastic 
syringe. The use of a normal microliter pipette was not feasible due to the high viscosity of 
the samples. After boiling, the precipitated protein was removed by centrifugation at 
13000 × g and the supernatant was used for further analysis. 
8.2.6 Enzymatic digestion of hyaluronan 
To determine the total hyaluronan content of the samples, the polysaccharide was digested 
by addition of bovine testicular hyaluronidase (BTH, Neopermease®, kindly provided by 
Sanabo, Vienna, Austria) as described in Chapter 6 (Section 6.2.2) but using the supernatant, 
prepared accoding to Section 8.2.5 instead of hyaluronan solution as substrate. To ensure 
exhaustive digestion, an enzyme solution of 20000 IU/mL (based on the declaration by the 
supplier) was prepared. 50 µL of the enzyme solution were added to 400 µL of the 
incubation mixture. The digestion mixture was then placed in a water bath and incubated at 
37 °C for 72 h. 
8.2.7 Colorimetric quantification 
The exhaustively digested samples from Section 8.2.6 as well as analogously diluted aliquots 
of the undigested counterparts from Section 8.2.5 were subjected to the Morgan-Elson 
reaction10-13 and the absorbance was measured at 586 nm as explained in detail in Chapter 5 
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(Section 5.2.3). By this procedure, the total content of hyaluronan was determined from the 
digested samples by the amount of N-acetyl-D-glucosamine ends liberated during enzymatic 
cleavage. In contrast, from the undigested synovial fluid the reducing (N-acetyl-D-
glucosamine) ends, initially present in the sample, were measured, allowing for a rough 
comparison of the average chain length. N-Acetyl-D-glucosamine (Fluka, Buchs, Switzerland) 
served as calibration standard. Therefore, the measured values were expressed as N-acetyl-
D-glucosamine equivalents. 
8.2.8 Determination of hyaluronan content by CZE–ESI-TOF-MS 
In addition to the colorimetric quantification, the digested synovial fluids (cf. Section 8.2.6) 
were analyzed by CZE–ESI-TOF-MS (cf. Chapter 3). Samples were filtrated through a Phenex-
NY 4 mm syringe filter 0.2 µm (Phenomenex, Aschaffenburg, Germany) and injected 
(pressure-free injection, 30 s) into the capillary (25 µm × 28 cm). The tetrasaccharide (n2) 
liberated by enzymatic cleavage was quantified using the respective oligosaccharide 
standard (oligoHA from Hyalose, Oklahoma City, OK, USA) for calibration. The standard was 
purchased from AMSBIO (Abingdon, UK). Hyaluronan content was calculated from the peak 
heights of three consecutive injections of the same sample. 
8.2.9 HPAEC–PAD of digested and undigested samples 
After filtration through a Phenex-NY 4 mm syringe filter 0.2 µm (Phenomenex, 
Aschaffenburg, Germany), aliquots of the digested samples were also analyzed using the 
HPAEC–PAD method from Chapter 4. In this case, the amount of tetrasaccharide (n2) was 
determined from the peak area by calibration with the standard substance oligoHA (Hyalose, 
Oklahoma City, OK, USA). Furthermore, HPAEC–PAD was applied to determine small 
oligosaccharides in the undigested synovial fluids (diluted 1:5, cf. Section 8.2.5). For this 
purpose, protein and high molecular weight hyaluronan were removed by ultrafiltration at 
13900 × g using Nanosep® Centrifugal Devices 10 K (Pall Life Sciences, Ann Arbor, MI, USA). 
8.2.10 Hyaluronan analysis by gel electrophoresis 
Polyacrylamide gel electrophoresis of hyaluronan was carried out according to previously 
reported protocols14-16 using 10% polyacrylamide separation gels and 5% stacking gels. A 
tris/borate/EDTA (TBE) buffer (pH = 8.3) was used as gel buffer as well as running buffer. In 
detail, the buffer contained 89 mM tris(hydroxymethyl)aminomethane (tris, USB, Cleveland, 
OH, USA), 82 mM boric acid (Merck, Darmstadt, Germany), and 2 mM EDTA (Merck, 
Darmstadt, Germany). For one separation gel, 5 mL of TBE buffer were mixed with 2.5 mL of 
acrylamide/bisacrylamide solution 30% (Sigma-Aldrich, Munich, Germany). 3.75 µL of 
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N,N,N’,N’-tetramethylethylenediamine (TEMED, Serva, Heidelberg, Germany) and 37.5 µL of 
a 10% (w/v) solution of ammonium peroxodisulfate (APS, Serva, Heidelberg, Germany) 
started the reaction. By contrast, the stacking gel was prepared from 4.1 mL of TBE buffer, 
0.85 mL of acrylamide/bisacrylamide solution 30%, 3.75 µL of TEMED, and 50 µL of APS 
solution (10% in water). Gel chambers were 10 cm × 10 cm × 0.8 cm in size.  
Due to incomplete precipitation of protein by boiling, residual protein was found to interfere 
with hyaluronan detection. Therefore, samples were additionally incubated with 
proteinase K from Tritirachium album (Merck, Darmstadt, Germany). The activity of the 
enzyme was specified by the supplier as 0.027 Anson units per mg. A solution of 20 mg/mL in 
phosphate buffered saline (PBS) with 10 mM calcium chloride was prepared. 3 µL of this 
solution were added to 27 µL of sample. The mixture was incubated at 50 °C for 17 h. 5 parts 
of the sample were mixed with 1 part of 2 M sucrose (Merck, Darmstadt, Germany) in TBE 
buffer. 10 µL per lane were applied to the gel. The tracking dye bromophenol blue (Aldrich, 
Beerse, Belgium) and aqueous solutions of sulfonated polystyrenes (Fluka, Buchs, 
Switzerland) as size markers (990 kDa, 32 kDa, and 17 kDa) were treated equally. 
Electrophoresis was performed with a PerfectBlue gel electrophoresis system (Twin S, 
Peqlab, Erlangen, Germany) at 250 V for 20 min, at 500 V for additional 10 min, and finally at 
400 V for approximately 15 min. Under the given conditions (TBE running buffer, pH = 8.3), 
proteinase K did not migrate into the gel and, hence, did not interfere with the subsequent 
visualization of the saccharides. 
The combined alcian blue and silver staining was based on a method by Ikegami-Kawai and 
Takahashi14 and performed following the protocol described by Hamberger.16 At first, the gel 
was stained in the dark with a 0.5% (w/v) solution of alcian blue 8GX (Sigma, St. Louis, MO, 
USA) in 2% (v/v) acetic acid (prepared from concentrated acetic acid, Merck, Darmstadt, 
Germany). After 30 min the gel was transferred to 2% (v/v) acetic acid and destained for 
additional 30 min. After alcian blue staining, a silver staining procedure according to Merril 
et al.,17 basically performed in four steps (plus several washing steps), was carried out. All 
reagents used for silver staining were from Merck (Darmstadt, Germany). In the first step, 
the gel was treated with an oxidation solution of potassium dichromate (3.4 mM) and nitric 
acid (3.2 mM) for 5 min. After three short washing intervals (5 min each) with water, the gel 
was soaked in a silver nitrate solution (12 mM) for 20 min. Prior to the developing step, the 
gel was again washed in water for 3 × 5 min, and then transferred to a solution of 5 g of 
sodium carbonate and 100 µL of formaldehyde in 200 mL of water. When bands had become 
visible, the reaction was stopped by transferring the gel to 5% (v/v) acetic acid. After 15 min, 
the gel was put into water and stored for further analysis. 
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8.2.11 Zymography 
Zymography with hyaluronan substrate gels, previously described by Cherr et al.,18 was 
essentially carried out according to Hamberger.16 Polyacrylamide gels were prepared in 
chambers of 10 cm × 10 cm × 0.8 cm. Reagents were obtained from the same suppliers as 
stated in Section 8.2.10. Sodium dodecyl sulfate (SDS) was from Sigma-Aldrich (Munich, 
Germany). For the separation gel (12% polyacrylamide), 2.4 mL of acrylamide/bisacrylamide 
solution 30%, 1.56 mL of buffer A (1.5 M tris, 0.4% SDS, pH = 8.8), and 2.0 mL of water were 
mixed. 81.5 µL of a 5 mg/mL solution of hyaluronan from Streptococcus zooepidemicus 
(Aqua Biochem, Dessau, Germany) were added to yield a substrate gel containing 67 µg/mL 
hyaluronan. Polymerization was started by addition of 3 µL of TEMED and 40 µL of a 10% 
(m/v) solution of APS in water. The stacking gel (5% polyacrylamide) was produced 
analogously from 0.5 mL of acrylamide/bisacrylamide solution 30%, 1.25 mL of buffer B 
(0.5 M tris, 0.4% SDS, pH = 6.8), 3.25 mL of water, 3 µL of TEMED, and 50 µL of APS solution 
(10% in water). Running buffer (pH = 8.3) contained 25 mM tris, 200 mM glycine (Merck, 
Darmstadt, Germany), and 0.1% (w/v) SDS. 
Sample buffer (kindly provided by Dr. Janina Hamberger) consisted of 200 mM tris-HCl buffer 
(pH = 6.8), 20% (v/v) glycerol (Merck, Darmstadt, Germany), 10% (w/v) SDS (Sigma-Aldrich, 
Munich, Germany), and 0.05% (w/v) bromophenol blue (Aldrich, Beerse, Belgium). Tris was 
from USB (Cleveland, OH, USA). Untreated (not boiled) synovial fluid samples were diluted 
1:10 by addition of phosphate buffer (pH = 7.2, 10 mM). Human citrate-phosphate-dextrose 
(CPD) plasma, diluted in the same manner, served as control. 10 µL of the sample dilution 
were mixed with 10 µL of sample buffer. From this mixture, 10 µL per lane were applied to 
the gel. Electrophoresis was performed at 150 kV with the PerfectBlue gel electrophoresis 
system (Twin S, Peqlab, Erlangen, Germany) for approximately 90 min. 
After electrophoresis, SDS was replaced by triton X-100 (Carl Roth, Karlsruhe, Germany). For 
this purpose, the gel was treated with a 2.5% (v/v) solution of triton X-100 for 30 min. 
Afterwards the gel was washed with water for 5 min and with incubation buffer for 
additional 30 min. The gel was transferred to a glass trough with incubation buffer. The 
buffer had been prepared as described in Chapter 6 (Section 6.2.2) but adjusted to a pH 
value of 4.0 instead of 5.0. After incubation at 37 °C overnight (24 h), the gel was stained 
with a 0.5% (w/v) solution of alcian blue 8GX (Sigma, St. Louis, MO, USA) in acetic acid. In 
contrast to Section 8.2.10, the staining reagent contained 7% (v/v) of acetic acid instead of 
2% (v/v). The gel was destained with 7% (v/v) acetic acid until light bands became visible on 
the blue background. 
Proteins were counterstained with a 0.1% (w/v) solution of Coomassie Brillant Blue G-250 
(Serva, Heidelberg, Germany) in 50% (v/v) methanol and 10% (v/v) acetic acid. After a final 
destaining step in an aqueous solution of 7% (v/v) acetic acid and 10% (v/v) methanol, the 
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gel was scanned with a Bio-Rad GS-710 gel scanner using Bio-Rad Quantity One software 
(Bio-Rad, Munich, Germany). The scanner settings were chosen by analogy with the settings 
for Coomassie-stained gels. Glacial acetic acid and methanol were from Merck (Darmstadt, 
Germany). 
8.3 Results and discussion 
8.3.1 Macroscopic characterization and microscopic findings 
Aliquots of the synovial fluid samples were transferred to a white glass plate to characterize 
the macroscopic appearance (Figure 8.1). In addition, the color was also assessed directly in 
a 1.5 mL plastic vial. Due to the increased thickness of the light absorbing layer, appearance 
was slightly darker. The detailed color descriptions according to RAL K7 CLASSIC® are listed in 
Table 8.2 for all samples.  
Table 8.2: Color description of the synovial fluid samples by comparison with RAL K7 CLASSIC® standard. Colors 
of a drop on a white glass plate and of a relatively thick sample layer in a 1.5 mL plastic vial are listed. 
Sample Drop color on white glass plate Color as seen in 1.5 mL plastic vial 
 RAL number RAL color name RAL number RAL color name 
1 2000 Yellow orange 2001 Red orange 
2 1014 Ivory 1017 Saffron yellow 
3 — (colorless) 1014 Ivory 
4 1015 Light ivory 1017 Saffron yellow 
5 — (colorless) 1015 Light ivory 
6 1014 Ivory 1000 Green beige 
7 1013 Oyster white 1015 Light ivory 
8 — (colorless) 1014 Ivory 
9 1015 Light ivory 1017 Saffron yellow 
10 1015 Light ivory 1034 Pastel yellow 
11 2000 Yellow orange 2001 Red orange 
12 2002 Vermilion 3003 Ruby red 
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Figure 8.1: Aliquots of the synovial fluid samples on a white glass plate. Colors of the drops are compared to a 
RAL K7 CLASSIC® card. Numbers on the glass plate indicate sample numbers. 
Samples 1 and 11 were of reddish color, sample 12 was intensely red. In addition, the latter 
also contained noticeable blood clots. Small traces of blood were also observed in sample 9. 
It should be noted that especially the blood content does not necessarily reflect the original 
situation in the joint. Contamination could also have occurred during surgery. In contrast, 
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samples 3, 5, and 8 were clear and colorless. The other samples were also clear, being 
slightly white to beige or yellowish in color. 
Microscopically, significant numbers of neutrophils were found in one sample (Figure 8.2 A), 
whereas all other smears contained only low amounts of leucocytes, mainly lymphocytes 
(Figure 8.2 B, C). 
 
A 
 
 
B 
 
 
C 
 
 
Figure 8.2: Microscopic images of synovial fluid smears after Pappenheim’s staining. Neutrophils were 
observed in sample 7 (A). All other samples contained only small amounts of leucocytes (mainly lymphocytes), 
examples from the samples 1 (B) and 11 (C). 
High numbers of neutrophils are typically observed in synovial fluid of patients suffering 
from inflammatory joint diseases like rheumatoid arthritis19, 20 or gout.21 Surprisingly, this 
was not the case for sample 9, the only one associated with rheumatoid arthritis. In contrast, 
neutrophils were observed in the synovial fluid number 7. However, neutrophils have also 
been reported in synovial fluids from patients with non-rheumatoid arthritis.19  
8.3.2 Viscoelastic properties 
Normal synovial fluid is a non-Newtonian fluid. Its rheological properties were reported to 
depend on the content and molecular mass of hyaluronan.3, 22 More detailed rheological 
studies clearly suggested that the viscoelastic properties of pathological synovial fluids differ 
for inflammatory and non-inflammatory arthritis.23, 24 For this reason, rheological 
characterization of the synovial fluid samples was carried out by oscillatory experiments with 
parallel plate geometry. Thereby, the viscoelastic properties can be described by a complex 
number, the complex shear rigidity modulus (G*, absolute value: |G*|). This complex shear 
rigidity modulus can be expressed by its real part (G’, storage modulus) and its imaginary 
part (G’’, loss modulus). Briefly, the storage modulus represents the elastic component of 
the shear rigidity. The loss modulus reflects the viscous properties. The whole system can 
also be characterized by the phase angle (δ) of the sinusoidal curves of shear rate and shear 
stress versus time, ranging from 0° (elastic behavior) to 90° (viscous behavior). 
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In a frequency sweep experiment (Figure 8.3), oscillatory frequency was continuously 
increased, torque was kept low. Consequently, this kind of experiment does not destruct the 
sample.  
 
Figure 8.3: Frequency sweep experiment. At controlled torque, frequency of the oscillation was varied in a 
range of 0.01–10 Hz. Storage modulus (G’, blue), loss modulus (G’’, red), absolute value of the complex shear 
rigidity modulus (|G*|, black), and rigidity phase angle (δ, green) are plotted versus frequency. 
Taking a closer look at the obtained curves, several differences can be identified. Firstly, the 
values of the moduli (|G*|, G’, and G’’) observed at low frequency (at the beginning of the 
frequency sweep) vary in a range of approximately two orders of magnitude. Although the 
experiments described in literature cannot be compared directly to the experiment 
presented here, generally higher values for the measured viscosity parameters were 
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observed for the physiological state and non-inflammatory arthritis than for inflammatory 
joint diseases.23, 24 With increasing frequency, comparable values are reached for all 
samples, but the curves differ in their slope. Finally, the relative positions of the curves for G’ 
and G’’ are of interest. In general, the viscous (G’’) component of complex shear rigidity is 
dominant for low frequencies, the elastic component (G’) is more pronounced at high 
frequencies. However, the curves intersect at different frequency values. 
It was previously described that high molecular weight hyaluronan is responsible for the 
elastic properties of synovial fluid and that enzymatic cleavage results in a loss of viscoelastic 
properties.24 The same study reported that the gap between the curves expressing the 
elastic and viscous component is more pronounced for inflammatory arthritis than for non-
inflammatory joint diseases.24 Therefore, it may be speculated that a relatively high storage 
modulus (G’) compared to the loss modulus (G’’) reflects an intact structure and high 
average molecular weight of hyaluronan in the synovial fluid. Assuming this correlation, low 
relative values for G’ and crossovers at higher frequency values would be hints for 
pronounced fragmentation, probably due to enzymatic cleavage, defects in synthesis, and 
inflammatory processes. Three samples (numbers 4, 5, and 12), however, clearly showed 
two crossovers of the curves (Figure 8.3 D, E, L). The observation is even more obvious for 
the phase angle curves. Regarding the occurrence of a maximum for δ, two additional graphs 
(Figure 8.3 C, K), belonging to the samples 3 and 11, probably show additional crossovers for 
G’ and G’’ at lower frequency (outside the measured range). Similar observations, probably 
due to two elastic species, were also reported in the article by Thurston and Greiling.24 
In a second experiment, the oscillatory stress was steadily increased at a constant frequency 
of 1 Hz (Figure 8.4). These conditions led to destruction of the samples. The drop in the 
storage modulus accompanied by a simultaneous increase in the rigidity phase angle 
indicates the breakup of the sample structure.  
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Figure 8.4: Stress sweep experiment. Increasing oscillatory stress of 1–1000 Pa was applied at a constant 
frequency of 1 Hz. Storage modulus (G’, blue), loss modulus (G’’, red), absolute value of the complex shear 
rigidity modulus (|G*|, black), and rigidity phase angle (δ, green) are plotted versus oscillatory stress. 
Except for sample 11 (Figure 8.4 K), G’’ was initially higher than G’. The faster decrease in the 
storage modulus, confirmed that mainly the elastic component got lost when the structure 
of the hyaluronan containing matrix was broken. In all cases, the destruction began at an 
oscillatory stress of 10–100 Pa. As a matter of course, the differences of about two orders of 
magnitude for |G*|, G’, and G’’, observed in the frequency sweep experiment (cf. Figure 
8.3.), were confirmed. 
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8.3.3 Protein content 
Protein content of the synovial fluid samples was determined by a single experiment in 
duplicate. The results are depicted in Figure 8.5. All samples contained relatively high 
amounts of protein, ranging from 26.9 mg/mL (number 4) to 59.8 mg/mL (number 12). 
 
Figure 8.5: Protein content of the synovial fluid samples as determined by the Bradford method. Data are 
presented as mean values of one experiment performed in duplicate. 
8.3.4 Total hyaluronan content 
Hyaluronan of all samples was enzymatically degraded to give the tetrasaccharide (n2). The 
initial content of hyaluronan was determined by quantification of n2. Analysis according to 
the Morgan-Elson assay was performed in three independent experiments. A single injection 
was performed for analysis by HPAEC–PAD, and three consecutive injections of the same 
sample were carried out for CZE–ESI-TOF-MS. Figure 8.6 compares the results from the 
different quantification methods. It should again be noted that for the colorimetric 
quantification N-acetyl-D-glucosamine served as calibration standard, whereas commercially 
available tetrasaccharide was used as reference compound for chromatography and 
electrophoresis. 
Sample
1 2 3 4 5 6 7 8 9 10 11 12
P
ro
te
in
 c
o
n
te
n
t 
o
f 
sy
n
o
v
ia
l 
fl
u
id
 (
m
g
/m
L)
0
10
20
30
40
50
60
70
166 8 Analysis of synovial fluid samples 
 
 
Figure 8.6: Total hyaluronan content of the synovial fluids determined via quantification of the product of 
enzymatic cleavage. Morgan-Elson reaction (green): quantification of free ends, calibration with N-acetyl-D-
glucosamine, mean ± SEM of three independent experiments (N = 3). HPAEC–PAD (red): tetrasaccharide (n2) as 
calibration standard, evaluation of peak areas of the n2 peak, single injection. CZE–ESI-TOF-MS (blue): 
tetrasaccharide (n2) as calibration standard, evaluation of peak heights of the n2 peak, three consecutive 
injections of the same sample, mean.  
Due to methodological reasons and especially because of the differences regarding the 
calibration standard, the absolute values, determined by colorimetry compared to the 
chromatographic and electrophoretic quantification, varied. Nevertheless, the relative 
comparison of the samples and the general results are in good accordance. The highest 
hyaluronan contents were determined in samples 1 and 9, the lowest in sample 4. All other 
values were in a medium range.  
8.3.5 Size distribution of hyaluronan 
The amount of reducing ends of hyaluronan polysaccharide chains, originally present in the 
synovial fluid, can act as a first rough indicator for the average molecular weight of 
hyaluronan. Therefore, the undigested samples were analyzed using the colorimetric 
method with N-acetyl-D-glucosamine as calibration standard. Three independent 
experiments were performed. The results are summarized in Figure 8.7. 
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Figure 8.7: Free hyaluronan ends in the undigested synovial fluids given as N-acetyl-D-glucosamine equivalents 
from the colorimetric assay. All dilution steps were considered. Data are presented as mean ± SEM of three 
independent experiments (N = 3). 
The highest “concentrations of reducing ends” were measured for samples 7, 9, 11, and 12. 
Whereas the high total hyaluronan content has to be considered for number 9, the other 
samples had only a medium content of hyaluronan (cf. Figure 8.6). Therefore, it may be 
assumed that in the samples 7, 11, and 12 hyaluronan is degraded or incompletely 
polymerized to a relatively high extent. When the hyaluronan content was extremely low 
(especially for sample 4), the amount of free ends in the undigested synovial fluids, of 
course, was extremely low, too. In these cases, it cannot be ruled out that the tiny amounts 
of hyaluronan might have been degraded, and the concentrations of the resulting fragments 
(free ends) were below the limit of quantification.  
To further scrutinize the size distribution of the hyaluronan from the synovial fluid samples, 
a gel electrophoretic separation was performed (Figure 8.8). According to gel 
electrophoresis, samples 3, 5, and 8 showed the lowest degradation of hyaluronic acid. 
Interestingly, this finding is in good accordance to the macroscopically clear and colorless 
(physiological) appearance observed in Section 8.3.1. Samples 1, 4, 9, 10, and 12 contained 
the highest band intensity in the low molecular weight sector. For number 9 and number 12 
this is consistent with the estimation from Figure 8.7. However, there was no general 
correlation. The high amount of low molecular weight hyaluronan together with high 
Sample
1 2 3 4 5 6 7 8 9 10 11 12
Fr
e
e
 e
n
d
s 
p
e
r 
m
L 
sy
n
o
v
ia
l 
fl
u
id
 (
µ
m
o
l)
0.0
0.1
0.2
0.3
0.4
0.5
168 8 Analysis of synovial fluid samples 
 
hyaluronan content in sample 9, associated with the diagnosis of rheumatoid arthritis (cf. 
Table 8.1), confirm the findings of Ragan and Meyer.4 They suggested an elevated synthesis 
of hyaluronan with a low degree of polymerization rather than increased hyaluronidase 
action in rheumatoid arthritis.4 Finally, sample 4 is worth a closer look. This particular 
synovial fluid showed the lowest protein content, the lowest viscoelastic moduli, the lowest 
total hyaluronan content, and high degree of degradation in gel electrophoresis. Obviously, a 
low content of protein and hyaluronan, in addition to low average molecular weight of the 
hyaluronan, result in the weak viscoelastic properties observed. 
 
 
 
Figure 8.8: Determination of hyaluronan by polyacrylamide gel (10%) electrophoresis, combined alcian blue 
and silver staining. Synovial fluid samples (after boiling and treatment with proteinase K) labeled according to 
the sample number (1–12). M1 (10 µL) and M2 (5 µL): sulfonated polystyrenes as size markers. 
By polyacrylamide gel electrophoresis, oligosaccharides could be detected down to a 
molecular weight of approximately 17 kDa. In search for very small oligosaccharides derived 
from enzymatic hyaluronan degradation, ultrafiltrated aliquots of the diluted but undigested 
synovial fluids were additionally analyzed by HPAEC–PAD (Figure 8.9). 
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Figure 8.9: HPAEC–PAD of the ultrafiltrated synovial fluids. Chromatography conditions: CarboPac
TM
 PA200, 
100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min.  
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Although the peaks detected in the samples 1–12 are supposed to correspond, at least in 
part, to the expected analytes, chromatography was insufficient to unambiguously assign 
the signals to hyaluronan oligosaccharides or other matrix components. Unfortunately, due 
to the very low analyte concentrations, CZE–ESI-TOF-MS was not sensitive enough. 
Consequently, a different approach was chosen. Sample 12 (Figure 8.9 L), which was the only 
one to show a clear series of small peaks in the respective region of the chromatogram, was 
spiked with the standard oligosaccharides (n2, n3, n4). In this way, three peaks could be 
assigned to these oligosaccharides by their retention time (Figure 8.10). Nevertheless, the n2 
peak seems to overlap with a second peak from an unidentified matrix component. 
 
Figure 8.10: Spiking of the ultrafiltrate from sample 12 with standard oligosaccharides (n2, n3, n4). HPAEC–PAD: 
CarboPac
TM
 PA200, 100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
Except for sample 12, the n3 and n4 peaks were not observed. The peak at the retention time 
observed for n2, owing to the mentioned overlap, cannot be unambiguously assigned to the 
hyaluronan tetrasaccharide. Thus, the presence of small hyaluronan oligosaccharides was 
only proven for sample 12.  
8.3.6 Hyaluronidase activity 
To evaluate if different amounts of hyaluronidase as a potential constituent of synovial fluid 
caused the observed differences in viscoelastic properties as well as hyaluronan size 
distribution, zymography with hyaluronan substrate gels was performed. After incubation at 
pH = 4 and staining of the gels, light bands on dark background indicated enzymatic activity 
(Figure 8.11). 
Hyaluronidase activity was found in almost all synovial fluid samples to variable extent. Only 
sample 8 showed no significant activity. Furthermore, in sample 6 and in sample 7 the 
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activity was rather weak. Relatively high activity was determined for sample 4, which had 
also shown low viscoelastic moduli, low hyaluronan content, and high degradation in the gel 
electrophoresis experiment. 
 
 
 
Figure 8.11: Determination of hyaluronidase activity by zymography (incubation at pH = 4.0) followed by alcian 
blue staining and Coomassie counterstaining. Light bands on dark background indicate enzymatic activity. 
Synovial fluid samples labeled according to the sample number (1–12). Human CPD plasma (P) served as 
control. Samples and control were diluted in the same manner. 
By comparison to a plasma control, the active protein in synovial fluid samples was proven 
to be identical to plasma hyaluronidase. However, enzymatic activity was much higher in 
plasma than in the synovial fluids. Moreover, it cannot be ruled out that hyaluronidase 
activity in the synovial fluid might, at least in part, result from blood contamination. 
8.4 Summary and conclusion 
CZE–ESI-TOF-MS and HPAEC–PAD were successfully applied to the quantification of 
hyaluronan in synovial fluids after digestion of the polysaccharide. HPAEC–PAD also proved 
to be a valuable tool for the search of traces of small hyaluronan oligosaccharides in 
biological matrices. In combination with several complementary methods, a detailed 
characterization of 12 synovial fluid samples was achieved. Especially rheology yielded 
obvious differences in the viscoelastic properties. Polyacrylamide gel electrophoresis proved 
that the hyaluronan from the synovial fluids was fragmented into low molecular weight 
saccharides to a variable extent. For extremely low hyaluronan contents and high 
fragmentation (sample 4), the relation to very weak viscoelastic properties was self-evident. 
Hyaluronidase activity was found in most samples. Nevertheless, this could also originate 
from blood contamination. Although diagnoses were similar, differences in synovial fluid 
analysis were obvious. However, no general correlation between diagnoses and the 
analytical results was observed. 
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Dunn et al. reported on high variability in the properties of synovial fluids under controlled 
conditions and therefore found no statistically significant differences between osteoarthritis 
patients and healthy volunteers.7 Consequently, although it cannot be ruled out that in our 
experiments artifacts (long-term freezing of the samples) contributed to variability, the 
results probably reflect the interindividual natural situation. 
8.5 References 
1. Meyer, K.; Smyth, E. M.; Dawson, M. H. The isolation of a mucopolysaccaride from synovial fluid. J. 
Biol. Chem. 1939, 128, 319-327. 
2. Meyer, K. The biological significance of hyaluronic acid and hyaluronidase. Physiol. Rev. 1947, 27, 
335-359. 
3. Sundblad, L. The chemistry of synovial fluid with special regard to hyaluronic acid. Acta Orthop. 
Scand. 1950, 20, 105-113. 
4. Ragan, C.; Meyer, K. The hyaluronic acid of synovial fluid in rheumatoid arthritis. J. Clin. Invest. 1949, 
28, 56-59. 
5. Dahl, L. B.; Dahl, I. M.; Engstrom-Laurent, A.; Granath, K. Concentration and molecular weight of 
sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other 
arthropathies. Ann. Rheum. Dis. 1985, 44, 817-822. 
6. Stafford, C. T.; Niedermeier, W.; Holley, H. L.; Pigman, W. Studies on the concentration and intrinsic 
viscosity of hyaluronic acid in synovial fluids of patients with rheumatic diseases. Ann. Rheum. Dis. 
1964, 23, 152-157. 
7. Dunn, S.; Kolomytkin, O. V.; Marino, A. A. Pathophysiology of osteoarthritis: evidence against the 
viscoelastic theory. Pathobiology 2009, 76, 322-328. 
8. Hascall, V. C.; Laurent, T. C. Hyaluronan: structure and physical properties. Glycoforum 1997. 
(http://glycoforum.gr.jp/science/hyaluronan/HA01/HA01E.html) 
9. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254. 
10. Muckenschnabel, I.; Bernhardt, G.; Spruß, T.; Dietl, B.; Buschauer, A. Quantitation of hyaluronidases 
by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients 
and healthy volunteers. Cancer Lett. 1998, 131, 13-20. 
11. Gacesa, P.; Savitsky, M. J.; Dodgson, K. S.; Olavesen, A. H. A recommended procedure for the 
estimation of bovine testicular hyaluronidase in the presence of human serum. Anal. Biochem. 1981, 
118, 76-84. 
12. Reissig, J. L.; Storminger, J. L.; Leloir, L. F. A modified colorimetric method for the estimation of N-
acetylamino sugars. J. Biol. Chem. 1955, 217, 959-966. 
13. Morgan, W. T.; Elson, L. A. A colorimetric method for the determination of N-acetylglucosamine and 
N-acetylchrondrosamine. Biochem. J. 1934, 28, 988-995. 
14. Ikegami-Kawai, M.; Takahashi, T. Microanalysis of hyaluronan oligosaccharides by polyacrylamide gel 
electrophoresis and its application to assay of hyaluronidase activity. Anal. Biochem. 2002, 311, 157-
165. 
8.5 References  173 
 
15. Min, H.; Cowman, M. K. Combined alcian blue and silver staining of glycosaminoglycans in 
polyacrylamide gels: application to electrophoretic analysis of molecular weight distribution. Anal. 
Biochem. 1986, 155, 275-285. 
16. Hamberger, J. Characterization of mammalian hyaluronidase-2 activity and identification of inhibitors 
of Streptococcal hyaluronan lyase. PhD thesis, University of Regensburg, Regensburg, 2012. 
17. Merril, C. R.; Goldman, D.; Sedman, S. A.; Ebert, M. H. Ultrasensitive stain for proteins in 
polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science 1981, 211, 1437-
1438. 
18. Cherr, G. N.; Meyers, S. A.; Yudin, A. I.; VandeVoort, C. A.; Myles, D. G.; Primakoff, P.; Overstreet, J. 
W. The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms 
exhibiting hyaluronidase activity. Dev. Biol. 1996, 175, 142-153. 
19. Bayliss, C. E.; Dawkins, R. L.; Cullity, G.; Davis, R. E.; Houliston, J. B. Laboratory diagnosis of 
rheumatoid arthritis. Prospective study of 85 patients. Ann. Rheum. Dis. 1975, 34, 395-402. 
20. Harris, E. D., Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 
1990, 322, 1277-1289. 
21. Cronstein, B. N.; Terkeltaub, R. The inflammatory process of gout and its treatment. Arthritis Res. 
Ther. 2006, 8 Suppl 1, S3. 
22. Sundblad, L. Determination of anomalous viscosity in pathological joint fluids. Scand. J. Clin. Lab. 
Invest. 1954, 6, 288-294. 
23. Schurz, J.; Ribitsch, V.; Rainer, F. Rheologische Untersuchungen an Synovia und Synoviamodellen. 
Rheol. Acta 1979, 18, 139-150. 
24. Thurston, G. B.; Greiling, H. Viscoelastic properties of pathological synovial fluids for a wide range of 
oscillatory shear rates and frequencies. Rheol. Acta 1978, 17, 433-445. 
 
  
174 8 Analysis of synovial fluid samples 
 
 
175 
 
9 In vitro studies on the interaction of hyaluronan and 
hyaluronan oligosaccharides with human cells 
9.1 Introduction 
Hyaluronan and hyaluronan oligosaccharides are supposed to play an important role in 
tissue regeneration and wound repair.1, 2 West and Kumar reported stimulating effects of 
hyaluronan oligosaccharides comprising 3–16 disaccharide units (n3–n16) on proliferation of 
bovine aortic endothelial cells, whereas high molecular weight hyaluronan (at 
concentrations above 100 µg/mL) inhibited cell proliferation and disrupted newly formed 
monolayers.3 Animal studies also provided hints to angiogenic effects of small 
oligosaccharides leading to accelerated wound healing.4 The hyaluronan receptors CD44 and 
RHAMM are supposed to influence the complex processes of wound healing and 
vascularization.5-7 Previous studies by Hamberger aimed at elucidating the effect of products 
from enzymatic digests of hyaluronan on the proliferation of human microvascular 
endothelial cells (HMEC-1).8 Inspired by these experiments, we decided to follow up this 
matter combining the conventional crystal violet assay with the sensitive approach of 
electric cell–substrate impedance sensing (ECIS). 
Electric cell–substrate impedance sensing is based on the observation that changes in 
morphology and density of cells growing on a gold film electrode can be measured via the 
impedance of the system when alternating electric fields are applied.9 While attaching and 
spreading on the gold film electrode, cells cause a measurable change in impedance, 
allowing for quantitative and continuous real-time analysis.10 Hence, ECIS has already been 
successfully applied to determine attachment and spreading of cells on artificial surfaces,11 
cell motility,12 and invasive behavior of metastatic cells in vitro.13 Noiri et al. used a direct 
current pulse to wound a layer of endothelial cells and measured the recovery of the cell 
layer by ECIS.14 Later, this approach was further optimized and characterized in detail.15 
Thereby, an alternating current pulse was used, causing a defined lesion only on the surface 
of the electrode.15 In view of the high sensitivity of ECIS concerning a broad range of changes 
in cell shape, cell movement, and proliferation, this method was considered for studying the 
cellular effects of hyaluronan and hyaluronan oligosaccharides. 
Apart from wound healing and angiogenesis, the polysaccharide itself, hyaluronidase 
activity, and the enzymatic degradation products of hyaluronan are supposed to be involved 
in cancer and metastasis.16, 17 Overexpression of hyaluronidase by human colorectal 
adenocarcinoma cells (HT-29) increased the number of metastases especially in the liver and 
lung of nude mice bearing orthotopic xenografts.18 Hyaluronidase activity was proven in 
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tumor cell lysates as well as, after sample concentration, in conditioned cell culture media at 
the pH optimum of the enzymes.18 However, metabolic products of hyaluronan or 
hyaluronan oligosaccharides were not detected in the surrounding cell culture medium due 
to the lack of suitable analytical methods. Thus, we envisaged the analysis of hyaluronan 
oligosaccharides in cell culture media with regard to cellular uptake or alteration in size 
distribution by hyaluronidase activity. 
9.2 Materials and methods 
9.2.1 Cell lines and cell culture conditions 
Immortalized human microvascular endothelial cells (HMEC-1)19 were kindly provided by 
Prof. Dr. Joachim Wegener (Institute of Analytical Chemistry, Chemo- and Biosensors, 
University of Regensburg). Human colorectal adenocarcinoma cells (HT-29), the human 
breast adenocarcinoma cell line MDA-MB-231, and the human melanoma cell line SK-MEL-3 
were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and 
stored according to the seed stock concept.20 SK-MEL-3 cells overexpressing human PH-20 
(clone SK-MEL-3 PH # 14) were established and characterized by Oettl.21 HT-29 cells were 
modified by Jarzyna with regard to overexpression of human hyaluronidase-1 (clone Valt).
18 
All cells were grown in suitable cell culture media (Table 9.1) at 37 °C in water-saturated 
atmosphere of 95% air and 5% carbon dioxide (CO2). Cell culture flasks were from Sarstedt 
(Nümbrecht, Germany). Fetal calf serum (FCS) was from Biochrom (Berlin, Germany). Sodium 
hydrogen carbonate (NaHCO3) was from Merck (Darmstadt, Germany). For passaging, cells 
were trypsinized with 0.05% trypsin and 0.02% EDTA in PBS, prepared from a trypsin/EDTA 
concentrate (PAA Laboratories, Pasching, Austria). 
Table 9.1: Cell culture media. HT-29 cells with Hyal-1 overexpression and control cells were cultured with 10% 
FCS instead of 5% (standard conditions). 
Cell line Cell culture medium  FCS Other supplements 
HMEC-1 Endothelial Cell Growth Medium 10% Supplement mix 
MDA-MB-231 McCoy’s 5 A Medium with L-glutamine 5% NaHCO3 (2.2 g/L) 
HT-29 McCoy’s 5 A Medium with L-glutamine 5% or 10% NaHCO3 (2.2 g/L) 
SK-MEL-3 McCoy’s 5 A Medium with L-glutamine 10% NaHCO3 (2.2 g/L) 
 
Endothelial Cell Growth Medium and corresponding supplement mix were from PromoCell 
(Heidelberg, Germany). The complete medium (after addition of supplement mix) contained 
FCS (2%, v/v, in addition to FCS supplementation listed in Table 9.1), endothelial cell growth 
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supplement (0.4%, v/v), recombinant human epidermal growth factor (0.1 ng/mL), 
recombinant human basic fibroblast growth factor (1 ng/mL), heparin (90 µg/mL), and 
hydrocortisone (1 µg/mL). McCoy’s 5 A Medium with L-glutamine was prepared from 
powder (Sigma-Aldrich, Munich, Germany). 
According to previously described conditions, parallel cultures of clones with hyaluronidase 
overexpression were cultured in selective media to ensure maintenance of phenotype. 
Medium for SK-MEL-3 with PH-20 overexpression contained geniticin (G-418) sulfate 
(500 µg/mL, Biochrom, Berlin, Germany).21 Hygromycin B (800 µg/mL, A. G. Scientific, San 
Diego, CA, USA) was used for HT-29 with Hyal-1 overexpression.18  
In contrast to the conditions in our lab, FCS for culture of HMEC-1 in Prof. Wegener`s 
(Institute of Analytical Chemistry, Chemo- and Biosensors, University of Regensburg) lab was 
from PAA (Pasching, Austria). Penicillin G (100 U/mL) and streptomycin (100 µg/mL) were 
added, using a penicillin/streptomycin concentrate (100 x, PAA, Pasching, Austria). 
Additionaly, medium was supplemented with 2.5 µg/mL amphotericin B (AppliChem, 
Darmstadt, Germany). Apart from these exceptions, composition of the medium (cf. Table 
9.1) and cell culture conditions were as described above. 
9.2.2 Test substances 
Hyaluronan from Streptococcus zooepidemicus (Aqua Biochem, Dessau, Germany), Hyalo-
Oligo with an average molecular weight below 10 kDa (Kewpie, also named Q. P. Corp., 
Tokyo, Japan), and the purified hexasaccharide (n3, prepared and quantified by colorimetry 
as described in Chapter 5) were investigated in cellular assays. As the hexasaccharide (n3) is 
the prevailing reaction product when hyaluronan is degraded by rhHyal-1 (cf. Chapter 7), this 
oligosaccharide was chosen. Bovine testicular hyaluronidase (BTH, Neopermease®) was a 
kind gift from Sanabo (Vienna, Austria). N-Acetyl-D-glucosamine (NAG) was from Fluka 
(Buchs, Switzerland), D-glucuronic acid (GA) and cisplatin were from Sigma-Aldrich (Munich, 
Germany). 
9.2.3 Flow cytometry 
The flow cytometric determination of hyaluronan receptors was based on the protocol by 
Hamberger.8 After trypsinization, cells were suspended in phosphate-buffered saline (PBS) 
containing 10% (v/v) of fetal calf serum (FCS). The suspension was centrifuged at 400 × g for 
5 min, washed once with PBS (without FCS), and centrifuged again. A suspension of 1 · 106 to 
2 · 106 cells/mL was prepared with PBS/FCS. To aliquots of 500 µL, the respective primary 
antibody was added to yield an appropriate dilution (anti-RHAMM: 1:500, anti-CD44: 1:100). 
The monoclonal rabbit antibody against human CD168/RHAMM (catalog #: 3139-1, clone ID: 
EPR4055, lot: YH031609C, Epitomics, Burlingame, CA, USA) was identical to that used by 
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Hamberger.8 In contrast to Hamberger’s conditions, a polyclonal anti-CD44 antibody 
produced in rabbit (human protein atlas #: HPA005785, lot: B41535, Prestige 
Antibodies/Sigma-Aldrich, Steinheim, Germany) was used. Cells were incubated with the 
primary antibody for 1 h. After three washing steps with PBS, cells were suspended in PBS 
supplemented with 3% (w/v) of bovine serum albumin containing the secondary antibody 
(goat anti-rabbit IgG, phycoerythrin-conjugated, code # 611-108-122, Rockland 
Immunochemicals, Gilbertsville, PA, USA) at a dilution of 1:250. Cells were incubated in the 
dark for 1 h, washed twice with PBS, and suspended in PBS/BSA. Flow cytometric analysis 
was conducted with a FACSCaliburTM (Becton Dickinson, Heidelberg, Germany) using the 
following instrument settings: FSC: E−1, SSC: 310, FL-2, flow: high. WinMDI 2.9 software 
was used for data evaluation. 
9.2.4 Electric cell–substrate impedance sensing (ECIS) of endothelial cells 
Electric cell–substrate impedance sensing (ECIS) was performed in Prof. Wegener`s (Institute 
of Analytical Chemistry, Chemo- and Biosensors, University of Regensburg) lab. 
Measurements were carried out with an ECIS 1600R system (Applied BioPhysics, Troy, NY, 
USA), equipped with an Elevated Field Module (EFM). Prior to usage, electrode arrays were 
coated with collagen (Biochrom, Berlin, Germany). High molecular weight hyaluronan, a low 
molecular weight hyaluronan oligosaccharide mixture, and purified hexasaccharide (n3, 
100 mg/mL stock solution) were dissolved in FCS-free cell culture medium (without 
supplement mix, without antibiotics). The solutions were sterilized by filtration through a 
0.22 µm filter. After addition of 2.5% FCS, the medium contained 1 mg/mL of the test 
compounds. It should be noted again that n3 was not weighted but quantified by 
colorimetry. Standard cell culture medium (with supplement, 10% FCS) and blank assay 
medium (without supplement, 2.5% FCS) served as control. 
For an electric wound healing assay,
15
 HMEC-1 cells were seeded to form a confluent 
monolayer in 8W1E (8 wells, 1 electrode/well, Figure 9.1 A) disposable electrode arrays 
(Applied BioPhysics, Troy, NY, USA). After incubation overnight (37 °C, 5% CO2), medium was 
replaced by fresh medium containing the test substances. The measurement was started. 
After approximately 2 h of equilibration, an electric wounding pulse (sine pulse, frequency: 
40 kHz, amplitude: 5 V, duration: 30 s) was applied to kill the cells on the electrode surface. 
After recovery of the cell layer the experiment was repeated, applying a second (identical) 
wounding pulse. 
For monitoring cell proliferation, 8W10E+ (8 wells, 40 electrodes/well, Figure 9.1 B) arrays 
(Applied BioPhysics, Troy, NY, USA) were used. Cells were seeded at 2% confluency and 
increasing coverage of the electrodes as a function of time was measured for 142 h. All other 
conditions were identical to the wound healing assay. After 142 h, an additional electric 
wounding pulse was elicited as described above.   
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Figure 9.1: Arrays 8W1E (A) and 8W10E+ (B) for ECIS. Images of the whole arrays taken from the product 
information sheet (http://www.biophysics.com/Product%20Sheets/ABP_ArraySheet.pdf), magnified images 
(high resolution) kindly provided by Applied BioPhysics. Use of all images with kind permission from Applied 
BioPhysics (Troy, NY, USA). 
9.2.5 Crystal violet cell proliferation assay 
A previously desribed crystal violet assay22, 23 was applied to measure proliferation of the 
HMEC-1 cells. By analogy with ECIS arrays (cf. Section 9.2.3) flat-bottomed 96-well plates 
(Greiner, Frickenhausen, Germany) were coated with collagen. 100 µL of cell suspension per 
well were seeded in the plate to reach 2% confluency. After 24 h of incubation under 
standard conditions (37 °C, 5% CO2) the medium was replaced by 200 µL of fresh medium 
containing the test compounds. As described in Section 9.2.3, the substances were dissolved 
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in FCS-free cell culture medium (without supplement mix) and filtrated through Millex-GP 
0.22 µm syringe filter units (Merck-Millipore, Darmstadt, Germany). By addition of 2.5% of 
sterile FCS, the desired concentration of the test compounds was yielded. Cisplatin was 
applied as concentrated (100 µM) stock solution in dimethylformamide. For each substance 
or concentration, 16 wells were used. 
After different periods of incubation (37 °C, 5% CO2), cell culture medium was discarded. 
Cells were fixed with 1% (v/v) glutardialdehyde (Merck, Darmstadt, Germany) in PBS. 
Afterwards, cells were covered with PBS and the plates were stored at 4 °C until the end of 
the experiment. PBS was discarded and cells in all 96-well plates were stained 
simultaneously with an aqueous solution (0.02%, w/v) of crystal violet (Merck, Darmstadt, 
Germany). Unbound dye was washed off with water. Finally, cell-bound crystal violet was 
dissolved by addition of 180 µL of 70% ethanol per well. 
Absorbance was measured at 580 nm with a Tecan GENios Pro plate reader (Tecan, 
Crailsheim, Germany). Data were recorded with the corresponding XFluor GENios Pro 
software V.4.55. Cell proliferation curves were obtained by plotting absorbance versus 
incubation time with SigmaPlot for Windows 11.2.0.5 (Systat Software Inc., San Jose, CA, 
USA). 
To exclude pH effects at high concentrations of acidic saccharides, an additional experiment 
with HEPES-buffered medium was performed. A 1 M aqueous solution of HEPES (Serva, 
Heidelberg, Germany) was prepared and adjusted to pH = 8.2. Due to the concentration 
dependency of the pKa value, a pH of 7.4 was reached after addition to the medium yielding 
a final HEPES concentration of 30 mM. After dissolution of the hyaluronan oligosaccharides 
and prior to filtration, pH was additionally titrated to physiological values by addition of 
sodium hydroxide solution if necessary (at high concentrations of HA oligosaccharides). 
9.2.6 Collection and analysis of wound material 
Wound material from volunteers was provided by Prof. Dr. Sigrid Karrer (Department of 
Dermatology, University of Regensburg). Three silicone-coated foam dressings (Mepilex®, 
Mölnlycke Health Care, Erkrath, Germany), soaked with exudate, were collected. However, 
sufficient amounts of material were only obtained from one foam dressing by squeezing and 
subsequent centrifugation. An additional sample of debris, scraped off from the wound, was 
also provided. After ultrafiltration using Nanosep® Centrifugal Devices 10 K (Pall Life 
Sciences, Ann Arbor, MI, USA), samples were analyzed by HPAEC–PAD as described in 
Chapter 4. In addition, 1:10 dilutions were analyzed and compared to human CPD plasma by 
zymography according to the protocol from Chapter 8 (Section 8.2.11). Until analysis, all 
samples were stored at −80 °C. 
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9.2.7 Analysis of conditioned cell culture media 
Hyaluronidase overexpressing SK-MEL-3 and HT-29 clones and the respective wild type 
controls were seeded in a 24-well plate (2 mL of 1.5 · 105 cells/mL suspension per well). After 
24 h (37 °C, 5% CO2), culture medium was replaced by FCS-free (to prevent hyaluronidase 
contamination from serum) medium containing 1 mg/mL of a hyaluronan oligosaccharide 
mixture (MW < 10 kDa). The oligosaccharides were dissolved in the medium and filtrated 
through Millex-GP 0.22 µm syringe filter units (Merck-Millipore, Darmstadt, Germany). Cell-
free controls with oligosaccharide mixture alone (negative control) or oligosaccharide 
mixture with 1000 IU/mL of BTH (positive control) were incubated under the same 
conditions. After 7 days, cell culture media were deproteinized by boiling for 10 min, 
centrifugation at 13000 × g for 10 min, and filtration through a Phenex-NY 4 mm syringe 
filter 0.2 µm (Phenomenex, Aschaffenburg, Germany). Samples were diluted 1:2 with 
purified water and analyzed by HPAEC–PAD (cf. Chapter 4). 
9.3 Results and discussion 
9.3.1 Flow cytometry 
The hyaluronan receptor CD44 was previously detected on the surface of the human 
microvascular endothelial cell line HMEC-1.24 Having observed an inhibitory effect of an anti-
CD44 antibody on migration and proliferation of HMEC-1 cells, Trochon et al. proposed CD44 
to be involved in these processes.25 Moreover, wound healing in mice was reported to be 
promoted by hyaluronan oligosaccharides,4 whereas delayed wound healing was observed in 
CD44-deficient mice.26 Savani et al. suggested that both CD44 and RHAMM are involved in 
proliferation and migration of endothelial cells.6 Thereby, proliferation of the human 
endothelial cell line HUVEC could only be inhibited by an anti-CD44 (not by anti-RHAMM) 
antibody, whereas migration was inhibited by anti-RHAMM (not by anti-CD44).6 Based on 
studies with porcine iliac vascular endothelial cells (PIEC), Gao et al. suggested that RHAMM, 
rather than CD44, was responsible for the proposed stimulation of angiogenesis and wound 
healing processes by hyaluronan oligosaccharides.27 Hence, the expression of CD44 and 
RHAMM was investigated by flow cytometry. After binding of the primary antibody, directed 
against the respective receptor protein, bound antibody was detected with a phycoerythrin-
conjugated secondary antibody (Figure 9.2).  
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A 
HMEC-1 
B 
HT-29 
C 
MDA-MB-231 
Figure 9.2: Flow cytometric determination of hyaluronan receptors RHAMM and CD44 on HMEC-1 (A), HT-29 
(B), and MDA-MB-231 (C) cells. Curves show autofluorescence of the cells (grey), phycoerythrin-conjugated 
secondary antibody alone (black), monoclonal anti-RHAMM (red), and polyclonal anti-CD44 (blue). Cell 
populations in gate 1 were considered in the histograms. 
In a previous study, RHAMM but not CD44 was detected on HMEC-1 cells by flow cytometry 
with monoclonal primary antibodies against the respective proteins.8 Nevertheless, using a 
polyclonal anti-CD44 antibody instead, we succeeded in proving the protein on these cells. 
As already speculated by Hamberger, the monoclonal primary antibody probably was not 
suitable for the recognition of the CD44 isoform present on HMEC-1 cells.8 With regard to 
RHAMM, previous results8, 24 were confirmed (Figure 9.2 A). Moreover, comparable 
expression of CD44 and RHAMM was measured by Savani et al. on different human 
endothelial cells (HUVEC).6 This is in accordance with the results of Xu et al., who  compared 
HMEC-1 and HUVEC with respect to CD44.24  
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The human colorectal adenocarcinoma cell line HT-29 is known to express the CD44 
protein.28 MDA-MB-231 cells were previously reported to express elevated levels of both 
RHAMM and CD44.29 Hence, these cell lines were chosen as references. Both controls 
showed the expected high expression of CD44. RHAMM was additionally detected on MDA-
MB-231, but not on HT-29 cells (Figure 9.2 B, C). 
9.3.2 Electric wound healing model 
In an electric wound healing model, based on the assay by Keese et. al.,15 the influence of 
hyaluronan and hyaluronan oligosaccharides on the recovery HMEC-1 cell layers was 
studied. Two arrays were measured in parallel. It was previously reported that capacitance 
measurements at high frequencies are ideal for determination of electrode coverage, 
showing a linear correlation.11 Hence, capacitance measured at 32 kHz was plotted versus 
incubation time for both arrays (Figure 9.3). Owing to the insulating properties of cells, a 
high degree of electrode coverage results in low capacitance and vice versa. Hence, an 
immediate increase in capacitance was observed as soon as the wounding pulse was applied. 
Along with recovery of the cell layer the capacitance continuously decreased until it reached 
the initial values for the cell-covered electrode.  
As becomes obvious from Figure 9.3, high molecular weight hyaluronan and the 
oligosaccharide mixture (both at 1 mg/mL) did not influence this process. Interestingly, there 
was also no difference between the control medium (2.5% FCS, no supplement mix) and the 
supplemented medium with high FCS content. Probably, the supplement mix and higher 
amount of FCS are only necessary for longer periods of incubation. By contrast, the 
hexasaccharide (n3) led to a measurable delay in recovery after the high electric field pulse. 
The effect was even more pronounced after the second wounding pulse. In this case, the 
initial capacitance values (indicating a completely covered electrode) were not reached. 
Hyaluronan oligosaccharides were often related to increased endothelial cell proliferation 
and wound healing.3, 4 By contrast, our observations suggest an inhibitory, rather than a 
stimulating, effect of the hexasaccharide (n3) at a concentration of 1 mg/mL. Hence, our 
results are in line with the observation by Banarjee and Toole that 500 µg/mL of the 
hexasaccharide (but not the tetrasaccharide, D-glucuronic acid, and N-acetyl-D-glucosamine) 
completely inhibited endothelial cell migration and tube formation.30 
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Figure 9.3: Electric wound healing assay using HMEC-1 cells. Array 1 (A): high molecular weight hyaluronan 
(1 mg/mL) and hyaluronan oligosaccharide mixture (1 mg/mL) compared to control (medium + 2.5% FCS). 
Array 2 (B): purified hexasaccharide (n3, 1 mg/mL) and supplemented medium (supplement mix, 10% FCS) 
compared to control. Capacitance measured at 32 kHz. Wounding pulses: 5 V (amplitude), 40 kHz, 30 s. 
9.3.3 Proliferation of HMEC-1 cells 
Proliferation assays were performed to investigate if the inhibition of cell layer recovery in 
the wounding experiment by n3 originated from reduced cell proliferation or other 
parameters, for instance, cell migration or differences in attachment to the electrode 
surface. Thereby, ECIS was combined with the conventional crystal violet assay.  
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Real-time measurement by ECIS (Figure 9.4) revealed considerable acceleration of cell 
proliferation by addition of the supplement mix and high FCS content. The hyaluronan 
hexasaccharide (n3) obviously inhibited cell proliferation.  
 
 
Figure 9.4: Electric cell proliferation assay using HMEC-1 cells. Array 1 (A): high molecular weight hyaluronan 
(1 mg/mL) and hyaluronan oligosaccharide mixture (1 mg/mL) compared to control (medium + 2.5% FCS). 
Array 2 (B): purified hexasaccharide (n3, 1 mg/mL) and supplemented medium (supplement mix, 10% FCS) 
compared to control. Capacitance measured at 32 kHz. Additional wounding pulse: 5 V (amplitude), 40 kHz, 
30 s. 
The curves for high molecular weight hyaluronan and the oligosaccharide mixture were 
comparable to the control, but showed a relatively high variability considering absolute 
values. With regard to the absolute values of capacitance, it should be noted that the 
differences between Figure 9.3 and Figure 9.4 are caused by the number of electrodes per 
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well (1 versus 40) for the respective arrays. For the same reason, identical wounding did not 
lead to effective killing of the cells in the experiment depicted in Figure 9.4. Applying the 
same voltage pulse, the average current at each electrode of the 8W10E+ array (parallel 
circuit) was only 1/40 of the current using the 8W1E array, according to Kirchhoff’s nodal 
rule. 
In view of better interpretability, the curves from Figure 9.4 were normalized by dividing the 
measured capacitance (C) by the respective capacitance at t = 0 (C0). The normalized curves 
for the initial 140 h of the experiment (proliferation without the wounding pulse) are 
depicted in Figure 9.5.  
By normalization, small differences between the ECIS curves for hyaluronan, the 
oligosaccharide mixture, and control became visible. Under the influence of high molecular 
weight hyaluronan the decrease in capacitance, which is proportional to the increase in 
electrode coverage,11 was slightly slower compared to control but reached similar values 
after 140 h. Furthermore, the hyaluronan oligosaccharide mixture tended to further 
decelerate the occupation of the electrode surface by the cells, not reaching exactly the 
same values as control after 140 h. These findings are reflected by the results from a crystal 
violet cell proliferation assay, performed simultaneously under identical conditions (Figure 
9.6 A). In a second assay, different concentrations of the hyaluronan oligosaccharide mixture 
were tested. Previous studies had revealed no effect of this mixture on proliferation of 
HMEC-1 cells at concentrations of 5–100 µg/mL.8 Hence, we focused on the range of 0.5–
10 mg/mL (Figure 9.6 B). In contrast to the first experiment, proliferation was not inhibited 
at 1 mg/mL. At higher concentrations, proliferation was decelerated and completely 
inhibited at 10 mg/mL. However, at these high concentrations the addition of hyaluronan 
oligosaccharides significantly acidified the cell culture medium. This issue will be discussed 
later in this section. 
To exclude that the suppression of cell proliferation by n3 was caused by unspecific effects, 
mixtures of N-acetyl-D-glucosamine and D-glucuronic acid (each 10–1000 µM) and each of 
the sugars alone (1000 µM) were investigated (Figure 9.6 C). No effect was detected, 
suggesting that a specific interaction is responsible for the lack of cell proliferation in the 
presence of n3 at a concentration of 1 mg/mL (≈ 865 µM). Co-incubation of the cells with 
hyaluronan and bovine testicular hyaluronidase (BTH) revealed no difference compared to 
hyaluronan alone (Figure 9.6 C). However, the slight reduction of proliferation rate by 
hyaluronan (cf. Figure 9.6 A) was confirmed, whereas BTH alone had no effect. 
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Figure 9.5: Normalization of the HMEC-1 proliferation curves from Figure 9.4. Capacitance divided by the 
respective value at t = 0 (C0). Only the first 140 h of the experiment are depicted. Array 1 (A): high molecular 
weight hyaluronan (1 mg/mL) and hyaluronan oligosaccharide mixture (1 mg/mL) compared to control 
(medium + 2.5% FCS). Array 2 (B): purified hexasaccharide (n3, 1 mg/mL) and supplemented medium 
(supplement mix, 10% FCS) compared to control. Capacitance measured at 32 kHz. 
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Figure 9.6: Influence of hyaluronan and hyaluronan oligosaccharides on the proliferation of HMEC-1 cells. 
Growth curves determined by the crystal violet assay. Comparison of hyaluronan and hyaluronan 
oligosaccharides (A), concentration-dependent effect of a hyaluronan oligosaccharide mixture (B), D-glucuronic 
acid (GA) and N-acetyl-D-glucosamine (NAG) alone and in combination (C), co-incubation with hyaluronan and 
BTH (D). Data presented as means ± SD of 16 wells on the same plate. 
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The stimulating effect of medium containing the supplement mix and additional FCS on 
HMEC-1 proliferation, observed in the ECIS experiment (cf. Figure 9.4 and Figure 9.5), was 
confirmed by simultaneously performed crystal violet assays (Figure 9.7 A). The reference 
compound cisplatin (100 nM) considerably inhibited cell proliferation (Figure 9.7 A), albeit 
the effect was much less prominent than observed for 1 mg/mL (≈ 865 µM) of the 
hyaluronan hexasaccharide (cf. Figure 9.6 A). Moreover, we were interested in the effect of 
the supplement mix alone. Hence, the FCS content was reduced to 2.5%, the same content 
used for negative control. As the supplement mix already contains FCS (yielding 2.0% FCS in 
the readily prepared medium), this portion was considered in an additional test medium to 
investigate the contribution of the other ingredients of the supplement mix (Figure 9.7 B). 
Both supplemented media clearly stimulated cell proliferation. Thereby, no differences 
between 2.5% and 4.5% FCS content were found, indicating other components of the 
supplement mix to be responsible for the stimulation of cell growth. 
  
Figure 9.7: Influence of supplement, FCS content, and the reference substance cisplatin on proliferation of 
HMEC-1 cells. Growth curves determined by the crystal violet assay. Stimulating effect of supplemented 
medium (supplement mix + 10% FCS) and inhibition of cell proliferation by cisplatin (A), influence of the 
supplement mix (containing FCS) and its non-FCS components alone (B). Data presented as means ± SD of 16 
wells on the same plate. 
The mixture of hyaluronan oligosaccharides affected endothelial cell proliferation only at 
concentrations, at which acidification of the culture medium must be kept in mind (cf. Figure 
9.6 B). To exclude this parameter, buffering capacity of the cell culture medium was 
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increased by addition of HEPES at a concentration of 30 mM (Figure 9.8). In HEPES-buffered 
medium, the oligosaccharide mixture did not influence proliferation of HMEC-1 cells. 
However, the inhibitory effect of the hyaluronan hexasaccharide (n3) was confirmed. 
 
Figure 9.8: Influence of the hyaluronan hexasaccharide (n3, 1 mg/mL) and high concentrations of hyaluronan 
oligosaccharides (2.5–10 mg/mL) on proliferation of HMEC-1 cells in additionally HEPES-buffered (30 mM) 
medium. Growth curves determined by the crystal violet assay. Data presented as means ± SD of 16 wells on 
the same plate. 
In summary, high molecular weight hyaluronan and a low molecular weight hyaluronan 
oligosaccharide mixture had no clear-cut effect on endothelial cell proliferation. At 1 mg/mL 
no response or only a slight inhibitory effect was observed. Stronger inhibition by higher 
concentrations of the oligosaccharide mixture was probably caused by acidification of the 
culture medium. In accordance with previous studies,30 a high concentration (1 mg/mL) 
(≈ 865 µM) of the hyaluronan hexasaccharide (n3) completely inhibited endothelial cell 
proliferation in both ECIS and crystal violet assay.  
It is known from binding experiments using a different cell line that n3 binds to hyaluronan 
receptors on the cell surface, albeit with lower affinity than the polymer.31 A common model 
suggests that polyvalent (high affinity) binding of high molecular weight hyaluronan to CD44 
and other hyaluronan receptors induces the respective signaling cascades, whereas 
competitive monovalent (low affinity) binding of small oligosaccharides (n3–n9) inhibits 
constitutive kinase activation.32, 33 In this context, hyaluronan oligosaccharides are discussed 
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as possible sensitizers in view of overcoming drug resistance in cancer cells.34, 35 As discussed 
(cf. Section 9.3.1), hyaluronan receptors are presumably involved in the proliferation of 
endothelial cells.6, 25-27 In contrast to our findings, Gao et. al described stimulation of 
(porcine) endothelial cell proliferation by hyaluronan oligosaccharides (mixture of n2–n10) via 
RHAMM-mediated signaling.27 With bovine endothelial cells, small oligosaccharides (n3–n16) 
were also reported to induce proliferation and to show an inhibitory effect only at high 
concentrations of 2–4 mg/mL.3 Thus, specific effects of hyaluronan oligosaccharides are 
discussed controversially. Moreover, the biological responses seem to depend not only on 
size but also on the concentration of the respective saccharides.  
9.3.4 Analysis of wound material 
Applicability of HPAEC–PAD to ultrafiltrates of exudate and debris from wounds was proven. 
Although exudate and debris gave different chromatograms, numerous peaks were visible in 
both of them (Figure 9.9). However, none of these peaks could be assigned to one of the 
hyaluronan oligosaccharides.  
 
Figure 9.9: Ultrafiltrates of wound material analyzed by HPAEC–PAD: exudate isolated from a sponge/foam 
dressing (A) and debris (B). Chromatography conditions: CarboPac
TM
 PA200, 10 µL of sample injected, 100 mM 
sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min.  
Zymography revealed no measurable hyaluronidase activity in the samples at pH = 4.0 (not 
shown). As hyaluronidase activity had been detected in human plasma and in synovial fluids 
(cf. Chapter 8), comparable results were expected for wound material. However, the 
exudation process possibly leads to strong dilution, resulting in much lower enzymatic 
activity compared to plasma. Nevertheless, it cannot be ruled out that difficulties in sample 
collection and preparation, especially obtaining the material from the foam dressing, are 
responsible for the negative zymographic results. Hence, optimization of sample collection 
should precede further analytical studies. 
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9.3.5 HPAEC–PAD of hyaluronan oligosaccharide-supplemented conditioned 
cell culture media 
Like wound material (cf. Section 9.3.4) and synovial fluids (cf. Chapter 8), conditioned cell 
media were successfully analyzed by HPAEC–PAD. However, conditioned media, from wild 
type and from hyaluronidase overexpressing clones of HT-29 (Figure 9.10) and SK-MEL-3 
(Figure 9.11) cells, showed no signs of hyaluronidase activity or oligosaccharide 
internalization.  
 
Figure 9.10: HPAEC–PAD of cell culture media from HT-29 cells, supplemented with hyaluronan oligosaccharide 
mixture (1 mg/mL). Controls: blank medium (A), negative control without cells (B), positive control containing 
1000 IU/mL of BTH (C). Conditioned media: wild type cells (D), Hyal-1 overexpressing clone without (E) and with 
addition of hygromycin B (F). Oligosaccharides (nx) labeled according to the number of disaccharide units (x). 
Chromatography conditions: CarboPac
TM
 PA200, 10 µL of sample (1:2 dilution) injected, 100 mM sodium 
hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
The composition of the added oligosaccharide mixture was not altered compared to a cell-
free control. Nevertheless, previous work by Jarzina showed that activity in conditioned 
media was very low and could be determined by colorimetry only after sample 
concentration and at optimum pH.18 Hence, it may be doubted that formation of relevant 
amounts of small oligosaccharides occurs under physiological conditions. Nevertheless, it 
should be mentioned that cells were kept in FCS-free medium to exclude serum as a source 
of hyaluronidase activity. As a consequence, cells showed almost no proliferation. However, 
cells with high proliferation rate might behave differently with regard to degradation of 
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components of the extracellular matrix, particularly hyaluronan. The positive control (with 
BTH) contained n2–n4 and minor amounts of n5. As discussed in Chapter 6, the 
tetrasaccharide (n2) could be found as the main product of BTH. Hence, the distribution 
observed in the cell culture medium is congruent with the observations from Chapter 6. In 
conditioned media from SK-MEL-3 cells (Figure 9.11 D–F), an additional peak, eluting shortly 
before the n3 peak, occurred. As this peak was not present in control and HT-29 media, it 
probably has to be assigned to a specific product of SK-MEL-3 cell metabolism. 
 
Figure 9.11: HPAEC–PAD of cell culture media from SK-MEL-3 cells, supplemented with 1 mg/mL of hyaluronan 
oligosaccharide mixture. Controls: blank medium (A), negative control without cells (B), positive control 
containing 1000 IU/mL of BTH (C). Conditioned media: wild type cells (D), PH-20 overexpressing clone without 
(E) and with addition of geniticin sulfate (F). Oligosaccharides (nx) labeled according to the number of 
disaccharide units (x). Chromatography conditions: CarboPac
TM
 PA200, 10 µL of sample (1:2 dilution) injected, 
100 mM sodium hydroxide, gradient of 200–900 mM sodium acetate, 40 °C, 0.5 mL/min. 
9.4 Summary and conclusion 
The hyaluronan receptors CD44 and RHAMM were proven on the surface of a human 
microvasular endothelial cell line (HMEC-1) by flow cytometry. Further studies focused on 
the effect of hyaluronan and its degradation products on migration and proliferation of 
these cells. Thereby, an electric wound healing model was used. Cells on an electrode 
surface were killed by an alternating current pulse. Recovery of the cell layer by migration 
and proliferation was measured by electric cell–substrate impedance sensing (ECIS). ECIS 
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was also successfully applied in combination with the conventional crystal violet assay to 
determine cell proliferation.  
Hyaluronan and a low molecular weight hyaluronan oligosaccharide mixture exhibited no or 
only slight inhibitory effects. At higher concentrations of the oligosaccharide mixture, acidic 
pH was identified as the reason for reduced cell proliferation. In good accordance with 
previous studies by Banerjee and Toole,30 strong inhibition by 1 mg/mL (≈ 865 µM) of the 
hyaluronan hexasaccharide (n3) was observed in both, the wound healing and the 
proliferation experiment. Considering a common hypothesis, it may be assumed that 
monovalent binding of n3 (present at high concentrations) thereby prevents polyvalent 
binding of hyaluronan to its receptors on the cell surface.33 By contrast, hyaluronan 
oligosaccharides are often reported to stimulate endothelial cell proliferation and 
angiogenesis.3, 4, 27  
From analysis of wound material and conditioned cell culture media it may be doubted that 
distinct oligosaccharides are produced in relevant concentrations in vivo. In a dynamic 
process of anabolic and catabolic hyaluronan metabolism, the portion of the smallest 
oligosaccharides must be assumed to be far below the tested concentration of 1 mg/mL. 
Supplementation of cell culture media with an oligosaccharide mixture did not reveal any 
changes in size distribution of the saccharides even when hyaluronidase overexpressing cells 
were cultured in these media, indicating no or only extremely low hyaluronidase activity in 
the environment of the cells at physiological pH. However, applicability of HPAEC–PAD on 
samples of wound material and cell culture media was proven. 
Nevertheless, biological processes like angiogenesis and wound healing are much more 
complex than reflected by in vitro assays. Moreover, the effects of hyaluronan 
oligosaccharides may vary not only in a size-dependent manner but also with regard to their 
concentration and the biological model. Hence, further studies in view of angiogenesis were 
performed, using the more complex test system of the chorioallantoic membrane (CAM) 
assay (cf. Chapter 10). 
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10 Studies on potential effects of hyaluronan and its 
oligosaccharides on angiogenesis in the CAM assay 
10.1 Introduction 
Hyaluronan is supposed to be responsible for the formation and maintenance of avascular 
regions in certain tissues.1 In contrast, oligosaccharides from hyaluronan degradation were 
reported to induce angiogenesis in the chorioallantoic membrane (CAM) assay.2, 3 
Furthermore, a size-dependent effect of hyaluronan on endothelial cell proliferation was 
described.4 In 2001, an article by Savani et al. proposed an involvement of the hyaluronan 
receptors CD44 and RHAMM in endothelial cell function and angiogenesis.5 Moreover, Gao 
et al. reported on potential proangiogenic effects in wound healing models in vitro.6 In a 
consecutive study, the same group confirmed these results by in vivo experiments on dermal 
wound healing in mice.7 Also in rat skin, an increase in the number of blood vessels was 
observed after application of hyaluronan oligosaccharides.8 
Due to their putative relevance in angiogenic processes, hyaluronan and its degradation 
products were also suggested to play an important role in tumor vascularization.9, 10 In line 
with this assumption, hyaluronidase expression by tumor cells was reported to induce 
angiogenesis.11 Thus, hyaluronidase isoenzymes might be involved in the regulation of 
normal and pathological angiogenic processes by formation of characteristic degradation 
products. Therefore, potential effects of hyaluronan and hyaluronan oligosaccharides were 
investigated in the chorioallantoic membrane (CAM) assay. This assay was chosen due to its 
feasibility and because there are reports in literature on similar studies.2, 3 Moreover, the 
outcome of experiments with this system (in between in vitro and in vivo conditions) was 
expected to facilitate the decision if further in vivo studies were reasonable.  
The CAM assay can be performed in various modifications and is applicable to studies of 
both induction and inhibition of angiogenesis.12 After the CAM has formed from the allantois 
and the chorion epithelium on the fourth day of embryonic development, a phase of 
proliferation and differentiation of primitive blood vessels into a complex vascular system 
follows until day eight.12 The rate of capillary formation remains extremely high until day 
eleven.12 Within this period of CAM development, usually the assay is performed with six to 
ten days old embryos. In the following experiments, substances were applied to the CAM on 
the sixth day. Vascularization was evaluated on day seven or nine, respectively. Thereby, 
previously reported protocols for the CAM assay13-16 were adopted with slight modifications. 
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10.2 Materials and methods 
10.2.1 Test substances 
Hyaluronan from Streptococcus zooepidemicus (Aqua Biochem, Dessau, Germany), Hyalo-
Oligo with an average molecular weight below 10 kDa (Kewpie, also named Q. P. Corp., 
Tokyo, Japan), and the purified hexasaccharide (n3, prepared as described in Chapter 5) were 
tested. Thalidomide (Calbiochem-Novabiochem, La Jolla, CA, USA), sodium dodecyl sulfate 
(Sigma-Aldrich, Munich, Germany), and basic fibroblast growth factor (bFGF, PeproTech, 
Rocky Hill, NJ, USA) served as reference substances. The growth factor was kindly provided 
by Dr. Jörg Teßmar (Department of Pharmaceutical Technology, University of Regensburg). 
5(6)-Carboxyfluorescein, used as fluorescent marker, was purchased from Fluka (Buchs, 
Switzerland). Substances were dissolved in water purified with a Milli-Q system (Millipore, 
Eschborn, Germany) or phosphate buffered saline (PBS), respectively. 
10.2.2 Eggs and incubation conditions 
Fertilized chicken eggs were purchased from Brüterei Süd (Regenstauf, Germany). Eggshells 
were wiped with 70% ethanol to avoid contamination. Afterwards, the eggs were kept in an 
incubator (Hemel, Verl, Germany) at 80% relative humidity and 37 °C for three days. Lying in 
a horizontal position, the eggs were rotated several times. 
10.2.3 Opening of the chicken eggs 
On the third day, eggs were positioned vertically with the blunt side to the top. Eggs were 
left in this position for 30 min before they were opened as depicted in Figure 10.1. After the 
eggshell had been removed at the blunt side and the opened egg had been covered with a 
piece of plastic wrap, the eggs were further incubated at 37 °C until day six. 
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Figure 10.1: Opening of the eggs. The egg was positioned with the blunt side to the top (A). Afterwards, the 
eggshell was pierced at the blunt side (B) and in the lower third of the egg (C). Through the lower hole, 10–
15 mL of albumen were aspired with a syringe (D–F). Residual albumen around the hole was wiped off (G) and 
the hole closed with a piece of adhesive tape (H). With a pair of tweezers the eggshell at the blunt side was 
removed carefully, starting from the hole at the top (I, J). If necessary, additional albumen was removed with 
the syringe (K). The opened egg (L) was covered with a piece of plastic wrap (M) which was additionally fixed 
with a rubber band (N, O).  
200 10 Studies on potential effects of hyaluronan and its oligosaccharides on angiogenesis in the CAM assay 
 
10.2.4 Application of the test compounds 
A 2.5% solution of pegGOLD Universal Agarose (Peqlab, Erlangen, Germany) was used to 
prepare pellets (Figure 10.2 B, C) or rings (Figure 10.2 G, H) as supports for the test 
compounds. On day six of the incubation period, 50 µg of the test substances (0.5 µg for 
bFGF) were administered to the agarose supports, which were positioned on the CAM. The 
exact procedure is illustrated by the photographs in Figure 10.2. 
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Figure 10.2: Application of test compounds. For the preparation of pellets, polytetrafluoroethylene sticks were 
sanitized with 70% ethanol (A). Agarose was dissolved at 60 °C together with heat-stable test compounds (B). 
Heat-sensitive substances were added after complete dissolution of agarose. 10 µL of the agarose solution 
were pipetted on top of the fixed sticks (C). On day six, the CAM was clearly visible (D). The agarose pellet was 
carefully placed on the membrane (E). Eggs were covered with a labeled piece of plastic wrap (F). Alternatively, 
agarose rings were prepared in a metal plate by filling the holes with agarose and subsequent punching (G). 
The rings (H) could equally be placed on the CAM and filled with a test solution (I).  
When using agarose pellets, heating of the test substances cannot be avoided. Heat-
sensitive substances were added after dissolving the agarose at 60 °C. When applying the 
biopolymer hyaluronan in a pellet, the polysaccharide is most probably enclosed in the gel 
structure and will show only minimal diffusion. Consequently, the biological effect might be 
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biased. For this reason, agarose rings were preferred for the investigation of hyaluronan and 
the corresponding oligosaccharides. For the preparation of these rings (cf. Figure 10.2 G, H), 
30–50 µL of agarose solution were pipetted into the holes of a metal plate which had been 
closed with adhesive foil from one side. The plate was comparable to common 96-well plates 
in size and shape. After punching and after removing the foil, the obtained rings could be 
easily pressed out of the plate. Rings prepared from 50 µL of agarose solution were 
preferred due to higher stability. By the use of agarose rings, 10 µL of test solution or 
suspension (in the case of thalidomide) could be placed on the CAM without any heating of 
the test compound. After substance application, eggs were again incubated until day seven 
or day nine, respectively. 
10.2.5 Stereo microscopy and evaluation score 
On day seven or day nine of incubation, the vascularization of the CAM was assessed by 
stereo microscopy with an Olympus SZ-III zoom stereo microscope (Olympus, Tokyo, Japan). 
To optimize the distance for convenient handling and to improve the illumination, the stereo 
microscope was equipped with an accessory lens (factor: 0.5) and an LED ring light with four 
lighting zones (Müller Optronics, Erfurt, Germany). Prior to stereo microscopy, long-life 
cream from a local LIDL store (Regensburg, Germany) was injected underneath the CAM to 
increase contrast (Figure 10.3). The vascularization of the membrane was evaluated 
according to a score discussed below (cf. Section 10.3.4). 
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Figure 10.3: Preparation of eggs for stereo microscopy. Long-life cream was injected underneath the CAM to 
increase contrast. Blood vessels became clearly visible on the white background. 
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10.2.6 Preparation, staining, and microscopy of chorioallantoic membranes 
Representative membranes from all groups were dissected and placed in Bouin’s solution for 
fixation. The CAM was embedded in paraffin, cut with a microtome, and stained with 
hematoxilin and eosin (H&E stain). The preparations were then microscopically examined 
with regard to histological peculiarities, especially concerning blood vessels.  
10.3 Results and discussion 
10.3.1 Suitability of agarose rings 
A solution of the fluorescent dye 5(6)-carboxyfluorescein was placed in the middle of an 
agarose ring to study its ability to hold applied test substances in situ. Only little spreading 
into the agarose gel and along larger blood vessels was observed, proving the suitability of 
agarose rings for this test system (Figure 10.4).  
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Figure 10.4: Evaluation of agarose rings for substance application. 5(6)-Carboxyfluorescein was placed in the 
agarose ring (A). A microscopic image (illuminated with blue light) clearly shows the flurorescence inside the 
ring (B). Later, the fluorescent dye was also detected in the middle of the ring, in the agarose gel, and 
associated with larger blood vessels (C).  
10.3.2  Normal chorioallantoic membranes 
On day seven (Figure 10.5 A) as well as on day nine (Figure 10.5 B, C), the normal CAM was 
characterized by uniform vascularization. Homogeneously branched blood vessels were 
found outside and inside the PBS-filled agarose ring (Figure 10.5 C). Figure 10.5 B and Figure 
10.5 C show the same egg before and after injection of long-life cream, respectively. By 
comparison of the two images, two beneficial effects of this procedure become obvious. 
Apart from increasing the contrast, the injection of the contrast agent underneath the CAM 
facilitates the discrimination between blood vessels of the yolk and the CAM. 
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Figure 10.5: The normal CAM on day seven (A) and on day nine with PBS-filled agarose ring (B). Comparison of 
the same egg before (B) and after injection of long-life cream (C) demonstrates the beneficial effect of the 
increased contrast and better discrimination between blood vessels of yolk and CAM. 
10.3.3 Irritation of the chorioallantoic membrane 
Sodium dodecyl sulfate (SDS) served as model substance to cause irritation of the CAM. 
50 µg of SDS were applied using agarose pellets. On day seven, wheel-shaped irritations with 
central necroses, accompanied by hemorrhages, were observed (Figure 10.6 A). Zooming in 
on the necrotic structure, a ring of blood vessels around the necrotic center was clearly 
visible (Figure 10.6 B). In some cases, necrosis without a pronounced ring structure occurred 
(Figure 10.6 C). 
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Figure 10.6: CAM irritation caused by SDS. Overview (A) and detailed image (B) of a wheel-shaped irritation 
with central necrosis, example of a necrotic area without pronounced blood vessel ring (C). 
10.3.4 Scoring of effects 
The reference substance thalidomide led to a reduction of blood vessel density. The 
assignment of inhibition score values, as described in literature,13-16 was performed with the 
help of expert knowledge, contributed by PD Dr. Dietrich Paper (personal communication). 
In contrast to literature,13 score values of 0.5 were not set 0, when calculating the overall 
scores. Typical examples for the assignment of the individual score values are depicted in 
(Figure 10.7). The score value 0 was assigned to a normal CAM with homogeneous 
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vascularization (example from day seven, A). Figure 10.7 B and Figure 10.7 C show inhibition 
of angiogenesis on day seven (after application of pellets) with score values of 1 and 2, 
respectively. Examples from day nine (rings) had score values of 0.5 due to slightly reduced 
vascularization inside the ring (Figure 10.7 D), 1 (Figure 10.7 E), and 2 (Figure 10.7 F). The 
highest score value (2) was used when large areas inside and around the ring were avascular. 
A value of 0.5 was used in case of abnormal shapes of blood vessels or slightly reduced 
densities, lacking avascular regions. 
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Figure 10.7: Assignment of score values. Examples from day seven: score 0 (A), score 1 (B), and score 2 (C). 
Examples from day nine: score 0.5 (D), score 1 (E), and score 2 (F). 
10.3.5 Impact of hyaluronan and hyaluronan oligosaccharides on 
angiogenesis 
The influence of hyaluronan and hyaluronan oligosaccharides on angiogenesis was 
investigated in two ways. In the first study, purified water was used as solvent for the test 
substances. In a second approach, PBS was used instead to exclude irritation caused by pH 
or hypoosmolarity. The results were heterogeneous. Overall, there was no evidence for 
induction of angiogenesis, not even in the bFGF group. Particularly, wheel-shaped structures, 
as described by West et al.,2 were not observed at all. Hence, further evaluation was focused 
on the reduction of vascularization and defects in blood vessel formation. For this purpose, 
the score described in Section 10.3.4 was applied. The results are presented in Figure 10.8. 
The score values for all substances are summarized in Figure 10.8 A–F. For each series of 
eggs, total scores were calculated. Each score value was multiplied by the respective number 
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of eggs. The sum of these products was divided by the total number of living eggs in the 
series (Figure 10.8 G). 
In comparison to PBS, score values were higher for water. Although the eggs in the two 
experiments might also have differed in blood vessel formation, this indicates some 
additional effect of the solvent water. Interestingly, the total score was identical for both 
experiments in the group with high molecular weight hyaluronan. Possibly, the water-
binding properties of hyaluronan reduced an irritation of the CAM. However, more reliable 
results were probably obtained with PBS as solvent. Focusing on these values, the total score 
was considerably increased for both, thalidomide and high molecular weight hyaluronan, 
compared to all other groups. Low molecular weight hyaluronan oligosaccharide mixture, 
purified hexasaccharides (n3), and bFGF yielded values comparable to blank. Although there 
was no clear evidence on the impact of hyaluronan on angiogenesis in this experiment, high 
molecular weight hyaluronan seemed antiangiogenic to some extent. The formation of 
avascular zones in the presence of high molecular weight hyaluronan is in good accordance 
with observations by Feinberg and Beebe.1 In contrast, induction of CAM vascularization, 
previously reported for hyaluronan oligosaccharides,2, 3 was not confirmed by our 
experiments. Moreover, histological examination of CAM preparations did not reveal any 
peculiarities (not shown). 
Finally, the failure of bFGF as a proangiogenic control deserves a closer look. It might be 
speculated that the used human growth factor is not suitable for the hen’s egg system. 
However, the rate of vascularization was extremely high in the respective period of CAM 
development. Therefore, the sensitivity of a biological system, optimized by nature, to 
identify potential proangiogenic stimuli (both, growth factors and oligosaccharides) can be 
expected to be low. In addition, although generally accepted, visual assessment might be too 
imprecise for evaluation.  
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Figure 10.8: Score values for solvent (water/PBS) alone (A), thalidomide (B), bFGF (C), high molecular weight 
hyaluronan (HMW HA, D), oligosaccharide mixture (LMW HA, E), and hexasaccharide (n3, F). Total score (G). 
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10.4 Summary and conclusion 
The chorioalantoic membrane (CAM) assay was used for studies on the potential size-
dependent impact of hyaluronan and its oligosaccharides on angiogenesis. Instead of pellets, 
agarose rings were used to administer the test compounds. The application of a fluorescent 
dye thereby proved the ability of the rings to hold the test solution in situ. 
Our experiments raised doubts regarding the reported proangiogenic effect of hyaluronan 
oligosaccharides.2, 3 Wheel-shaped structures, very roughly comparable to the description by 
West et al.,2 were only observed for unspecific irritation of the CAM by sodium dodecyl 
sulfate. In contrast, high molecular weight hyaluronan tended to induce avascular regions in 
a higher number of eggs compared to the controls. Of course, this observation is no proof of 
antiangiogenic effects by the polysaccharide. Nevertheless, this conclusion would be in 
accordance with literature.1 However, the poor outcome of this study does not justify 
subsequent animal experiments. 
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11 Summary and outlook 
11.1 Method development 
Hyaluronan and hyaluronan oligosaccharides, which are produced when the polysaccharide 
is enzymatically degraded by the action of hyaluronidases, are supposed to have various 
size-dependent biological effects. To study the (patho)physiological role of these 
oligosaccharides, appropriate analytical and bioanalytical methods are a prerequisite. Hence, 
hyphenated chromatographic and electrophoretic techniques were developed and 
optimized. Focusing on small oligosaccharides, these hyphenated methods complement the 
conventional approaches (Figure 11.1). 
 
Figure 11.1: Hyaluronan and hyaluronan oligosaccharides: their proposed size-dependent biological effects and 
the respective analytical approaches. Methods developed and optimized in this work are highlighted in orange. 
Modified from: Asari, A. Novel functions of hyaluronan oligosaccharides. Glycoforum 2005. 
(http://www.glycoforum.gr.jp/science/hyaluronan/HA12a/HA12aE.html). 
Each method has its particularities, predestining a technique for a certain size range of the 
oligosaccharides as well as for specific analytical problems (Table 11.1).  
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Table 11.1: Suggested analytical methods depending on the number of hyalobiuronic acid moieties. 
Hyalobiurionic 
acid moieties 
Method Detection Particularities 
All Morgan-Elson Colorimetry No information on size distribution 
> 1500 Viscosimetry Outflow time Sensitive for changes in average size,  
no information on size distribution 
25–80 Gel electrophoresis Alcian blue/silver 
staining 
Suitable for polysaccharide to medium-sized 
oligosaccharides 
> 20 Turbidimetry Light scattering No information on size distribution 
2–25 Anion exchange 
chromatography 
Pulsed 
amperometry 
High sensitivity, wide range of 
oligosaccharides 
1–20 Capillary zone 
electrophoresis 
Far-UV,  
ESI-TOF-MS 
Fast at-line analysis and mass information 
using MS, low sample volume 
1–4 HPTLC, TLC Reflectometry, 
MS coupling 
Simple procedure, parallel analysis of 
multiple samples 
 
Capillary zone electrophoresis coupled to time-of-flight mass spectrometry (CZE–ESI-TOF-
MS) is suited for oligosaccharides comprising up to 20 disaccharide moieties (n1–n20). The 
method was optimized with regard to fast separations. Together with minimal sample 
pretreatment, this allows for assessment of hyaluronidase activity quasi in real-time. MS also 
enables the unambiguous identification of substrates and products. Moreover, CZE–ESI-TOF-
MS with short capillaries requires only very small sample volumes (about 990 pL). Hence, 
this method should be chosen if only small amounts of sample solution are available (cf. 
Chapter 3). 
High performance anion exchange chromatography with pulsed amperometric detection 
(HPAEC–PAD) was optimized for the sensitive determination of oligosaccharides comprising 
2–25 hyalobiuronic acid moieties (n2–n25). Oligosaccharides with higher degree of 
polymerization can also be detected at a lower resolution. Hence, HPAEC and gel 
electrophoresis perfectly complement each other for studying hyaluronan degradation 
covering a broad range of differently sized products. High sensitivity with an LOD of 0.2–
0.3 pmol (depending on the analyte) for oligosaccharides consisting of 2–4 disaccharide units 
(n2–n4) recommends the method for determination of low concentrations (cf. Chapter 4). 
High performance thin layer chromatography (HPTLC) is most convenient for rapid quality 
control of purified oligosaccharides (n2–n4). Using a reagent-free derivatization of amino-
modified silica, HPTLC enabled the rapid densitometric quantification. Coupling of thin layer 
chromatography (TLC) on normal phase with mass spectrometry was successfully applied to 
the qualitative analysis of these samples (cf. Chapter 5) 
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Hence, together with conventional techniques, the developed approaches solve a broad 
variety of analytical problems associated with the biological role of hyaluronan and 
hyaluronidases. To develop these methods further, future work may focus on automation 
especially of the CZE–ESI-TOF-MS protocol. Moreover, application of the presented 
techniques to other analytes of interest (e. g. chondroitin sulfates) should be possible.  
11.2 In vitro studies on hyaluronidases 
Enzymological in vitro characterization of hyaluronidases is a prerequisite for understanding 
the particularities of different isoenzymes. However, conclusions with regard to the 
biological role of these enzymes in vivo remain speculative without knowledge of the specific 
substrates, the degradation mechanisms, and the products. Thus, the newly developed 
analytical methods were applied to the study of hyaluronidases of different origins. HPAEC–
PAD proved to be ideal for monitoring the time-dependent degradation of a low molecular 
weight hyaluronan oligosaccharide mixture. By contrast, fast CZE–ESI-TOF-MS was preferably 
used for at-line analysis of the degradation of purified oligosaccharides.  
Product spectra of bovine testicular hyaluronidase (BTH) and bacterial hyaluronidase from 
Streptococcus agalactiae, strain 4755, were compared (cf. Chapter 6). BTH exhibited a 
complex degradation profile of hydrolysis and transglycosylation reactions, leading to a 
mixture of different oligosaccharides as end products. With the bacterial enzyme, the 
unsaturated disaccharide (n1*) accumulated, other oligosaccharides were liberated 
intermediately during the reaction. Thereby, the unsaturated tetrasaccharide (n2*) seemed 
to be preferred. By analogy with n2*, the saturated tetrasaccharide (n2) was also accepted as 
substrate. Hence, this minimal substrate was used for determination of kinetic parameters 
according to the Michaelis-Menten theory for Streptococcus agalactiae hyaluronidase. The 
minimal substrate was digested at pH = 5.0, using 5 IU/mL (according to the declaration of 
the supplier) of the enzyme. Samples were analyzed by HPAEC–PAD. Km = 923 ± 106 µM and 
vmax = 3.68 ± 0.20 nmol/min were determined. 
Recombinant human Hyal-1 (rhHyal-1), PH-20 (rhPH-20), and PEGylated PH-20 (PEG-
rhPH-20) were characterized with regard to pH profiles and degradation of hyaluronan 
oligosaccharides (cf. Chapter 7). All three enzymes had optima at acidic pH values of 4.0 
(rhPH-20 and PEG-rhPH-20) and 3.5 (rh-Hyal-1), respectively. No assay-dependent 
differences were observed. Degradation of hyaluronan oligosaccharides was similar to BTH. 
Nevertheless, differences with regard to the product spectra, depending on pH, were 
identified.  
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Testing of L-ascorbic acid-6-O-hexadecanoate (vitamin C palmitate), indomethacin, and 
diclofenac (within a concentration range of 50–1000 µM) with regard to inhibitory effects on 
rhHyal-1 and rhPH-20 (cf. Chapter 7) revealed only very weak inhibition. Only vitamin C 
palmitate showed IC50 values of 156 ± 14 µM and 168 ± 48 µM, depending on the assay 
conditions. As increasing concentration of the enzyme led to dramatic loss in maximum 
inhibition, evaluable curves were only obtained at low enzyme activity. Necessarily, long 
incubation periods were required for the assay. 
As the applicability of HPAEC–PAD and CZE–ESI-TOF-MS for in vitro studies on hyaluronidase 
isoenzymes has been proven, these methods can easily be used for the characterization of 
hyaluronidases from other sources like venoms from snakes and hymenoptera, additional 
bacterial species (especially pathogens), or isolates from human tissues. Moreover, 
determination of the Michaelis-Menten kinetics of the different isoenzymes is necessary for 
characterization of both the enzymes and the inhibitors. However, potent and selective 
inhibitors for human hyaluronidases, needed as pharmacological tools as well as potential 
drugs, are still lacking. Hence, the search for these substances is still a challenging task. 
11.3 Bioanalytical and biological investigations 
In view of the biological role of hyaluronan, hyaluronan oligosaccharides, and 
hyaluronidases, synovial fluid samples were analyzed (cf. Chapter 8). Although the samples 
differed with regard to hyaluronan content, size distribution of hyaluronan, hyaluronidase 
activity, and viscoelastic properties, no correlation of the different parameters could be 
identified. Nevertheless, HPAEC–PAD and CZE–ESI-TOF-MS were proven to be suitable for 
the determination of hyaluronan and hyaluronan oligosaccharides from a biological matrix. 
In combination with colorimetry, gel electrophoresis, rheology, and zymography a broad 
characterization of the samples was possible. 
Finally, hyaluronan, a hyaluronan oligosaccharide mixture, and purified oligosaccharides 
were used for biological investigations in different assays. By electrical cell–substrate 
impedance sensing (ECIS), an inhibitory effect of the hexasaccharide (n3) on recovery of 
electrode coverage with endothelial cells (HMEC-1) after an electrical wounding pulse was 
observed. Similar effects were found in an ECIS cell proliferation experiment and in the 
crystal violet assay (cf. Chapter 9). However, the hexasaccharide (n3) was applied at 1 mg/mL 
(≈ 865 µM). It may be doubted that such high concentrations occur under physiological 
conditions. Native hyaluronan and a more complex mixture of oligosaccharides (both 
1 mg/mL) had no effects on endothelial cells. At very high concentrations, the 
oligosaccharide mixture led to an acidification of the culture media. 
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As cell migration and proliferation are important in wound healing processes, single samples 
of wound exudate and debris were analyzed by HPAEC–PAD and zymography. Neither small 
oligosaccharides nor hyaluronidase activity were proven. In view of their putative role in 
hyaluronan oligosaccharide signaling, expression of hyaluronan receptors RHAMM and CD44 
by different cell lines was analyzed using flow cytometry (cf. Chapter 9).  
Oligosaccharides added to cell culture media were not degraded, even during culture of 
hyaluronidase overexpressing cells (cf. Chapter 9). Hence, it may be concluded that no 
considerable amounts of hyaluronidases were secreted into the media or that activity at 
physiological pH was too low to affect the size distribution of a supplemented 
oligosaccharide mixture.  
A chorioallantoic membrane (CAM) assay was performed (cf. Chapter 10) to study putative 
effects of hyaluronan oligosaccharides on angiogenesis. Oligosaccharides had no effect, 
whereas there was a weak tendency to antiangiogenesis in the presence of high molecular 
weight hyaluronan. Nevertheless, further studies would be necessary to verify this 
observation.  
Hyaluronan and its degradation products are supposed to be involved in manifold 
(patho)physiological processes. Hence, cellular assays and other biological tests will always 
be necessary to elucidate their biological role (e. g. in cancer or inflammation). The analytical 
approaches presented in this work are valuable tools for quality control of purified 
oligosaccharides for biological assays as well as for the determination of hyaluronan and 
hyaluronan oligosaccharides (resulting from hyaluronidase activity) in biological matrices.
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